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Abstract
Neutrophil apoptosis is an important process in the control of inflammation. This
event results in a shut down of neutrophil secretory responses and initiates the
phagocytic clearance of intact senescent cells by a novel recognition and uptake
pathway that does not incite a pro-inflammatory macrophage response. While the
mechanisms involved in regulating neutrophil survival and death are poorly
understood, there is now considerable evidence to indicate that this process is not
immutable since the rate at which these cells undergo apoptosis, at least in vitro, can
be altered. Indeed, many pro-inflammatory mediators have been demonstrated to
inhibit neutrophil apoptosis in vitro, suggesting that such agents act not only in a
priming or secretagogue capacity but also increase neutrophil functional longevity by
delaying apoptosis. We have examined whether this hypothesis holds true for all
neutrophil priming agents, in particular TNFa, a potent neutrophil priming agent
which has been variably reported to either induce, delay, or have no effect on the rate
of constitutive neutrophil apoptosis.
We have shown that incubation of neutrophils with various priming and/or activating
agents for 20 hr either inhibited (LPS, LTB4, GM-CSF, IP6) or had no effect on
(fMLP, PAF) the rate of neutrophil apoptosis. TNFa however, despite causing a
significant inhibition of apoptosis at 20 hr, promoted apoptosis in a subpopulation of
cells at earlier times (<12 hr) when the constitutive rate of apoptosis is still low; this
v
effect was not observed with any of the other priming or activating agents examined
at this time.
The early pro-apoptotic effect of TNFa was confirmed by DNA fragmentation and
propidium iodide binding and shown to be concentration-dependent with a near-
identical EC50 value (2.8 ng/ml) to that observed for TNFa-priming of fMLP-
stimulated superoxide anion generation. Moreover, the early cytocidal effect of this
cytokine was detectable within 2 hr, abolished by TNFa neutralizing antibody, and
was not associated with any change in cell viability or recovery. Of note, TNFa-
stimulated apoptosis was abolished by pre-incubation of neutrophils with selective
blocking antibodies to both the TNFR55 (which contains the classical death-domain
sequence and is entirely responsible for the TNFa priming effect in suspension
neutrophils) and TNFR75 receptor subtypes. Moreover, the TNFR55-selective
mutants (E146K, R32W-S86T) induced neutrophil apoptosis but with a potency 14-
fold lower than wild type TNFa, while the TNFR75-selective mutant (D143F) did
not induce apoptosis. These data indicate that TNFa has the ability apparently
unique to this priming agent to induce apoptosis in human neutrophils at early time
points via a mechanism whereby the TNFR75 facilitates and permits TNFR55-
mediated induction of cell death. Of relevance to the inflamed site, the ability of
TNFa to accelerate apoptosis was completely lost if neutrophils were primed with
PAF (1 pM, 10 min) or aged for 6 hr, prior to TNFa addition.
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The pro-apoptotic effect of TNFa was not mimicked by cell-permeable synthetic
ceramides or neutral sphingomyelinase, suggesting that a sphingomyelin/ceramide
triggered death pathway as observed in certain leukaemic cell lines may not be the
principal signalling route employed by TNFa in human neutrophils. Inhibition of
p38 MAP kinase and MAPKK-1 potentiated the pro-apoptotic effect of TNFa, while
suppressing the protective effect of LPS at a later (20 hr) time, implicating the p38
and p42/44 MAP kinases in the protection of neutrophils against apoptotic stimuli.
Finally, although human neutrophils appear quite resistant to oxidant-induced killing
(e.g. by H202, hyperoxia or NADPH oxidase activation), and wortmannin which
ablates superoxide anion generation in these cells actually augmented TNFa-induced
killing, cell culture under hypoxic conditions was the one intervention that resulted in
a dramatic abrogation of the pro-apoptotic effect of TNFa. This latter finding
implicates either an oxygen-dependent step in TNFa-mediated neutrophil apoptosis
or the capacity for the survival response triggered by anoxia to override the TNFa
killing effect.
These data suggest that the major increase in TNFa which is such a characteristic
feature of the early inflammatory response may provide a very important signal for
neutrophil clearance via the induction of apoptosis. The unconventional dependency
of this response on both TNFR55 and TNFR75 and the restriction of the latter
receptor subtype to myeloid cells suggests a unique mode of action of TNFa in these
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1.1.1 General structure, contents and origin
The neutrophilic polymorphonuclear leukocyte originates from the myeloid series in
the bone marrow and is the most numerous of the circulating phagocytes,
representing in most species 50 to 60% of the circulating white blood cell population.
On electron microscopy this terminally-differentiated cell has a mean diameter of
approximately 7 pm and is characterized by a multilobed chromatin-dense nucleus
and distinctive cytoplasmic granules which distinguish it from other granulocytes.
Neutrophil granules contain an array of enzymes, receptors and antimicrobial
proteins which participate in the many functions of the cell. Traditionally, neutrophil
granules were classified by their staining for peroxidase i.e. peroxidase-positive
(azurophil or primary) or peroxidase-negative (specific or secondary); however this
proved to be too simplistic to account for differential exocytosis of granule protein
and incorporation of granule membrane into plasma membrane, hence a new
classification was devised, sorting granules into four sub-populations (Borregaard et
al., 1993).
1.1.1a Secretory vesicles
The secretory vesicle membrane contains the adhesion receptor CD1 lb/CD 18 (Mac-
1), which is essential for integrin-mediated neutrophil adhesion (Sengelov et al.,
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1993a, Calafat et al., 1993), in addition to the A-formyl-methionyl-leucyl-
phenylalanine (fMLP) receptor (Jesaitis et al., 1982), alkaline phosphatase, and
cytochrome bsss (the membrane component of the NADPH oxidase; Calafat et al.,
1993); FcRIII receptors (for the Fc component of antibodies) and decay accelerating
factor may also be present (Tosi and Zakem, 1992, Berger and Medof, 1987). These
vesicles are the most readily and rapidly mobilised of the neutrophil granules
(Sengelov et al., 1993b), allowing swift upregulation of plasmalemmal CD1 lb/CD 18
(promoting adhesive events) and fMLP receptor numbers (augmenting cellular
chemoattractant responsiveness).
1.1.1b Specific (secondary) granules
These spherical, oval or elongated granules are defined by their lactoferrin content;
they are also an important source of cytochrome bsss (Borregaard and Tauber, 1984),
adhesion molecules (Bainton et al., 1987) and fMLP receptors (Fletcher and Gallin,
1983).
1.1.1c Gelatinase (tertiary) granules
Smaller than specific granules, gelatinase granules constitute approximately 25% of
all peroxidase-negative granules. They are mainly composed of the protease
gelatinase, which may be involved in digesting the vascular basement membrane to
allow neutrophil extravasation (Weiss and Peppin, 1986).
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1.1.Id Azurophilic (peroxidase-positive) granules
Azurophilic granules store most of the proteolytic and bactericidal proteins
(myeloperoxidase, cathepsins, elastase, (3-glucuronidase, lysozyme, defensins etc.)
and contain no receptors or adhesion molecules in their membranes. Mobilisation of
these granules is slow and limited.
While it is likely that the majority of the constituents of neutrophil granules have
evolved to promote rapid tissue migration and effective bacterial killing, it is
apparent that inappropriate or excessive release of these agents would be highly toxic
to host tissue. While the neutrophil does not contain large amounts of subcellular
structures such as Golgi apparatus and mitochondria, it does however have
significant endoplasmic reticulum content. The plasma membrane is of fundamental
importance in this highly responsive cell since it houses the receptors which detect
inflammatory events and signalling molecules and provides the link between the
extracellular milieu and the intracellular environment for many receptor-mediated
events including chemotaxis, phagocytosis, secretion, aggregation and the oxidative
burst. An intimate communications network must therefore operate between the
membrane and the secretory and specific granules which renew many major
membrane components and also with the cellular cytoskeleton which lies mainly in
the sub-membrane region and is responsible for the complex motility functions of the
neutrophil.
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Neutrophils are produced in the human bone marrow at a rate of 10n cells per day
(Cannistra and Griffin, 1988). Constitutive granulocytopoeisis is controlled by
stromal cell-derived growth factors such as interleukin 3 (IL-3), and granulocyte
colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating
factor (GM-CSF) which are lineage specific and direct the production and
differentiation of bone marrow progenitor cells. These factors play an important role
in the control of inflammation since their release is highly sensitive to cytokines such
as IL-1 and TNFa which are generated at sites of inflammation; thus the rate of
neutrophil differentiation can increase as much as 10-fold during the response to
infection, inflammation or stress (Cannistra and Griffin, 1988). Mature neutrophils
retained within the bone marrow constitute an important reservoir of cells which can
be stimulated to egress into the bloodstream (e.g. by a decreased neutrophil count in
blood perfusing the marrow) where they distribute between circulating and
'marginating pools' of neutrophils temporarily sequestered in the microvascular beds
of the lung, spleen and liver. Circulating and marginating pools can exchange with
each other, however little is understood about the fate or size of these interrelated
tissue pools (MacNee and Selby, 1990).
Studies using radiolabelled neutrophils have indicated that they have a short half-life
(approximately 4 hr) in the blood (Price and Dale, 1977) and although it is unclear
why these cells turn over so rapidly in healthy subjects, this may be related to their




Neutrophils form part of the natural (non specific) immune system and are the first
cells to be summoned to sites of infection or injury (Schleimer et ah, 1989) where
their primary role is to phagocytose and destroy invading micro-organisms.
Accordingly, neutrophils have evolved a variety of rapid, and co-ordinated responses
which allow them to reach an area of inflammation and react appropriately to the
inciting agent. For example, neutrophil motility requires regulation of adhesion and
cytoskeletal reorganization. Upon recognition of a foreign agent, phagocytosis,
secretion of pre-formed proteolytic enzymes and bactericidal proteins, and de novo
production of reactive oxygen intermediates ensues. Collectively these are termed
the 'effector' responses of neutrophils, however they also limit microbial growth
thereby allowing time for adaptive (specific) immunological responses to develop
(Mannion et al., 1990). With an excessive number ofmicrobes, however, neutrophil
defenses are ineffective in the absence of opsonins and various agents that amplify
the inflammatory response which emphasises the co-operative interaction between
natural and adaptive components of the immune system.
Cationic proteins and proteolytic enzymes, stored within the cytoplasmic granules,
are released into phagolysomes and/or extracellulary (Borregaard et al., 1993).
Reactive oxygen intermediates are produced by the NADPH oxidase, a
multicomponent enzyme complex which transfers electrons from NADPH to
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molecular oxygen to generate superoxide anions. Neutrophil targets include bacteria
(particularly streptococci), fungi, protozoa, viruses, virally infected cells and tumour
cells (Ratcliffe et al., 1988).
The fundamental importance of the neutrophil in defense is illustrated by the marked
propensity of the host to develop infection in conditions of deficiency in number
and/or function. Examples of these disorders include neutropaenia induced by
chemotherapeutic agents, chronic granulomatous disease, where components of the
NADPH oxidase are absent or defective (Smith and Curnutte, 1991), leukocyte
motility disorders, where the regulation of cytoskeletal events required for motility is
abnormal (Howard et al., 1994), leukocyte adhesion disorders, where adhesion
molecule functions are deficient (Albelda et al., 1994) and disorders of granule
secretion such as the Chediak-Higashi syndrome (Wolff et al., 1972).
1.1.3 Role of the neutrophil in inflammation
The initial phase in an acute inflammatory response is recruitment of neutrophils to
the infected site by chemotactic agents which induce polarization and directed
locomotion along a chemotactic gradient. A foreign agent, such as a bacterium, may
drive chemotaxis by a variety ofmechanisms: (i) directly, by the release of
chemotactic peptides from its surface (e.g. fMLP), (ii) via complement activation and
C5a generation, or (iii) by induction of macrophage production of leukotriene B4
(LTB4), C-X-C chemokine family members such as IL-8 (Baggioloini et al., 1989),
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or other cytokines such as TNFa and IL-1 which further amplify neutrophil
recruitment by the secondary stimulation of other local cells to produce chemokines.
Since neutrophils themselves are an important source of chemokines, including IL-8,
the opportunity exists for autoregulation of further neutrophil migration (Kunkel et
al„ 1995).
Neutrophil arrest in the microcirculation initiates the interaction between the
leukocyte and the endothelial cells and is a pre-requisite for endothelial
transmigration. In most tissues, neutrophil sequestration and emigration occurs
primarily within the post-capillary venules (Shaw, 1980, Downey et al., 1993,
Doerschuk et al., 1994), however in the lung, the principal route of leukocyte
retention, margination and emigration is in the pulmonary capillary (Schmid-
Schonbein et al., 1980). In the systemic microvasculature, sequestration results as a
consequence of the increased expression/activation of neutrophil surface adhesion
molecules, however in the pulmonary circulation, alterations in neutrophil
rheological properties, especially a reduction in their deformabilty, may also play an
important contributory role. A variety of chemotactic factors have been shown to
induce a modest reduction in neutrophil deformability which directly correlates with
vascular sequestration (Worthern et al., 1989, Drost et al., 1992).
Neutrophils first roll or loosely tether themselves to the microvasculature wall via
low-affinity interactions mediated by the selectin family of adhesion molecules, in
particular L-selectin (CD62-L) on the neutrophil and E- and P-selectins (CD62-E and
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CD62-P respectively) on the endothelial cell (Bavilacqua and Nelson, 1993, Albeda
et al., 1994). This process does not necessarily result in neutrophil transmigration
however, and chemoattractant-mediated activation of p2-integrin adhesion molecules,
in particular CD1 lb/CD 18 (Mac-1) (Kishimoto et ah, 1989, Jutila et al., 1989), and
the subsequent high-affinity binding of neutrophils to endothelial intracellular
adhesion molecules (ICAM-1 and ICAM-2) must occur for subsequent neutrophil
translocation to a site of inflammation (Smith et al., 1989, Dustin et al., 1986).
Under the influence of a chemotactic gradient, generated both locally and by
diffusion of chemoattractants from the inflammatory focus, neutrophils emigrate
between the endothelial cell layer of the microvascalture wall, penetrate the basement
membrane and migrate through the interstitium toward the area of infection
(diapedesis) where they finally adhere to extracellular matrix components such as
laminin and fibronectin (Nathan and Sanchez, 1990, Cronstein and Weissmann,
1993). A wide variety of adhesion molecules have been identified and characterized
on phagocytic cells (Cronstein and Weissmann, 1993).
On arrival at the inflammatory focus, the primary function of the neutrophil is the
recognition, phagocytosis and destruction of pathogens. Phagocytosis involves two
stages; recognition and internalization of the inciting agent into the phagosome and
subsequent killing/neutralization and digestion of the foreign material. The
neutrophil must first recognize a foreign particle before engulfment can occur and in
some instances this is mediated by direct binding to materials such as
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lipopolysaccharide (LPS) on the surface of the foreign organism. In most cases
however, the particle must be opsonized by plasma binding proteins which may be
specific (immunoglobulin) or non-specific (e.g. complement, fibronectin, C-reactive
protein) to allow neutrophil receptor-mediated recognition (i.e. Fc and complement
receptors, CR1 and CR3). For engulfment of an opsonized particle to occur,
pseudopods rich in filamentous actin must form and surround the particle; this
process requires actin polymerization and is therefore blocked by agents such
cytochalasins (Zigmond and Hirsch, 1972). During phagocytosis, there is intra-
phagosomal release of toxic oxygen metabolites (1.1.3a) which requires the initiation
of an intense burst of oxygen consumption (Baldridge and Gerard, 1933), known as
the respiratory burst, and cytosolic granules fuse with the invaginating plasma
membrane (1.1.1) creating a highly toxic microenvironment. Other metabolic
pathways are also activated by phagocytosis (e.g. Delia Bianca et ah, 1993) including
the synthesis of bioactive lipids such as platelet-activating factor (PAF) and LTB4
(Clancy et ah, 1983, Chilton et ah, 1984) and a number of cytokines (1.1.3b).
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1.1.3a Production of reactive oxygen intermediates
The net reaction of the respiratory burst is the transfer of electrons from NADPH to
oxygen, producing superoxide anions:
NADPH + H+ + 202 NADPH+ + 2H+ + 202"
NADPH produced by the cytosolic hexose monophosphate shunt functions as an
electron donor to effect a one electron reduction of each of two atoms ofmolecular
oxygen (Babior et al., 1973). The 02~ formed dismutates to form hydrogen peroxide,
a reaction catalysed by superoxide dismutase:
202" + 2H+ 02 + H202
In the presence of halide ions (preferentially chloride ions) and H202,
myeloperoxidase released from neutrophil azurophil granules can catalyse the
generation of hypohalous acids, such as hypochlorous acid:
H202 + HC1 HOC1 + H20
The cytotoxic effects of hypochlorous acid include: oxidation/reduction ofmembrane
proteins, leading to increased bacterial cell permeability (Albrich et al., 1986),
oxidation of components of the bacterial respiratory chain (Rakita et al., 1989),
membrane peroxidation (Winterbourn et al., 1992) and the formation of chloramine
(Bernofsky, 1991). Additional reactive products such as hydroxyl radical and singlet
oxygen may also be formed, but as a consequence of their short longevity, detection
is difficult and their role is uncertain (reviewed in Rosen et al., 1995).
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1.1.3b Cytokine production
Protein synthesis by neutrophils can be elicited by a variety of agonists including
fMLP, TNFct and GM-CSF (Beaulieu et al., 1992), and several cytokines are
produced including IL-1 (Tiku et al., 1986), IL-6 (Cicco et al., 1990), IL-8 (Bazzoni
et al., 1991) G-CSF and M-CSF (Lindemann et al., 1989), and TNFa (Dubravek et
al., 1990). Since a large number of neutrophils are recruited to inflammatory foci,
the impact of cytokine synthesis by these cells may be highly significant.
1.1.4 Neutrophil-mediated tissue injury
While neutrophils are essential for host defense they have also been implicated in the
pathophysiology of a variety of inflammatory conditions such as the adult respiratory
distress syndrome (ARDS) (reviewed by Donnelly and Haslett, 1992), pulmonary
fibrosis (e.g. Behr et al., 1991), vasculitic diseases (reviewed by Savage and Rees,
1994), rheumatoid arthritis (Robinson et al., 1992) and ischemia-reperfusion injury
(reviewed by Williams, 1994). Neutrophil-derived hydrolytic enzymes and
oxidatively inactivated protease inhibitors have been detected in fluids isolated from
inflammatory sites (Weiss, 1989). In addition, it has been postulated that chronic
activation of neutrophils may also initiate tumour development since some reactive
oxygen intermediates cause DNA damage in vitro (Weitzman and Gordon, 1990) and
proteases promote tumour cell migration (Opdenakker and Van Damme, 1992).
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Under normal conditions neutrophils can migrate to sites of infection without
damaging host tissue. The secretory processes activated during this process (e.g. to
enable the expression of adhesion molecules and to activate signalling responses to
chemoattractants; Borregard et al., 1993) however are also linked to the activation of
microbicidal activity.
Neutrophil-mediated host tissue damage may arise through several independent
mechanisms. These include (i) premature activation during migration, (ii)
extracellular release ofmicrobicidal agents during 'frustrated phagocytosis' where
micro-organisms are either too large for full phagocytosis to occur, or evade this
process, (iii) removal of infected or damaged host cells and debris as an initial step in
tissue remodeling, (iv) overwhelming of the normal controls preventing generalised
activation, or (v) failure to terminate the acute inflammatory response.
1.1.5 Neutrophil priming
Priming refers to the process whereby an agent which has no secretory effect on its
own causes a dramatic upregulation of the response of the neutrophil to a secondary
stimulus (figure 1.1.5). Neutrophil priming was first reported by Guthrie and co¬
workers (1984) who demonstrated that pre-incubation of freshly isolated human
neutrophils with LPS did not in itself elicit a respiratory burst, but greatly potentiated
the oxidative response to fMLP, and to a far lesser extent than that observed with
PMA. Minimal superoxide anion generation was recorded in unprimed cells
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stimulated with fMLP; thus in view of the fact that neutrophil preparative methods
themselves may induce a degree of cell priming (Haslett et ah, 1985), truly unprimed
neutrophils in the circulation are likely to be entirely unresponsive to fMLP (with
respect to NADPH oxidase activation) if not exposed to a priming agent. A wide
array of physiological substances have been shown to act as priming agents and these
may be derived from macrophages (e.g. GM-CSF, TNFa), endothelial cells (PAF,
TNFa) or bacteria (e.g. LPS). The pre-incubation times required to obtain a
maximally primed response range from minutes (e.g. PAF, TNFa; Vercellotti et
1988, Berkow et ah, 1987) to a few hours (LPS, GM-CSF; Guthrie et al., 1984,
Weisbart et al., 1986), implying that these agents mediate neutrophil priming via
distinct signal transduction routes. Moreover, a thorough understanding of the
mechanism ofpriming is further complicated by the fact that sub-maximal
concentrations of classical 'activating' agents, such as fMLP, can also serve to prime
neutrophils (Bender et al., 1983), whereas the archetypal priming agent TNFa can
cause direct triggering of degranulation and respiratory burst activity in adherent
neutrophils (Nathan, 1987, Richter et al., 1989, Nathan et al., 1989, Dri et al., 1991).
In addition to the respiratory burst, priming of the degranulation response (Fittschen
et al., 1988) and of the generation of lipid mediators (principally arachidonic acid,
LTB4 and PAF; Doerfler et al., 1989, 1994, DiPersio et al., 1988) have been
described, and priming has been demonstrated to be tightly linked with both shape
change (Haslett et al., 1985) and adhesion molecule (CD1 lb/CD18) expression and
activity (Condliffe et al., 1996).
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Figure 1.1.5 Neutrophil priming
Priming of neutrophils by the products of activated macrophages (e.g. TNFa, GM-
CSF), endothelial cells (e.g. PAF) and bacteria (e.g. LPS) does not lead directly to
the release of toxic products but results in amplified secretion of reactive oxygen
intermediates and enzymes when a further stimulus (e.g. fMLP) is encountered.
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The capacity for neutrophils to recover from a primed state was recently
demonstrated by our group (Kitchen et ah, 1996b) where, in contrast to the very
protracted effects of TNFa, LPS and GM-CSF, incubation of neutrophils with a
maximal concentration of PAF induced rapid but transient receptor-mediated priming
with full recovery of cells to a state where only basal unprimed levels of fMLP-
stimulated superoxide anion generation, shape change and CD1 lb/CD 18 activity was
observable. Moreover, these cells had the ability to fully 're-prime' upon subsequent
stimulation with PAF or TNFa.
1.2 Apoptosis
It has now well established that the death of nucleated cells can be classified into two
distinct types, necrosis, or 'accidental' cell death, and apoptosis, or 'programmed'
cell death (Kerr et al., 1972, Wyllie et ah, 1980, Duvall and Wyllie, 1986).
Apoptosis occurs where death is predictable or planned, or where cell turnover is
physiologically rapid e.g. the elimination of autoreactive T-cells (Jenkinson et al.,
1989), involution of cells deprived of necessary growth factors (Duke and Cohen,
1986), morphogenetic death of cells during embryonic and early post-embryonic
development (Glucksmann, 1951), and in the killing of cells which serve as targets
for T, NK or antibody-dependent cell-mediated cytotoxic mechanisms (Duke et al.,
1983).
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During apoptosis, ultrastructural studies have shown that, in contrast to necrosis, the
cells shrink due to cytoplasmic condensation, and in some cell types, detachment of
cytoplasmic 'blebs' occurs; despite this, the plasma membrane stays intact and the
cells retain the ability to exclude vital dyes. Dramatic changes in the cell surface also
occur, such as exposure of phosphatidyl serine, loss ofmicrovilli, and the
development of invaginations (Morris et ah, 1984, Fadok et al., 1992). Organelles
such as mitochondria and cytoplasmic granules remain intact although the
endoplasmic reticulum may dilate. Nuclear changes, however, are the most
characteristic features of apoptosis: the chromatin rapidly condenses into dense
crescent-shaped aggregates at the periphery of the nucleus, which if multilobed, may
condense into a single spherical 'pyknotic' body.
The 'biological hallmark' of apoptosis is internucleosomal cleavage of chromatin
(Wyllie, 1980) whereby an endogenous endonuclease fragments DNA at linker sites
between nucleosomes to generate low molecular weight fragments of chromatin
which are integer multiples of 180-200 base pairs ofDNA associated with a
nucleosome (Arends et al., 1990).
Apoptotic cells are thereafter ingested and degraded very rapidly by phagocytes,
particularly macrophages, in vivo; so that in tissue sections apoptotic cells are usually
seen to be within other phagocytes (Alison and Sarraf, 1992. Furthermore, in these
examples, apoptosis is not associated with any evidence of local tissue injury or the
induction of an inflammatory response, suggesting that apoptosis may represent a
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tissue-injury limiting mechanism for the removal of senescent cells which has very
direct and obvious implications for the removal of granulocytes from an
inflammatory focus.
1.2 1 Neutrophil apoptosis
It is generally accepted that neutrophils meet their fate at the inflamed site with little
if any evidence to suggest that extravasated neutrophils return to the blood stream
either directly or via the lymphatic drainage system (Haslett and Henson, 1988). In
the face of such observations it was assumed previously that neutrophils present at an
inflammatory focus died by necrosis and that the cell debris was removed by local
macrophages (Hurley, 1983). However, neutrophils contain a variety of potentially
injurious agents (Henson and Johnson, 1987, Weiss, 1989) including proteases and
other enzymes with the capacity both to damage tissue directly (Weiss, 1989) and to
cleave matrix proteins into chemotactic fragments (Vartio et al., 1981), and hence
disintegration of these cells would serve to amplify the inflammatory response and
recruit even more inflammatory cells. Moreover, phagocytic clearance of such
neutrophil debris would be expected to cause an additional pro-inflammatory
response by the macrophage.
The classical lectures ofMetchnichoff (1891) showed that in vital preparations of
inflamed tissue there was evidence of an alternative fate for the neutrophil whereby
seemingly intact cells were removed by macrophages; however, the significance of
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these observations were overlooked for many years. Almost a century later, in vitro
experiments using cells purified from human peripheral blood demonstrated
recognition and phagocytosis of neutrophils when aged in culture for 24 hr by mature
monocyte-derived macrophages (Newman et ah, 1982). This process generated
interest as a possible tissue injury-limiting mechanism and further studies revealed
that the change in neutrophil phenotype which promoted recognition and
phagocytosis of these intact senescent cells was neutrophil apoptosis (Haslett et ah,
1987, Savill et ah, 1989a).
Subsequent experimental data obtained again using peripheral blood neutrophils
demonstrated that these cells undergo constitutive apoptosis in vitro with the
majority of neutrophils dying by this process after 24 hr in culture (Begley et ah,
1986, Lopez et ah, 1986, Colotta et ah, 1992, Lee et ah, 1993). This process was
associated with maintenance of membrane integrity, down-regulation of neutrophil
functions such as chemotaxis and phagocytosis, hypo-responsiveness to secretagogue
signals (Whyte et ah, 1993a), and the capacity to be phagocytosed intact by
macrophages (Savill et ah, 1989a and b, 1990b, 1992, Haslett et ah, 1989, Whyte et
ah, 1993a).
The usual response of the macrophage to phagocytosis of particles in vitro is the
release of inflammatory mediators (e.g. thromboxanes, enzymes and cytokines),
however the ingestion of apoptotic neutrophils does not excite a pro-inflammatory
response (Meagher et ah, 1992). Human monocyte-derived macrophage recognition
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of apoptotic neutrophils has been demonstrated to involve the macrophage av(33
(vitronectin receptor) and CD36 (thrombospondin receptor) which appear to co¬
operate with thrombospondin to bridge the macrophage to the apoptotic cell (Savill et
al., 1990b, 1992a) by a process which appears to be independent of new protein
synthesis (Whyte et al., 1997). Upregulation of thrombospondin-mediated
phagocytosis of cells undergoing apoptosis in vitro has been observed with pro¬
inflammatory cytokines (GM-CSF, IL-ip, interferon-y (IFNy), TNFa) and by
transforming growth factor (TGF)-ip which has both pro- and anti-inflammatory
properties (Ren and Savill, 1995). Finally, 'semi-professional' phagocytes, such as
mesangial cells and fibroblasts, have the capacity to recognize and ingest apoptotic
neutrophils in vitro (Savill et al., 1990a, Hall et al., 1994) which may provide support
for the macrophage system in vivo.
1.2.3 Modulation of neutrophil apoptosis
While the mechanisms regulating neutrophil survival and death are poorly
understood, there is now considerable evidence to suggest that this process is not
immutable since the rate at which these cells undergo apoptosis, at least in vitro, can
be altered. For example, a wide variety ofpro-inflammatory mediators such as LPS,
C5a, GM-CSF, IL-ip, IFNy and LTB4 have been shown to increase the survival of
these cells (Begley et al., 1986, Brach et al., 1992, Cox et al., 1992, Colotta et al.,
1992, Lee et al., 1993). Furthermore, the demonstration that LPS-mediated
inhibition of neutrophil apoptosis results in prolongation of neutrophil functional
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longevity, as assessed by secretion and chemotaxis, suggests that certain agents may
upregulate neutrophil function both by activating and/or priming for enhanced
functional responsiveness to secretagogue agonists and by delaying apoptosis (Lee et
al., 1993), as illustrated in figure 1.2.3A. While the mechanisms regulating cytokine-
mediated modulation of neutrophil apoptosis are poorly understood, there is data to
support a role for tyrosine phosphorylation and intracellular acidification in GM-CSF
and G-CSF-mediated inhibition of cell death respectively (Yousefi et al., 1994,
Gottlieb et al., 1995).
Although it is well established that the longevity of neutrophils can be altered by the
inhibition of apoptosis, these cells appear highly resistant to any attempt to accelerate
this process using physiological agonists. Indeed, even experimental stimuli that are
potent stimulators of apoptosis in other cell types, such as elevation of intracellular
Ca2+, extreme hypoxia and high dose corticosteroids, all inhibit rather than augment
apoptosis in neutrophils (Whyte et al., 1993b, Hannah et al., 1995, Cox, 1995,
Meagher et al., 1996).
While it is clear that neutrophil apoptosis can be induced pharmacologically e.g. by
inhibition of protein kinase C (PKC; Cousin et al., 1997, MKB Whyte, Ph. D Thesis,
1993), or by treatment with the protein synthesis inhibitors cycloheximide or
actinomycin D (Brach et al., 1992, Whyte et al., 1997), controversy exists in the
literature regarding the ability of physiological agonists to stimulate apoptosis in














Figure 1.2.3 Modulation of neutrophil apoptosis
Certain agents may upregulate neutrophil function by activation and/or priming for
enhanced functional responsiveness to secretagogue agonists and by delaying
apoptosis.
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et al., 1992), this effect was small, has not been reported by at least two other groups
(Takeda et ah, 1993, Biffl et ah, 1995), and the extent of constitutive apoptosis
recorded (10% cf. 15% in the presence of IL-6 at 24 hr) was very different to that
reported in all other comparable studies.
One cytokine of particular interest is TNFcc which is a powerful priming agent in
neutrophils yet has the capacity to induce apoptosis in a variety of cell types
including T-lymphocytes (Zheng et ah, 1995) and HL-60 cells (Obeid et ah, 1993).
The data from studies regarding the effects of TNFa on neutrophil longevity are
conflicting however, as they suggest that TNFa either inhibits (Colotta et ah, 1992),
has no effect on (Kwon et ah, 1988), or induces apoptosis (Takeda et ah, 1993) in
these cells.
Apoptosis thus not only determines the functional longevity of granulocytes but can
itself be modulated and controlled by external mediators with relevance to the control
of inflammation. Hence, in contrast with necrosis, it provides a neutrophil removal
mechanism which can also be influenced by inflammatory mediators. These data all
predict that this process plays an important role in the 'safe' disposal of intact but
effete neutrophils from an inflamed focus as illustrated in figure 1.2.3B. This view is
supported by recent demonstrations of this process occurring in vivo, for example in
endotoxin-induced experimental lung injury (Cox et ah, 1995), the neonatal
respiratory distress syndrome (Grigg et ah, 1991) and in experimental

























The first person to exploit the phenomenon of induction of haemorrhagic necrosis of
tumours during some coincidental pyrogenic bacterial infections was the New York
surgeon William Coley (1862-1936). Coley used preparations of Gram-positive and
Gram-negative bacteria for cancer therapy and claimed successes in some cases
(Coley, 1906), however the side effects of his treatment were intolerable and these
early attempts at therapy were stopped. Much later LPS was isolated as the active
component in comparable bacterial preparations to those administered by Coley
(Shear and Andervont, 1936, Hartwell et ah, 1943, Kahler et al., 1943, Shear et ah,
1943a and b, Shear, 1944) and the presence of an agent which was cytotoxic to
tumours in serum of Bacille Calmette-Guerin (BCG)-infected and LPS-challenged
animals was demonstrated by transfer experiments (O'Malley et ah, 1962, Carswell
et ah, 1975). This substance, which induced necrosis of the meth-A sarcoma in mice,
also killed transformed cells in vitro, including WEHI 164 cells (Espevik and Nissen-
Meyer, 1986). This otherwise undefined and unpurified substance was named
tumour necrosis factor.
In a parallel line of research, Cerami and co-workers, who were investigating the
underlying cause ofwasting in chronic infectious disease, observed that rabbits
infected with Trypanosoma brucei developed severe cachexia, losing up to 50% of
their live weight, despite a low parasitic load. Paradoxically, the final stage of
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wasting was marked by a profound accumulation of triglycerides in the serum which
was attributed to a systemic deficiency in the activity of lipoprotein lipase (Rouzer
and Cerami, 1980). The factor responsible for metabolic suppression of this enzyme
was also induced by LPS in certain endotoxin-sensitive mouse strains (C3H/HeN)
and moreover, this activity was transferable to LPS-resistant strains (C3H/HeJ;
Kawakami and Cerami, 1980). The ability of this factor to completely block lipase
activity was exploited in the development of a sensitive bioassay (Kawakami et ah,
1982) for a molecule that was subsequently referred to as 'cachectin' (see Beutler,
1992, Beutler and van Huffel, 1994). Endotoxin-stimulated macrophages were found
to be a major source of the TNF and cachectin activities (Mannel et al., 1980, Torti et
ah, 1985) and cachectin was found to be potently cytotoxic for WEHI 164 cells in
vitro, indicating a high degree of homology between these molecules (Beutler et al.,
1985). Molecular cloning and expression finally established that cachectin and TNF
were in fact the same molecule (Pennica et al., 1984, Wang et al., 1985).
TNF became known as TNFa when a third route of research led to the discovery of
lymphotoxin (LT), which was referred to initially as TNFp. LT was identified in
studies investigating the cytotoxic factors responsible for so-called 'by-stander'
killing (Granger and Williams, 1968) and the potential mediators of tissue damage in
delayed-type hypersensitivity (Ruddle and Waksman, 1967, 1968a, b) which focused
on a factor produced by T lymphocytes following antigenic or mitogenic stimulation.
The relationship of LT with TNF/cachectin was only determined after complete
sequencing of the molecule (Pennica et al., 1984, Gray et al., 1984). It now appears
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that much of the biological activity originally attributable to T cell LT was probably
derived mostly from TNFa, however it only became apparent subsequently that T
cells, as well as macrophages, produced TNFa (Kinkhabwala et al., 1990).
LT and TNFa share about 30% homology in their primary amino acid sequence; of
greater significance is the observation that these regions of sequence homology allow
for similarity in the tertiary and quaternary structure of the two molecules (Pennica et
al., 1984). LT, like TNFa, forms a trimeric structure (Eck et al., 1992) and is
sufficiently structurally conserved to bind to the same receptors as TNFa (TNFR55
and TNFR75; section 1.3.6) with similar affinity (Loetscher et al., 1991), although
the cellular response to this binding appears different (Schuchmann et al., 1995).
While LT lacks a hydrophobic transmembrane domain and is entirely secreted
(section 1.3.8), membrane LT has been detected on the surface of activated B and T
cells as well as T cell hybridomas, but in association with a 33 kDa glycoprotein
(Ware et al., 1992, Browning et al., 1991) identified subsequently as a member of the
TNF/NGF receptor family ligands (section 1.3.7) and named LTp; thus the original
LT is now known as LTa. The three related proteins are now universally referred to
as TNFa, LTa and LTp.
1.3.2 Source and structure of TNFa
The human TNFa gene is located on the short arm of chromosome 6 within the Class
III locus of the major histocompatibility complex (MHC) genes (Nedwin et al.,
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1985). About 70% of the amino acid sequence of TNFa was found to be conserved
when TNFa from nine mammalian species were compared. TNFa is expressed as a
26 kDa pre-peptide which is proteolytically cleaved to release the 17 kDa mature
protein of 157 amino acid residues from the cell surface (Kreigler et al., 1988). The
membrane-bound disintegrin metalloproteinase that processes precursor TNFa has
now been cloned and named TACE (for 'TNFa-converting enzyme'; Moss et al.,
1997). Both the secreted 17 kDa protein and the 26 kDa pre-peptide spontaneously
trimerize and form the bioactive ligand (Smith and Baglioni,, 1987). The three-
dimensional structure of the trimer has been determined (Eck et al., 1988) and a
model of ligand-receptor interaction deduced (Eck et al., 1992).
Mainly for historical and technical reasons, active TNFa was (and still is by some)
considered to act mostly as a (secreted) soluble protein, however this view is now
changing. Treatment ofmice with a metalloprotease inhibitor protected the animals
injected with a lethal dose of LPS from endotoxic shock (Mohler et al., 1994) which
suggests that it is secreted, not membrane-bound TNFa (mTNFa) that is the key
player in this pathological process. By 1988, mutant cell lines unable to secrete
TNFa were described and in this context, mTNFa proved to be as active as the
soluble forms in terms of cytotoxicity and anti-tumour activity (Kriegler et al., 1988,
Perez et al., 1990). Moreover, mTNFa has recently been demonstrated to have a pro-
apoptotic effect on WEHI 164 cells (Monastra et al., 1996). Another report has
demonstrated that engagement of TNFR55 and TNFR75 by mTNFa under cell-cell
contact conditions is able to trigger much more dynamic and perhaps qualitatively
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different effects than secreted TNFa and the authors suggest that the mTNFa may be
the prime activating ligand of TNFR75 (Grell et al., 1995). Taken together, these
findings suggest that secreted TNFa may only be observed under exceptional
physiological or pathophysiological conditions, perhaps triggered under
circumstances such as in massive bacteraemia, while mTNFa may play a more
important physiological role at much lower concentrations and be under careful
regulation at the levels of transcription, translation and secretion.
TNFa is produced principally by monocytes and macrophages in response to LPS,
however other sources of this cytokine include lymphocytes, fibroblasts, mast cells
and even neutrophils themselves (Dubravev et al., 1987). TNFa biosynthesis is
regulated at two levels, transcription and translation, which work in concert with
each other. The activation ofmacrophages by LPS causes a 50-fold increase in
TNFa messenger RNA and a 100-fold increase in translational efficiency. As a
result, the corresponding rate of TNFa protein production can increase by a factor of
several thousand. TNFa acts in concert with various other cytokines, in particular, its
activity parallels closely that of the interleukins IL-1 and IL-6.
1.3.3 The biological role of TNFa
TNFa plays a critically important role in mediating a number of physiological
immune events, including temperature regulation, bone and cartilage remodeling,
haematopoiesis and the regulation of extracellular matrix production. In addition,
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TNFa represents an integral component of normal host defense as it augments
immune cell antimicrobial, antiviral and tumouricidal activity, enhances neutrophil
adherence to endothelium, and is crucial to granuloma formation in response to
intracellular pathogens. Moreover, TNFa serves as a major host-derived inducer of
other bioactive mediators, including chemotactic and activating polypeptides and
lipids, and can further amplify its own biological effects by acting in an autocrine or
paracrine manner to stimulate secretion of additional TNFa from immune or non¬
immune cells. Flence, TNFa displays a broad spectrum of biological activities.
Many aspects of TNFa as a mediator of inflammation have been attributed to its
ability to influence neutrophil function. TNFa serves to upregulate many neutrophil
activities including priming for enhanced responsiveness to secretagogue agonists
(Klebanoff et ah, 1986, Shalaby et ah, 1985, Atkinson et ah, 1988), promotion of
adherence to endothelial cells and surfaces coated with extracellular matrix proteins
(Gamble et ah, 1985, Dri et ah, 1991, Thompson and Matsushima, 1992), inhibition
of chemotactic responsiveness to fMLP (Atkinson et ah, 1988), stimulation of
phagocytosis in response to both opsonized and unopsonized zymosan (Shalaby et
ah, 1985, Klebanoff et ah, 1986) and enhancement of zymosan-induced LTB4 release
(Petersen et ah, 1990). In addition, TNFa causes direct triggering of degranulation
and respiratory burst activity in adherent cells (Nathan, 1987, Richter et ah, 1989,
Nathan et ah, 1989, Dri et ah, 1991).
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1.3.4 The role of TNFa in disease
As a result of the high toxicity of TNFa in animals and humans this cytokine did not
fulfill initial expectations that it may prove to be of benefit in the treatment of cancer.
The tumouricidal action of TNFa is complex and may be direct or mediated through
its effects on endothelium and immune effector cells, depending on the system (Fiers,
1993). The haemorrhagic necrosis of tumours by TNFa results in part from the
activation of endothelium and consequent pro-coagulation effects (Bevilacqua et al.,
1986). The activation of neutrophils, monocytes, and lymphocytes (NK cells) can
also contribute to the anti-tumour effect of TNFa. However, stimulation of these
immunoregulatory cells and endothelium also leads to marked pro-inflammatory
effects which have been manifested in human clinical trials by fever, dose-limiting
hypotension, hepatotoxicity, pulmonary oedema, thrombocytopenia, intravascular
thrombosis and haemorrhage (Hauser et ah, 1990, Kilbourn et ah, 1990, Van Der Poll
et ah, 1992, Van Ostade et ah, 1993). It is these pro-inflammatory side effects which
have severely limited the use of systemically administered TNFa in patients with
malignancy (Jones and Selby, 1989, Taguchi and Sohmura, 1991).
Although TNFa is vital to the maintenance of immune homeostasis, the beneficial
effects of this cytokine usually predominate when small immunologically active
amounts are produced in tissues during host defense (Tracey et al., 1989). In
contrast, the over zealous production of TNFa can trigger circulatory shock and
severe tissue injury (Tracey et al., 1989, Tracey, 1992). Numerous studies have
demonstrated that TNFa mediates many of the pathological events induced by
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endotoxin which culminate in cardiovascular collapse; these include hypotension,
intravascular thrombosis, and severe pulmonary oedema and haemorrhage (Remick
et al., 1990) all ofwhich can be prevented by prophylactic administration of anti-
TNFa antibodies (Tracey et ah, 1987). Dysregulated TNFa activity has now been












Hypotension and tissue injury
Increased lung permeability
Cerebral inflammation and infarction
Tissue injury and renal failure
Inflammation and acute phase responses
Beta cell cytotoxicity
Activation of latent infection
Anaemia and whole-body protein loss
(cachexia)
Table 1.3.4 Diseases in which dysregulated TNFa activity has been implicated
(Adapted from Tracey, 1995)
It is now well established that inter-individual variation exists with respect to TNFa
production by peripheral blood mononuclear cells isolated from normal volunteers
(Molvig et al., 1988), and such differences have been genetically linked to HLA type
and to other polymorphic markers. Of interest, a recent study demonstrated that
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possession of a genetic variant in the. promoter of the TNFa gene (termed the TNF2
allele), which is associated with higher constitutive and inducible concentrations of
TNFa transcription, conferred increased susceptibility for the development of
cerebral malaria following Plasmodium falciparum infection and altered the clinical
outcome of this disease (McGuire et al., 1994). These observations suggest that a
predisposition to increased TNFa production may be associated with the
development of diabetes, systemic lupus erythematosus, and other autoimmune
disorders (Picot et al., 1993, Jacob et al., 1990)
1.3.5 TNFa-mediated cytotoxicity
Although TNFa exerts pleiotropic effects on a wide variety of cell types, much
attention has focused on its cytotoxic activities on malignant cell lines, and, while
this may not represent the major activity of TNFa in vivo, this effect has certainly
become a major hallmark of this cytokine. The biological activity of TNFa is usually
assayed on the basis of its cytotoxic capacity; the classical cell line for testing TNFa
is the fibrosarcoma L929 cell or the WEHI 164 cl 13 cell line (Ruff and Gifford,
1981, Espevik and Nissen-Meyer, 1986). Cells can die in at least two ways, either by
apoptosis or by necrosis/lysis. In the case of these cell lines, TNFa leads to rapid
lysis. To measure the titre of TNFa in solution, dilutions are added to cell
monolayers in microtitre plates and after a few days the surviving cells which
escaped lysis are quantified colorimetrically (Tada et al., 1986). There is likewise
much research interest in the signalling mechanisms regulating ability of TNFa along
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with other nerve growth factor (NGF)/TNF receptor family ligands (section 1.3.8) to
induce apoptosis in a variety of cells in particular T-lymphocytes (Zheng et al., 1995)
and HL-60 cells (Obeid et al., 1993).
1.3.6 TNF receptors
The wide range of TNFa activities is explained by the presence of TNF receptors
(TNFRs) on almost all nucleated cell types. Two distinct receptor subtypes for
TNFa with molecular masses of 55 kD (TNFR55) and 75 kD (TNFR75) have been
identified (Hohmann et al., 1990, Brockhaus et al., 1990), and human and mouse
cDNAs corresponding to both receptor types have been isolated and characterized
(Loetscher et al., 1990, Schall et al., 1990, Smith et al., 1990, Lewis et al., 1991,
Goodwin et al., 1991). The Kd values of TNFa for TNFR55 and TNFR75 are
approximately 0.5 nM and 0.1 nM respectively (Loetscher et al., 1990, Schall et al.,
1990, Smith et al., 1990). Of interest, human TNFa only reacts with the murine
TNFR55 and not the TNFR75. TNFR55 is found on almost all cell types whereas
TNFR75 is often more abundant on cells of haematopoietic lineage (Hohmann et al.,
1989, Brockhaus et al., 1990, Porteu et al., 1991) and is also expressed on
endothelium (Hohmann et al., 1990, Shalaby et al., 1990, Mackay et al., 1993). The
extracellular domains of the two human TNFRs are 28% identical and have no more
homology to each other than the other members of the NGF/TNF receptor
superfamily (section 1.3.7). Likewise, there is no significant homology between the
intracellular domains of the two TNFRs, indicating that these receptors almost
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certainly employ different signalling mechanisms (Lewis et al., 1991). TNFR55
contains a classical 'death-domain' sequence (Tartaglia et ah, 1993a) and has been
reported to be the sole mediator of the TNFa-mediated death signal in most non-
haematopoietic cell types (section 1.3.7). Despite this, the TNFR75, which lacks
such a death domain sequence, has been proposed to play the key role in mediating
TNFa-induced cytotoxicity in murine CD8+ peripheral T-cells (Zheng et al., 1995).
TNFa activates the TNFRs by inducing receptor aggregation mediated through the
trimeric nature of the ligand; after binding the TNFa-receptor complex is internalized
and degraded, as there is no recycling. The time course of events after TNFa binds
with its receptor have been followed using gold-particle labeled TNFa (Mosselmans
et al., 1988). The TNFa-TNFR complexes are internalized via clatherin-coated pits
(maximum reached at 5 min), move to endosomes (maximum at 15 min), and then to
multivesicle bodies (maximum at 30 min), and finally end up in the secondary
lysosomes, where they are degraded. The ability of TNFR-specific agonistic
antibodies to mimic TNFa activities is evidence that the sole function of TNFa is
clustering of its receptors and that no additional activities of this cytokine are
required after the ligand-receptor complex is internalized (Espevik et al., 1990).
Both TNFR55 and TNFR75 have now been targeted and deleted in 'gene knockout'
mice models; genetically engineered mice lacking the TNFR55 receptor are
moderately resistant to the lethal effects of LPS but highly susceptible to infection by
Listeria monocytogenes (Pfeffer et al., 1993, Rothe et al., 1993) while mice lacking
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the TNFR75 are moderately resistant to the lethal effect of TNFa itself and to dermal
necrosis evoked by repeated intradermal TNFa injections (Erickson et ah, 1994).
Animals lacking both TNFR55 and TNFR75 genes have the sum of these phenotypic
effects but no gross developmental defects, thus consistent with the distinct structures
of their cytoplasmic domains, the two TNFRs appear to fulfill different in vivo
functions. Of interest, deletion of both the TNFa and LTa genes, which eliminates
the only ligands known to interact with the two receptors, does not yield the same
phenotype as deletion of both receptors. On the contrary, mice in which the LTa
gene has been deleted, either alone or in combination with the TNFa gene, have no
lymph nodes and Peyer's patches and no splenic white pulp with the thymus grossly
preserved (De Togni et al., 1994).
The absolute number of TNFRs on human neutrophils is rather low, falling within
the range of 500-6000 (Shalaby et al., 1987, Larrick et al., 1987, Schleiffenbaum and
Fehr, 1990, Porteu and Nathan, 1990). Both TNFR55 and TNFR75 can be
proteolytically cleaved from the cell surface and thus form soluble TNFa binding
proteins (TNF-BPs), designated TNFR55-BP and TNFR75-BP, which retain their
ability to bind TNFa with high affinity (Olsson et al., 1989, Seckinger et al., 1989,
Engelmann et al., 1989). Several studies have now detected soluble binding proteins
in the urine from febrile patients (Seckinger et al., 1988), in serum and urine from
patients with renal insufficiency (Peetre et al., 1988), in normal urine (Engelmann et
al., 1989), and in the serum ultra-filtrates from patients with advanced cancer
(Gatanaga et al., 1990).
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These TNF-BPs could be assayed on the basis of their interference with the cytolytic
action of TNFa on target cells.
Neutrophils release TNF-BPs in response to both physiological and pharmacological
stimuli including LPS, fMLP, the calcium ionophore A23187 and PMA (Porteau and
Nathan, 1990, Lantz et ah, 1994, van der Poll et ah, 1995), while TNFa itself appears
to regulate the expression of its receptors by inducing selective shedding of TNFR75
and internalization of TNFR55 (Porteu and Hieblot, 1994). In addition, adherence of
neutrophils to a biological surface alone, without any additional stimuli, has been
demonstrated to be sufficient to induce release of TNFR55-BP and TNFR75-BP
from these cells (Lantz et al., 1994).
The release of TNF-BPs from neutrophils is accompanied by a decrease in TNFa
binding to the cell surface (Porteau and Nathan, 1990) which correlates to a decrease
in neutrophil responses to TNFa (Schleiffenbaum and Fehr, 1990) suggesting that
TNF-BP release may represent a deactivation mechanism whereby the organism
protects itself against an over-stimulation of these cells (Porteau and Nathan, 1990,
Schleiffenbaum and Fehr, 1990).
The major function of the TNF-BPs in vivo appears to be to modulate the availability
of biologically active TNFa; there is inhibition by competitive binding of the ligand,
but such an interaction may also stabilize TNFa in a complex with TNF-BPs thereby
acting as a reservoir of free and biologically active TNFa (Aderka et al., 1992).
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1.3.7 NGF/TNF receptor superfamily
TNFR55 and TNFR75 are members of a superfamily of receptors referred to as the
(low-affinity) NGF/TNF receptor family which are characterized by functional
trimerization and the presence of one to six cysteine-rich repeats of approximately 40
amino acids in the extracellular domain that provide the motif for binding to shared
structures in the ligands (Mallet and Barclay, 1991, Smith et ah, 1994) as illustrated
in figure 1.3.7. These receptors are widely distributed and serve co-stimulatory
and/or apoptosis-inducing functions, primarily in the immune system, but also in
many somatic tissues. The induction of apoptosis is most pronounced in those
receptors that contain a conserved sequence in the cytoplasmic region referred to as
the death domain (Tartaglia et ah, 1993a, Nagata and Goldstein, 1995, Chinnaiyan et
ah, 1996b, Kitson et ah, 1996, Marsters et al., 1996, Bodmer et al., 1997), a
homologous region that allows physical association with a number of effector
molecules via structurally similar death domain homology motifs.
Members of the low affinity-NGF/TNF family with intracellular death domains are
TNFR55 (Loetscher et al., 1990, Smith et al., 1990), Fas/Apo-l/CD95 (Itoh et al.,
1991, Oehm et al., 1992) and the very recently identified receptor WSL-
l/TRAMP/Apo-3/DR3 (death domain containing receptor 3) which is closely related
to TNFR55 but whose ligand remains uncertain (Chinnaiyan et al., 1996, Kitson et




Although several other members of the NGF/TNF receptor superfamily lack
intracellular death domains and conventionally provide a stimulatory or co-
stimulatory signal for growth/proliferation, growing evidence suggests that TNFR75,
CD40, and the LTp receptor, which binds the complex between LTa and LTp, can
also trigger cell death (Bigda et ah, 1994, Rabizadeh and Bredesen, 1994, Hess and
Englemann, 1996, Zheng et ah, 1995, VanArsdale et ah, 1997). Similarly, death
domain containing receptors can also provide stimulatory or co-stimulatory signals
under alternative conditions that relate to the position of the cell in the cell cycle or,
depending on the cell type, its activation state. Likewise, excessive signalling
through some of these receptors can induce severe inflammatory reactions including
tissue injury and shock. Mutations of the genes coding certain of these receptors or
their respective ligands can cause characteristic disturbances of lymphocytes,
derangement of the immune system or autoimmune disease.
1.3.8 NGF/TNF receptor family ligands
All of the ligands of the NGF/TNF receptor family recognize their receptors through
a shared structure composed of anti-parallel P-strands arranged to form a 'jelly-roll
P-sandwich'. The structural similarity of the ligands are reflected in their similar
mechanisms of receptor recognition and activation. All members of the TNFa ligand
family occur and act in homotrimeric forms (with the exception of the heterotrimeric
LTp which exists as a single LTa and two LTp subunits) stabilized primarily by
hydrophobic interactions, allowing each trimeric molecule to bind and aggregate
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multiple receptors leading to a spatially close transmembrane cluster of cytoplasmic
domains; this is thought to provide an intracellular binding site(s) for proteins that
serve as the effector molecules that activate the corresponding signalling pathways.
Indeed, all NGF/TNF family members are activated as a result ofjuxtaposition of
several receptors and can thus be artificially triggered by cross-linking with
antibodies. Of note, while the NGF receptor protein was actually the first family
member to be identified (Johnson et al., 1986), its low-affinity dimeric ligand is
structurally unrelated to the other ligands and is therefore not included as a member
of the ligand superfamily.
The TNF family of ligands act not only as soluble molecules, but also when still
associated with the surface of their producing cells. Most of these ligands are
produced as type II transmembrane cell surface proteins with the C-terminus on the
outer cell surface, a single transmembrane domain, and a short cytoplasmic tail;
soluble forms are derived proteolytically. Recently, it was shown that LTa is an
exception; although the homotrimer lacks a transmembrane domain and hence is
exclusively secreted, the transmembrane domain of LT(3 serves to anchor a LTa
subunit to the cell surface in the form of a LTaP complex (Browning et al., 1991,
Ware et al., 1992). There is no evidence to suggest that the LTaP complex is
secreted. This suggests that the mode of signal transmission will depend upon cell-
to-cell contact and the effects of the ligand will be restricted to the individual target
cell in intimate contact with the ligand-producing cell. The ligands for the
NGF/TNFR family which are currently known are summarized in table 1.3.8.
46
RECEPTOR LIGAND




LT(3R (Crowe et al., 1994) LTa/p-heterotrimers
CD40 (Stamenkovie et al., 1989) CD40L gp39 (Armitage et al., 1992)
CD30 (Durkop et al., 1992) CD30L (see Gruss et al., 1994)
CD27 (Camerini et al., 1991) CD27L (Goodwin et al., 1993a)
ILA/4-1BB (Kwon and Weissman, 1989, 4-1BBL (Goodwin et al., 1993b)
Schwartz et al., 1993)
WSL-1 /TRAMP/DR3/Apo-3 TRAIL? (Wiley et al., 1995)
Table 1.3.8 The NGF/TNF receptor family ligands
(mTNFa, membrane-associated TNFa; sTNFa, soluble TNFa; ILA, inducible
lymphocyte activator; TRAMP, tyrosine-rich acidic matrix protein; DR3, death
domain-containing receptor-3; TRAIL, TNF-related apoptosis-inducing ligand).
1.3.9 Signalling pathways involved in TNFa-mediated apoptosis
Exposure ofmost cells to TNFa results in activation of two transcription factors, AP-
1 (Brenner et al., 1989) and NFkB (Osborn et al., 1989) which mediate induction of
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cytokine and immunoregulatory genes, as well as metalloproteinases. NFkB is
comprised of a homo- or heterodimer ofDNA-binding proteins related to the proto-
oncogene c-Rel and in most cells exists in a latent (inactive) state in the cytoplasm
bound to inhibitory proteins (collectively called IkB) that mask its nuclear
localization signal. Activation ofNFkB by cytokines such as TNFa and IL-1 is
mediated by induction of phosphorylation of IkB which leads to subsequent
degradation by proteasomes (reviewed by Miyamoto and Verma, 1995). A cytokine-
activated protein kinase complex named IKK (for 'IkB kinase') has recently been
purified and cloned (DiDonato et al., 1997).
Several second messengers have been proposed to mediate the biological effects of
TNFR ligation, including various phospholipid breakdown products, arachidonic acid
2+
metabolites, free radicals, and increased intracellular Ca (reviewed by Beyaert and
Fiers, 1994). However, as highlighted in this latter report, it is not clear whether
these candidates are true second messengers or secondary effects of TNFR activation.
Several protein kinases have been found to be rapidly activated in response to TNFa,
including the as yet unidentified ceramide-activated kinase (Weigmann et al., 1994),
IkB kinase (DiDonato et al., 1996), and a TNFR55-associated serine/threonine kinase
(VanArsdale and Ware, 1994), as well as Raf-1 (Belka et al., 1995), Jun N-terminal
kinases (JNKs; Minden et al., 1994), and p38/Mpk2 (Raingeaud et al., 1995).
Activation of IkB kinase results in NFkB activation (Verma et al., 1995, DiDonato et
al., 1996), while Raf-1, JNK and p38/Mpk2 activation contribute to induction ofAP-
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1 activity (Karin, 1995); however the pathways by which TNFR ligation induces
activation of these protein kinases remains to be clarified.
The potential role of ceramide as a mediator of TNFa signalling has recently received
much attention (figure 1.3.9A). TNFa-induced phospholipid hydrolysis can result in
ceramide production (Kolesnick and Golde, 1994), and endogenous ceramide has
been shown to lead to activation ofNFkB (Weigmann et ah, 1994) and JNK (Verheij
et ah, 1996) and to induce apoptosis in leukaemic cell lines (Obeid et ah, 1993, Jarvis
et ah, 1994). It has also been proposed however that ceramide generation may be a
consequence of, rather than a trigger for, TNFa-induced cell death (Beyaert and
Fiers, 1994).
The identification of protein molecules that are recruited to TNFR55 and TNFR75
following ligand-induced trimerization (Rothe et ah, 1994, 1995a, Hsu et ah, 1995)
represented a major advance in understanding the early events in TNFa signalling
(figure 1.3.9B). To date, much of the knowledge of these proteins and their function
has been gained indirectly, for example by two-hybrid analysis of their interactive
properties in transfected yeast, or by assessment of their interactions when expressed
in transfected cells at supra-physiological levels and therefore the physiological
relevance of these observations must therefore be carefully evaluated.
Activation of TNFR55 leads to recruitment of the TNFR55-associated death domain







candidate direct PKC CAPP CAPK
targets:
downstream effectors: NFkB c-Myc PLD
biology: differentiation cell-cycle arrest apoptosis
Figure 1.3.9A Proposed scheme for the role of the sphingomyelin (SM) cycle in
signal transduction and the role of ceramide as a candidate second messenger.
Activation of TNFR55 results in activation of sphingomyelinase (SMase) to give rise
to hydrolysis of membrane sphingomyelin (SM) and the generation ofmembrane
ceramide. Ceramide, in turn, appears to modulate the activity of several targets,
including protein kinase C isozyme ^ (PKCt;), ceramide-activated protein
phosphatase (CAPP) and ceramide-activated protein kinase (CAPK). These (or other
targets) then couple the action of ceramide to intracellular events, such as the
activation ofNFkB, activation of the retinoblastoma gene product (Rb), regulation of
c-Myc expression, induction of cycloxygenase (Cox) and inhibition of phospholipase
D (PLD). Importantly, the ultimate effect of generating ceramide appears to be
closely related to the induction of differentiation, cell-cycle arrest, or apoptosis.
These distinct biological programs appear to be cell-type dependent and are
modulated by the activation of other signal transduction pathways such as the 1,2-
diacylglycerol (DAG)/PKC pathway. (Adapted from Pushkavera et al., 1995).
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Fas TNFR55 TNFR75
Figure 3.1.9B Schematic illustration of protein molecules recruited following
ligand-induced trimerization of TNFR55, TNFR75 or Fas
Induction of apoptosis occurs by recruitment of caspase 8, and possibly also caspase
2, to the receptors through protein-protein interactions that involve homophilic
binding of death domain and caspase pro-domain motifs. Cellular resistance to
TNFa-stimulated cytotoxicity involves synthesis of protective proteins via the
transcription factor NFkB. Activation ofNFkB involves the adapter proteins TRAF
and the serine/threonine kinase NIK. Motifs indicated in the figure are: the cysteine-
rich extracellular-domain motif that defines the NGF/TNF superfamily members
(yellow); the death domain (blue); the death effector domain, or 'MORT' domain
(the caspase 8 pro-domain motif; purple); the ICE/CED3 protease sequence motif
(green); TRAF2 carboxyl terminus (light pink); TRAF2 amino terminus (dark pink);
serine/threonine kinase motif (pink outline). (Adapted from Wallach, 1996).
TNFR75 results in the recruitment of TNFR-associated proteins 1 and 2 (TRAF1 and
TRAF2; Rothe et al., 1994). Recently TRADD was demonstrated to interact directly
with TRAF2 and Fas-associated protein with death domain (FADD; Hsu et ah,
1996a). The recruitment of TRAF2 to TNFR55 and TNFR75 may explain why both
receptor subtypes can signal overlapping responses despite a lack of homology in
their cytoplasmic domains. Indeed, TRAF2 appears to mediate both TNFR55 and
TNFR75-induced activation ofNFkB as well as that related to CD40 receptor
stimulation (Rothe et ah, 1995b, Hsu et ah, 1996a).
FADD, which is also referred to as MORT1 (for 'mediator of receptor-induced
cytotoxicity-1'), was originally identified as a protein which interacts with the
cytoplasmic domain of Fas (Boldin et ah, 1995, Chinnaiyan et ah, 1995) and is
structurally related to the cytoplasmic domain of TNFR55 (Itoh and Nagata, 1993,
Tartaglia et ah, 1993a and b). The death domain present in the cytoplasmic regions
of both these receptors mediates protein-protein interactions with other death-domain
containing proteins such as TRADD and FADD. Another death domain protein is
the serine/threonine protein kinase RIP (for 'receptor-interacting protein'; Stanger et
al., 1995, Hsu et ah, 1996b) which was again originally identified by its interaction
with Fas (Stranger et al., 1995) and has recently been shown to be recruited to the
TNFR55 signalling complex via TRADD and to participate in NFkB activation (Hsu
et al., 1996b). Studies using dominant-negative mutants have suggested that
TRADD is required for TNFR55-mediated apoptosis (Hsu et al., 1996a and b) and
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that expression of both TRADD and RIP death domains is sufficient to activate this
process (Hsu et al., 1995, Hsu et ah, 1996b, Stanger et ah, 1995).
Recruitment of FADD also appears to be necessary for induction of apoptosis by
TNFR55, however deletion analysis has revealed that, unlike with TRADD and RIP,
this activity is mediated by a 'death effector domain' in the N-terminal portion of the
molecule rather than its death domain (Chinnaiyan et al., 1995, Hsu et al., 1996a),
which has paradoxically been shown to block TNFa-stimulated apoptosis (Hsu et al.,
1996a, Chinnaiyan et al., 1996b). Recently, a new protein associated with the Fas-
FADD and TNFR55-TRADD-FADD receptor complex has been identified which
was initially named MACH (for 'MORT1-associating CED homologue'; Boldin et
al., 1996), FLICE (for 'FADD-like interleukin-ip converting enzyme', ICE; Muzio
et al., 1996) or Mch5 (Fernandes-Alnemri et al., 1996), and is now referred to as
caspase-8 (Alnemri et al., 1996) and hence is a direct activator of the protease
apoptotic cascade. The term 'caspase' was proposed to provide a unifying
nomenclature for the continuously increasing list ofmembers of the family of ICE-
related proteases; the 'c' denotes the presence of cysteine at the active site, while the
'as-pase' denotes the principle cleavage activity adjacent to aspartate residues (asp-)
and the number refers to the order of publication of the corresponding cDNAs
(Alnemri et al., 1996).
Caspase-8 possess two motifs near its N-terminus that associate with the death
effector domain of FADD which are linked to a C-terminal extension that encodes a
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novel caspase. It is not clear whether caspase-8 activation following Fas or TNFR55
ligation is dependent on its proteolytic processing, either by its own activity or
through effects of other proteases, or whether it occurs simply by interdigitation of
several protease molecules following the binding of their pro-domains to FADD.
There is evidence however, for processing of various other caspases subsequent to
caspase-8 recruitment (Boldin et ah, 1996, Muzio et ah, 1996) which is most likely
mediated by caspase-8 itself (Srinivasula et ah, 1996). Thus, caspase-8 appears to be
the first direct link between signalling events at the plasma membrane level and
engagement of the apoptotic machinery.
The cellular targets for caspase-8 remain to be identified, however one possibility is
that this enzyme may initiate a proteolytic cascade that leads to increased
mitochondrial permeability transition. The importance of the mitochondria as a
critical regulatory component in many forms of the apoptotic effector pathway has
recently emerged (Zamzami et al., 1996a and b, Susin et al., 1997) as evidence
accumulates to suggest that such a change in mitochondrial permeability is a critical
event integrating signalling inputs from varying pro-apoptotic stimuli and co¬
ordinates the degradative processes that result in cell death. Mitochondria undergo
permeability transition as a result of the formation ofmitochondrial mega channels,
(Zamzani et al., 1995), releasing both cytochrome C (Kluck et al., 1997) and AIF
(apoptosis inducing factor; Susin et al., 1997). While the function ofAIF remains to
be firmly established, there is evidence to indicate that cytochrome C is necessary for
activation of caspase-3. The release of cytochrome C from mitochondria is blocked
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by the proto-oncogene product Bcl-2 which appears to associate with and stabilize
the outer mitochondrial membrane, attenuating mitochondrial permeability transition.
The most recent discovery of a death adapter protein RAIDD suggested an additional
possible route TNFR55 or Fas ligation-mediated caspase activation. This protein
contains a C-terminal death domain that binds to the death domain ofRIP and also
contains an amino-terminal sequence homologous to that of the pro-domain of
caspase-2 (ICH-1). RAIDD can bind caspase-2 and recruit it to TNFR55 through
sequential interactions ofRAIDD, RIP, TRADD and TNFR55, however the
contribution of this pathway to TNFR55 and Fas-mediated cytotoxicity is still
unknown (Duan and Dixit, 1997).
Exposure of cells which under normal conditions are resistant to TNFR55-mediated
cytotoxicity to protein synthesis inhibitors can render them vulnerable to the
cytocidal effects of this cytokine. These data have been taken to imply that TNFa
may induce synthesis of a protein(s) which protects a cell from its own cytotoxic
effect (Hahn et al., 1985). A major advance in understanding this cellular self-
control mechanism was the discovery that deliberate activation ofNFkB can protect
cells against TNFa-mediated cytotoxicity and that by contrast, inhibition ofNFkB
activation can increase the sensitivity of TNFa-induced apoptosis (Beg and
Baltimore, 1996, Wang et al., 1996, Van Antwerp et al., 1996, Liu et al., 1996).
These observations point to NFkB as an important route of induction of anti-
apoptotic protective proteins. Of interest, IL-1, which despite binding to a distinct
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receptor, shares many of the pro-inflammatory activities of TNFcc, and PKC-
activating agents, both stimulate NFkB and enhance cellular resistance to TNFa-
mediated cytotoxicity (Holtmann and Wallach, 1987).
A serine/threonine protein kinase, NIK (for NFicB-inducing kinase), which binds to
TRAF2 and activates NFkB has been recently cloned and appears to be an essential
component of the NFKB-activating cascade involving TNFa and IL-1. NIK shows
high sequence homology to several kinases that signal within mitogen-activated
protein kinase (MAPK) cascades, specifically those that act as MAPKKKs, and
hence might function in a similar capacity to regulate NFkB. Over-expression of
NIK in cells has been shown to increase their resistance to the TNFa-mediated
cytotoxicity, whereas kinase-deficient mutants display increased TNFa sensitivity
(Malinin et ah, 1997).
Another component of the receptor-TRAF signally complex has very recently been
cloned and named TRIP (for 'TRAF-interacting protein'; Lee et ah, 1997). TRIP
associates with the TNFR75 (or CD30) signalling complex through its interaction
with TRAF proteins; when associated, TRIP inhibits the TRAF-2 mediated NFkB
activation that is required for cell activation, and protection against apoptosis thus
acting as a receptor-proximal regulator.
56
1.4 Aims
The major aim of the work carried out for this thesis was to determine and
characterize the precise effect of TNFa on regulating neutrophil apoptosis in vitro.
Having demonstrated that this cytokine acts in a unique way to enhance the rate of
constitutive neutrophil apoptosis at early times (6 hr) while inhibiting apoptosis at
more delayed times (>12 hr) the receptor subtype-dependency and regulation of these
events were studied and the potential intracellular effector mediators explored.
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Chapter 2: Materials and methods
2.1 Materials
The following reagents were obtained from Gibco Life Technologies (Paisley,
Scotland, UK): Iscove's Dulbecco's modified Eagles medium, without supplement
with L-glutamine (Iscoves DMEM) and culture supplements Penicillin (50
U/ml)/Streptomycin (50 U/ml).
The following reagents were obtained from the Sigma Chemical Company (Poole,
Dorset, UK): sterile, endotoxin-free Dulbecco's phosphate buffered saline, (PBS), pH
7.4 and PBS with 1.2 mM Ca2+ and 0.8 mM Mg2+, pH 7.4; dextran-500 (molecular
weight 500) was dissolved in sterile 0.9% saline (6% w/v) and stored at 4°C);
dimethyl sulfoxide (DMSO); fetal calf serum; trypan blue; propidium iodide;
proteinase K; neutral sphingomyelinase (from Bacillus cereus, 50 U/pl in 50%
glycerol/PBS, 50 mM Tris-HCl, pH 7.5); N6, 2'-0-dibutyryladenosine 3':5'
monophosphate (dibutyryl-cAMP) was dissolved in Iscove's MDM at 20 nM and
stored at -20°C; LPS (from E. Coli serotype OIILB4, y-irradiated) was dissolved in
PBS at 1 mg/ml, sonicated (ultrawave sonic bath, Belmont Instruments, Glasgow,
Scotland) for 10 min and stored at -20°C and individual aliquots were further
sonicated on thawing, immediately prior to use; cytochrome C (prepared from horse
heart) was stored at -20°C and dissolved in PBS pre-warmed to 37°C immediately
prior to use; superoxide dismutase (SOD) was dissolved in PBS at 7500 U/ml and
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stored at -20°C; PAF was dissolved in analar ethanol at 10 mM and stored at -80°C;
wortmannin (from Penicillium fumiculosum was dissolved at 10 mM in DMSO and
stored at -20°C; genestein was dissolved in DMSO at 100 mM and stored at -20°C,
A23187 was dissolved in DMSO at 10 mM and stored at 4°C; LTB4 was dissolved in
ethanol at 100 mg/ml and stored at -20°C; sphingosine (from bovine brain) was
dissolved at 15 ml in 95% ethanol/5% H202 and stored at -20oC; inositol
hexakisphosphate (InsP6, phytic acid, di-potassium salt) was dissolved immediately
prior to use at 1 mM in PBS with 25 mM HEPES (N-2-hydroxyethylpiperazine-N'-
ethane sulphonic acid, required to maintain pEl 7.0-7.4); fMLP was dissolved in
DMSO/PBS (5 mg fMLP in 70 pi DMSO made up to 11.35 ml with PBS) and stored
at 1 mM at -20°C;
The following reagents were obtained from Calbiochem-Novabiochem Ltd., Beeston,
Nottingham, UK: calyculin A was dissolved in ethanol at 1 mM and stored at -20°C;
N-[2-bromocinnamyl(amino)ethyl]-5-isoquinoline sulphonamide, HC1 (H-89,
dihydrochloride) was dissolved in ethanol at 5 mM and stored at -20°C; PD 098059
was dissolved in DMSO at 20 mM and stored at -20°C; Ro31-8220 was dissolved in
DMSO at 1 mM and stored at 4°C; tyrphostin AG 1288 was dissolved in DMSO at
10 mM and stored at -20°C; L-N5-(l-Iminoethyl) ornithine. Hydrochloride (L-NIO,
HC1) was dissolved in H202 at lOOmM and stored at -20°C; Ro20-1724 was dissolved
at 100 mM in DMSO and stored at -20°C;
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The following reagents were obtained from Genzyme Diagnostics, Kent, UK: rat
IgG2b anti-human TNFR75 mAb (1 mg/ml in PBS) was stored at 4°C; rat IgG2bK.lct
anti-human IL-2 receptor mAb (400 pg/ml in PBS) was stored at 4°C; GM-CSF
(1000 U/ml in PBS) was stored at -70°C.
The following reagents were obtained from R&D Systems Europe Ltd, Oxon, UK:
TNFa was dissolved in PBS at 10 pg/ml and stored at -80°C; IL-10 was dissolved in
PBS at lpg/ml and stored at -20°C; mouse IgG, anti-human TNFa neutralizing mAb
was dissolved in PBS at 500 pg/ml and stored at -70°C; mouse IgG, anti-human
TNFR55 mAb was dissolved in PBS at 500 pg/ml and stored at -20°C; goat IgG anti-
human TNFR55 agonist pAb was dissolved in PBS at 1 mg/ml and stored at -20°C.
Dexamethasone was purchased from David Bull Laboratories (Warwick, UK) and
stored at 4°C at a stock concentration of 8.3 mM; C2- and C6-ceramide (cell-
permeable ceramide analogues), from Matreya, Pleasant Gap, PA, USA, were
dissolved at 100 pM in ethanol and stored at -20°C; Diff-Quick stain [Solution I
(Eosin G in phosphate buffer, pH 6.0); Solution II (Thiazine blue in phosphate
buffer, pH 6.0] were from Baxter Healthcare Ltd., Glasgow, Scotland UK; Percoll
was from Pharmacia fine chemicals, Uppsala, Sweden; SB 203580 from SmithKline
Beecham, UK, was dissolved at 50 mM in DMSO and stored at -20°C.
All other chemicals were ofmolecular, reagent or cell culture grade and were




Human neutrophils were purified from the peripheral blood of healthy human
volunteers according to the method of Haslett et ah, (1985). Neutrophil isolation was
performed at room temperature, under sterile conditions and using endotoxin-free
reagents and plasticware (Falcon, Oxford, UK). Freshly drawn venous blood was
collected into 50 ml polypropylene tubes, anticoagulated (4 ml 3.8% sodium
citrate/36ml blood) and centrifuged (300g, 20 min). The platelet-rich plasma
supernatant was aspirated and centrifuged (2500g, 20 min) for production of platelet-
poor plasma (PPP) or used to prepare autologous serum in glass tubes by the addition
of CaCl2 (final concentration 20 pM) at 37°C. 5ml of 6% dextran (mol wt 500,000,
37°C) was added to pelleted cells from the initial centrifugation and 0.9% saline
(37°C) added to increase the volume to 50 ml per tube. The tubes were mixed gently
and allowed to stand for 30-40 min at room temperature until the majority of
erythrocytes had sedimented. The leukocyte-rich plasma was aspirated, centrifuged
(300g, 6 min), resuspended in 2 ml PPP and underlayered with 2 ml 42% followed
by 2 ml 51% plasma-Percoll (freshly prepared from 90% Percoll in 0.9% saline, and
PPP). The gradients were centrifuged (275g, 10 min) and polymorphonuclear cells
harvested from the 42%/51% Percoll interface. Mononuclear cells sedimented at the
PPP/42% Percoll interface. Purified cells were washed sequentially in 40 ml PPP, 40
ml Dulbecco's phosphate buffered saline (PBS), and 40 ml PBS with CaCl2 and
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MgCl2 and the cell concentration adjusted following haemocytometer counts. Cell
purity was assessed using May-Griinwald-Geimsa staining of methanol fixed
cytocentrifuge preparations (figure 2.2.1); mononuclear cell contamination was
routinely <0.1%.
The above density gradient centrifugation method does not separate neutrophilic
from eosinophilic or basophilic granulocytes, however harvested polymorphonuclear
cells generally consisted of <3% eosinophils, and basophils were rarely seen.
Preparations containing >5% eosinophils were discarded. Cell viability was assessed
by trypan blue exclusion and was routinely >99%. The typical yield for this isolation
method was 300-600x106 polymorphonuclear cells/240 ml whole blood.
2.2.2 Neutrophil culture
Freshly isolated neutrophils were routinely suspended at a density of 5xl06/ml in
Iscove's modified Dulbecco's medium (MDM) supplemented with 10% autologous
serum, 50 U/ml penicillin, and 50 U/ml streptomycin. Unless otherwise stated,
6.75x10"^ neutrophils were cultured in a final volume of 150 pi at 37°C in a
humidified 5% C02 atmosphere in flat-bottomed 96-well Falcon flexiwell plates
(Becton-Dickinson, UK) for the time periods indicated. Reagents to be examined in
this assay system were diluted to lOx the final concentration required in serum-
supplemented Iscove's MDM.
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Figure 2.2.2 May/Griinwald/Giemsa-stained cytospin preparation of human
neutrophils isolated on plasma/Percoll gradients
Freshly drawn, anticoagulated human blood was subjected to sedimentation with 6%
dextran prior to centrifugation through discontinuous 43%/51% plasma/Percoll
gradients exactly as described in 2.2. Polymorphonuclear cells were harvested from
the 42%/51 % interface and washed sequentially in PPP, calcium-free PBS and PBS
with calcium and magnesium. 100 p.1 of the resulting cell suspension (approximately
10 /ml) was spun (300g, 3 min) onto a glass slide by means of a centrifuge, and the
resulting cytoprep was stained with May-Grunwald-Giemsa.
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2.2.3 Assessment of neutrophil apoptosis
2.2.3a Assessment ofneutrophil apoptosis by morphological criteria
Neutrophil apoptosis was assessed morphologically according to the method of Savill
et ah, (1989a). Cells were gently re-suspended and 100 pi (approximately 5X105
neutrophils) harvested from each well, cytocentrifuged (300g, 3 min) and the
resulting slide preparations air dried, fixed and stained with May-Grtinwald-Giemsa.
Cell viability was assessed in parallel by trypan blue exclusion. Cell morphology
was examined by x 100 objective oil immersion light microscopy, and apoptotic
neutrophils defined as cells containing one or more darkly stained pyknotic nuclei
(figure 2.2.3a). For each condition examined, slides were prepared from triplicate
incubations and after coding, a total of at least 500 neutrophils were counted over a
minimum of five high power fields with the observer blinded to the assay conditions.
2.2.3b Assessment ofneutrophil apoptosis by propidium iodide staining
DNA fragmentation occuring during apoptosis was quantified by flow cytometric
analysis of permeabilised cells stained with the intercalating fluorescent dye
propidium iodide using a modification of the method ofNicoletti et ah, (1991). Cells
(4x105) were fixed in 100 pi ice-cold 70% ethanol at 4°C for 10 min, washed x3
(220g, 1 min) in PBS (4°C) and resuspended in 30 pi PBS and 30 pi RNAase (1
mg/ml). After gentle mixing, 60 pi of propidium iodide (100 pg/ml) was added and
the cells incubated in the dark at room temperature for 15 min; cells were stored
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Figure 2.2.3a Assessment of neutrophil apoptosis by morphological criteria
Human neutrophils were cultured in serum-supplemented Iscove's MDM for the time
period of interest; cells were resuspended and 100 pi (approximately 5x103)
neutrophils harvested from each well, cytocentrifuged (300g, 3 min) and the resulting
slide preparations air dried, fixed and stained with May-Grunwald-Giemsa. Cell
morphology was assessed by x 100 oil immersion light microscopy, and apoptotic
neutrophils defined as cells containing one or more darkly stained pyknotic nuclei
(example arrowed).
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overnight at 4°C prior to analysis using an EPICS Profile II (Coulter Electronics,
Luton, UK). Mean fluorescence values from a minimum of 5000 cells were
determined.
2.2.3c Assessment ofneutrophil apoptosis by chromatin fragmentation assay
Neutrophil DNA cleavage was assessed using a modification of a method previously
described for apoptotic lymphocytes (Trauth et al., 1989). Neutrophils were
harvested at varying times from culture, centrifuged (240g, 6 min), and resuspended
in 0.5 ml STE buffer (100 mM NaCl, 10 mM Tris, 1 mM EDTA, pEI 8.0) containing
1% sodium dodecyl sulphate (SDS) and 0.2 mg/ml proteinase K, and incubated
overnight at 37°C. Samples were extracted three times with chloroform: isoamyl
alcohol (24:1, v/v) and DNA precipitated with 2 volumes of ethanol and 0.1 volumes
NaCl overnight at -20°C. Following centrifugation (13,000g, 20 min, 4°C), the
remaining ethanol was allowed to evaporate at room temperature and the pellet
resuspended in TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM EDTA, pH 8.0)
and digested with 100 pg/ml ribonuclease at 37°C for 35 min. To each sample, 0.25
volumes of loading buffer (30% Ficoll 400, 0.25% bromophenol blue, 0.25% xylene
cyanol in TBE buffer) was added and the DNA electrophoresed in a 2% agarose gel
containing 75 pi ethidium bromide initially at 100V for 1 hr followed by 50V for 1
hr. In samples prepared from populations of cells containing significant numbers of
apoptotic neutrophils, electrophoresis showed a typical ladder pattern which is the
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biological hallmark of the endonuclease-dependent internucleosomal cleavage
associated with apoptosis (Wyllie, 1980).
2.2.4 Measurement of superoxide anion generation
The release of superoxide anion was determined by means of the superoxide
dismutase-inhibitable reduction of cytochrome c (see Kitchen et al., 1996b). Freshly
isolated neutrophils were re-suspended at 1 l.lxl06/ml in PBS containing CaCf and
MgCL, and 90 pi aliquots transferred to 2 ml round-bottomed polypropylene
Eppendorf tubes containing 10 pi TNFa (to give a final concentration of 0.05-50
ng/ml) or PBS (control), and placed in a Haake shaking water bath (100 cycles/min)
at 37°C. Each reaction was performed in quadruplicate. Samples were incubated in
the presence or absence of TNFa for 30 min at 37°C prior to the addition of 750 pi
freshly prepared cytochrome c (final concentration 1.2 mg/ml) to all samples and 50
pi of superoxide dismutase (20 pg/ml in PBS) to one sample in each quadruplicate.
After a final 15 min incubation with PBS or fMLP (100 nM), samples were placed on
ice and centrifuged (10,000g, 5 min, at 4°C). The optical density of the supematants
was determined using a spectrophotometer (Pye-Unicam 8700, Unicam Ltd,
Cambridge, UK) measuring peak height at 550 nm with the paired dismutase-
containing supernatants as reference. Superoxide release was calculated using the
extinction coefficient 21 x 103M"'.cm"' and expressed in nmoles released/106 cells.
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2.2.5 ELISA assay for TNFa
Extracellular immunoreactive human TNFa was quantified using a modification of
the double ligand method as previously described by Van Otteren et ah, (1995). Flat-
bottomed 96-well microtitre plates (Immulon 1, Dynatech) were coated with 100
pl/well mouse anti-human TNFa mAb (2.5 pg/ml in coating buffer, Dynatech) for 3
hr at 37°C and then washed with PBS (pH 7.5) containing 0.05% Tween-20 (PBS-
Tween-20). Microtitre plate-associated non-specific binding was blocked with
Dynatech blocking buffer (30 min, 37°C). The plates were washed four times (PBS-
Tween-20) and cell-free supernatants or TNFa standards (half-log dilutions of human
recombinant TNFa, from 7.8-500 pg/ml) were added in 100 pi aliquots in duplicate
and incubated for 16 hr at 4°C. The plates were washed four times (PBS-Tween-20),
followed by the addition of 100 pl/well rabbit polyclonal anti-human TNFa antibody
(1 pg/ml in assay diluent, Dynatech) and incubated for 3 hr at room temperature.
The plates were again washed, alkaline phosphatase conjugated donkey anti-rabbit
IgG added, and following a further incubation of 3 hr at room temperature, p-
nitrophenyl phosphate substrate added in 10% DEA buffer. The plates were then
read at 410 nm in an ELISA plate reader.
2.2.6 Flow cytometric analysis of TNFR55 and TNFR75 expression in human
neutrophils
Expression of TNFR55 and TNFR75 in human neutrophils was studied by indirect
immunofluorescence with primary antibody directed against TNFR55 or TNFR75
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and FITC-conjugated secondary antibody bound to the primary antibody detected
cytofluometrically.
Neutrophils were prepared, pre-incubated for 5 min with 1 pM PAF or buffer, and
then incubated (6.75x105 cells/150 pi Iscove's MDM containing 10 % autologous
serum) in flexiwell plates at 37°C as detailed in 2.2.2. At the appropriate time points
the cells were transferred to pre-chilled U-bottomed flexiwell plates (Becton-
Dickinson, UK), washed (220g, 1.5 min at 4°C) in 100 pi ice-cold was buffer (PBS
containing 0.2% BSA and 0.1% sodium azide) and resuspended in 40 pi of a
saturating concentration ofmouse anti-human TNFR55, TNFR75 (R&D Systems,
UK), or CD2 mAb as a negative control (UCHT-1 clone, IgGp SAPU, Carluke, UK).
After a 30 min period on ice the cells were washed twice and incubated with 40 pi
FITC-conjugated goat anti-mouse immunoglobulin (Dako, Buckinghamshire, UK;
diluted 1 in 40 with PBS/BSA/azide buffer). After washing, samples were analysed
using an EPICS Profile II (Coulter Electronics, Luton, UK) and mean fluorescence
from a minimum of 3000 cells determined.
Statistical analysis
All data are presented as mean ± SEM of the indicated number of experiments. Data
were analysed by the students t-test and where appropriate by one way analysis of
variance following Newman-Keuls procedure using InStat. P values less than 0.05
were considered significant.
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Chapter 3: Regulation of apoptosis in human neutrophils by TNFa
3.1 Intoduction
Neutrophil apoptosis, which results in the recognition and uptake of these cells by
macrophages, has been proposed as an important mechanism for the removal of
neutrophils from sites of inflammation (Savill et ah, 1989a and b, 1990, 1992a,
Haslett et ah, 1989, 1994). Experimental data obtained using human peripheral
neutrophils demonstrates that these cells undergo constitutive apoptosis when aged in
vitro and that this process is associated with maintenance ofmembrane integrity,
hyporesponsiveness to external secretagogue signals and the capacity to be
phagocytosed intact by macrophages and certain other cells with phagocytic potential
(Savill et ah, 1989a and b, 1990b, 1992a, Haslett et ah, 1989, Whyte et ah, 1993a).
The speed and capacity of the macrophage phagocytic response towards apoptotic
neutrophils, together with the observation that engulfment does not excite a pro¬
inflammatory macrophage response (Meagher et ah, 1992), predicts that this process
plays an important role in the safe disposal of intact but effete neutrophils from an
inflamed focus. This view is supported by the recent demonstration of this process
occurring in vivo for example in endotoxin-induced experimental lung injury (Cox et
ah, 1995), the neonatal respiratory distress syndrome (Grigg et ah, 1991), and
experimental glomerulonephritis (Savill et ah, 1992b).
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While the mechanism(s) regulating neutrophil survival and death are poorly
understood, there is now considerable evidence to show that this process is not
immutable in that the rate at which these cells undergo apoptosis, at least in vitro, can
be altered. For example, the colony-stimulating factors G-CSF and GM-CSF, LPS,
and hypoxia all increase survival in these cells by delaying apoptosis (Begley et al.,
1986, Brach et al., 1992, Cox et al., 1992, Lee et al., 1993, Hannah et al., 1995).
Furthermore, the inhibition of neutrophil apoptosis by LPS has been shown to be
associated with prolonged functional capacity as assessed by such parameters as the
ability of cells to polarize or degranulate following agonist stimulation (Lee et al.,
1993). These observations imply that certain agents may serve to upregulate
neutrophil function both via an early priming effect which leads to enhanced
functional responsiveness to agonist stimulation and subsequently by inhibiting cell
removal by delaying the onset of apoptosis.
One cytokine of particular interest in this paradigm is tumour necrosis factor-a
(TNFa) since this agent is a powerful neutrophil priming agent yet has the capacity
along with other NGF/TNF receptor family ligands to induce apoptosis in a number
of cell types including mouse lymph node T-cells and HL60 cells (Zheng et al., 1995,
Obeid et al., 1993) Despite this, a number of reports have indicated that TNFa has
the opposite effect i.e. delays apoptosis in human monocytes and neutrophils
(Mangan et al., 1991, Colotta et al., 1992) and prevents calcium-dependent cell death
in B104 lymphoma cells (Genestier et al., 1995). The aim of the work presented in
this chapter was to undertake a detailed characterization of the effect of TNFa on
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neutrophil apoptosis in vitro and compare any such effects to the actions of other
neutrophil priming agents.
3.2 Results
3.2.1 Effect of TNFa on the rate of neutrophil apoptosis in vitro
Co-incubation of human neutrophils with various priming agents for 20 hr either
inhibited (lOOng/ml LPS, 100 pM LTB4, 500 U/ml GM-CSF) or had no effect on (1
nM fMLP, 1 pM PAF), the extent of neutrophil apoptosis (3.2.1A). Inhibition of
neutrophil apoptosis at 20 hr was also observed with inositol hexakisphosphate
(InsP6), (figure 3.2.1 A), a recently identified neutrophil priming agent (Eggleton et
al., 1991, Kitchen et ah, 1996a). TNFa however, although causing a significant
decrease in the extent of neutrophil apoptosis observed at 20 hr caused a marked
increase in morphological apoptosis at an earlier time point (8 hr) when the
constitutive rate of apoptosis was still low (figure 3.2. IB). This effect was not
observed with any of the other priming agents tested at this time (figure 3.2. IB).
3.2.2 Time-course for the effect of TNFa on neutrophil apoptosis
A more detailed examination of the time course of the effects of TNFa on neutrophil
apoptosis is shown in figure 3.2.2. This demonstrated that TNFa induced apoptosis
at 3 and 6 hr but thereafter, the rate of apoptosis in untreated cells increased rapidly

















































Figure 3.2.1 Effects of priming agents on neutrophil apoptosis
Human neutrophils (5xl06/ml) were cultured either in serum-supplemented Iscove's
MDM alone (control) or in identical medium containing: (final concentration) fMLP
(1 nM), PAF (1 |iM), InsP6 (100 ng/ml), LTB4 (100 nM), GM-CSF (500 U/ml). or
TNFa (25 ng/ml). Neutrophils were harvested following 8 hr (B) or 20 hr (A) in
culture and apoptosis assessed morphologically. Data represent mean ± SEM of 5
separate experiments each performed in triplicate. (Data were analysed by one-way
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Figure 3.2.2 Time course for the effect of TNFa on apoptosis in neutrophils
Human neutrophils (5xl06/ml) were incubated in serum-supplemented Iscove's
MDM in the absence (hatched bars) or presence (closed bars) of 25 ng/ml TNFa.
the time periods indicated, the cells were harvested and assessed for the
morphological features of apoptosis. Data represent mean ± SEM of 6
determinations from 2 independent experiments. Where not shown, SEM values
<2% ofmeans.
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apoptosis between TNFa treated and untreated neutrophils. Thereafter, the extent of
apoptosis in TNFa treated cells was less than in untreated cells.
Assay of the TNFa concentrations present in cell supernatants by ELISA
demonstrated no decline in the level of exogenously added TNFa over the 20 hr
incubation period (table 3.2.2) and no evidence of spontaneous TNFa production
from the neutrophils themselves (Xing et ah, 1993; ELISA sensitivity 15.6 pg/ml).
Time Medium + TNFa Neutrophils ± TNFa Neutrophils - TNFa
(hr) (ng/ml) (ng/ml) (ng/ml)
0 8.87 ±0.59 10.29 ± 1.10 0*
3 8.33 ±0.54 7.84 ±0.62 0
6 9.18 ±0.90 8.67 ±0.97 0
12 8.96 ± 1.08 8.29 ±0.68 0
20 8.69 ±0.63 7.97 ±0.67 0
Table 3.2.2 Effect of incubation time and neutrophil presence on the
concentration of TNFa in culture supernatants
Ehiman neutrophils (5xl06/ml) or medium alone (Iscove's MDM containing 10%
autologous serum) were incubated in the presence (+TNFa) or absence (-TNFa) of
12.5 ng/ml TNFa in flexiwell plates in an humidified 5% C02 incubator at 37°C for
0-20 hr. At the time periods indicated, the cells were centrifuged (220g, 1 min), the
supernatants aspirated, frozen and immunoreactive human TNFa quantified by
ELISA as detailed in Materials and Methods section 2.2.5. Data represent mean ±
SEM of 6 measurements performed in 2 independent experiments. (*Assay
sensitivity 15.6 pg/ml).
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Assessment of cell recovery (haemocytometer counts) and viability (trypan blue
exclusion) at 6 and 20 hr demonstrated that TNFa did not significantly alter either of
these parameters (data not shown) excluding the possibility that the increased rates of
early apoptosis observed reflected either TNFa-induced adhesion of non-apoptotic
cells (Schleiffenbaum and Fehr, 1990) or a TNFa-induced switch between necrosis
and apoptosis as seen in human leukaemic cells treated with high concentrations of
alkylating agents (Lennon et ah, 1991).
3.2.3 Confirmation of TNFa-induced neutrophil apoptosis by DNA
fragmentation gel analysis
DNA fragmentation is considered to be the 'biological hallmark' of apoptosis,
whereby an endonuclease fragments DNA at linker sites between nucleosomes
generating a population of non-random DNA fragments of defined but varying sizes.
Since the DNA fragments are multimers of approximately 180 base pair nucleosomal
units a characteristic ladder pattern is observed when DNA extracted from apoptotic
cells is separated on agarose gels (Wyllie, 1980). Figure 3.2.3 shows that co-
incubation of neutrophils with 25 ng/ml TNFa for 6 hr induces a more intense and
non-random DNA fragmentation compared to non-treated cells hence confirming that







Figure 3.2.3 Effect of TNFa on DNA fragmentation in neutrophils
Human neutrophils (5xl06/ml) were incubated in serum-supplemented MDM in the
presence (+ lanes) or absence (- lanes) of 25 ng/ml TNFa. Cellular DNA was then
extracted as detailed in Materials and Methods (2.2.3c) and separated on a 2%
agarose gel. Lanes represent extracts from TNFa-treated and untreated cells from 2
separate experiments.
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3.2.4 Effect of TNFa on propidium iodide staining in neutrophils
The early pro-apoptotic and late anti-apoptotic effects of TNFa on human neutrophils
were further confirmed using propidium iodide DNA staining and flow cytometry.
The DNA fragmentation that occurs during apoptosis results in reduced binding of
propidium iodide and hence as a cell undergoes apoptosis there is decreased binding
of the fluorescent dye propidium iodide to DNA, which can be analysed by flow
cytometry (Nicoletti et al., 1991). Figure 3.2.4B shows the increase in the percentage
of cells with hypodiploid DNA content following TNFa treatment (% apoptosis 6 hr:
control 4.4 ± 0.3%, 12.5 ng/ml TNFa 18.2 ± 0.1%, p <0.05, n=3). These values
match exactly the extent of apoptosis assessed by morphological criteria in cells
incubated in parallel under identical conditions (% apoptosis 6 hr: control 4.6 ±
0.2%, 12.5 ng/ml TNFa 17.2 ± 1.4%) (figure 3.2.4A). The late inhibitory effect of
TNFa on neutrophil apoptosis (20 hr) was also confirmed using this technique
(figure 3.2.4B) (% low propidium iodide stained cells 20 hr: control, 55.9 ± 0.3%,
12.5 ng/ml TNFa 46.9 ± 1.5%, p <0.05, n=3).
78
Figure 3.2.4A Effect of TNFa on neutrophil morphology
Human neutrophils (5xl06/ml) were incubated in serum-supplemented Iscove's
MDM in the absence (A) or presence (B) of 12.5 ng/ml TNFa. Cytospin preparations
were made after 6 hr and cells were fixed, stained, and examined under lOOx
objective oil immersion light microscopy. Cells containing one or more darkly




Figure 3.2.4B Effect ofTNFa on propidium iodide staining in neutrophils
Human neutrophils (5xl06/ml) were incubated in serum-supplemented MDM in the
presence (right hand panels) or absence (left hand panels) of 12.5 ng/ml TNFa.
Following a 6 or 20 hr incubation period cells were resuspended in ice-cold 70%
ethanol, washed in PBS, and incubated with propidium iodide in the presence of
RNAase prior to analysis using an EPICS Profile Et. Mean fluorescence values are
shown for a minimum of 5000 cells for each condition with the histograms
representative of 6-9 determinations in 3 separate experiments. %
Apoptosis values quoted represent % 'low' propidium iodide staining cells present.
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3.2.5 Effect of TNFa neutralising antibody on TNFa-induction of apoptosis in
neutrophils
To confirm the specificity of the TNFa effect i.e. to eliminate the possibility that
potential contaminants present in the human recombinant TNFa preparation might be
responsible for the pro-apoptotic effect observed, the effect of TNFa was examined
after adsorption for 90 min at 37°C with a monoclonal TNFa neutralizing antibody.
As shown in figure 3.2.5, the adsorption of TNFa with the anti-TNFa antibody
eliminated the induction of apoptosis by TNFa and moreover the basal rate of
apoptosis at 6 hr was not affected by the TNFa neutralizing antibody.
3.2.6 Early time-course for the pro-apoptotic effect of TNFa in neutrophils
Figure 3.2.6 demonstrates that the early pro-apoptotic effect of TNFa was rapid
(observed in all experiments by 2 hr), time-dependent, and maximal in terms of the
ratio of apoptotic to non-apoptotic cells by 6 hr. In view of this a 6 hr time point was
selected for subsequent investigation of the pro-apoptotic effect of TNFa.
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Figure 3.2.5 Effect of TNFa neutralising antibody on basal and TNFa-
stimulated apoptosis in neutrophils
Human neutrophils (5xl06/ml) were cultured for 6 hr either in serum-supplemented
Iscove's MDM alone (control), TNFa (12.5 ng/ml), mouse IgG, anti-human TNFa
neutralizing mAb (1 pg/ml), or an identical concentration ofTNFa pre-incubated for
90 min at 37°C with the neutralising mAb (1 pg/ml). Neutrophils were harvested and
assessed for morphological features of apoptosis. Data represent mean ± SEM of 3
separate experiments, each performed in triplicate.
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Figure 3.2.6 Early time course for the effect of TNFa on apoptosis in
neutrophils
Human neutrophils (5xl06/ml) were cultured in serum-supplemented Iscove's MDM
in the absence (hatched bars) or presence (closed bars) of 25 ng/ml TNFa.
Neutrophils were harvested hourly for 8 hr and apoptosis assessed morphologically.
Data represent mean ± SEM of 3 separate experiments, each performed in triplicate.
Where not shown, SEM values are <2% ofmeans.
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3.2.7 Relationship between TNFa-induced priming, activation and apoptosis in
neutrophils
To explore the concentration-dependence of the pro-apoptotic effect of TNFa and to
compare the sensitivity of this response to the priming effect of TNFa, both direct
TNFa-stimulated superoxide anion generation and TNFa priming of fMLP (100
nM)-stimulated superoxide anion generation were assessed in parallel. Figure 3.2.7
demonstrates that all three responses to TNFa had similar concentration-
dependencies, with an EC50 value of 2.8 ng/ml for TNFa-induced apoptosis, however,
in view of the fact that the concentration-response curves for TNFa-induced priming
and direct stimulation of superoxide anion generation did not reach a plateau, it is
difficult to accurately assess the potency (i.e. EC50) of TNFa for these responses.
From this data, a just maximal concentration of TNFa (12.5 ng/ml) was selected for





Figure 3.2.7 Concentration-response relationships for TNFa-induced apoptosis,
priming and direct superoxide anion generation in neutrophils
Human neutrophils were incubated at 5xl06/ml with 0-100 ng/ml TNFa for
morphological assessment of apoptosis at 6 hr (A) or at 107/ml with 0-100 ng/ml
TNFa for 30 min prior to assessment of fMLP-stimulated (100 nM, 10 min) (C) or
spontaneous superoxide generation (B) using a cytochrome C reduction assay (see
Materials and Methods section 2.2.4). Data represent mean ± SEM from 3 separate
experiments, each performed in triplicate. Where not shown, SEM values are <2%
and fall within the symbols.
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3.3 Discussion
In our initial experiments we confirmed the previous observation that many priming
agents have the capacity also to inhibit the rate of constitutive apoptosis in
neutrophils. Hence in our hands agents such as LPS and GM-CSF cause an
approximately 50% reduction in the rate of apoptosis observed at 20 hr. Of note
however, other agents which have an equivalent priming efficacy as LPS and GM-
CSF e.g. PAF and low concentrations of fMLP (Condliffe et al., 1996, Kitchen et al.,
1996b) do not modulate the extent of apoptosis at 6 or 20 hr. FMLP at a full
activating concentration of 100 nM also had no effect on the apoptotic index (data
not shown).
In contrast to these observations we have demonstrated that TNFa has an apparently
unique bimodal effect on the rate of apoptosis in human neutrophils in vitro with the
capacity to induce early apoptosis in addition to decreasing the extent of apoptosis at
much later times. This may provide an explanation for the previous reports in which
TNFa has been variably reported to inhibit (Colotta et al., 1992), have no effect on
(Kwon et al., 1988), or induce apoptosis in human neutrophils (Takeda et al., 1993,
Tsuchida et al., 1995).
Neutrophils appear to be highly resistant to agonist-induced apoptosis and even
stimuli that are potent inducers of apoptosis in other cells types e.g. corticosteroid
treatment, elevation of intracellular calcium and hypoxia, all inhibit rather than
augment the rate of constitutive apoptosis in these cells (Meagher et al., 1996. Whyte
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et al., 1993b, Hannah et al.,1995). Hence, unlike all other neutrophil priming and
activating agents thus far tested, TNFa appears to be unique in its ability to induce
apoptosis in these cells. The only other naturally occurring cytokine reported to
induce apoptosis in human neutrophils is IL-6 (Afford et ah, 1992). These data need
to be interpreted with caution however as they were highly preliminary in nature and
the incubations were performed under suboptimal culture conditions in the absence
of serum, with the levels of apoptosis recorded at 24 hr in culture (10% v 15% in the
presence of IL-6) outwith apoptosis rates observed by all other comparable studies.
Furthermore, other groups have reported that IL-6 has no effect on neutrophil
apoptosis (Brach et ah, 1992, Takeda et ah, 1993), or even inhibits this response
(Colotta et ah, 1992, Biffl et ah, 1995). In the report by Biffl and co-workers (1995)
it was proposed that the anti-apoptotic effect of IL-6 on human neutrophils observed
was cell concentration-dependent and that this may explain the disparities in the
literature. Hence they demonstrated that at cell densities of 10xl06/ml and
20xl06/ml, IL-6 inhibited neutrophil apoptosis, however at neutrophil densities of
5xl06/ml and below this cytokine had no effect on the spontaneous rate of cell death.
They found no pro-apoptotic effect of IL-6 at any of the combinations of cell/IL-6
concentrations studied. Hence, TNFa appears to have an unique ability not shared by
any other neutrophil priming and activating agent to induce neutrophil apoptosis.
The observation that only a proportion of neutrophils undergo apoptosis in response
to TNFa is of particular interest since ELISA analysis of supernatants taken from
cells incubated with TNFa for up to 20 hr revealed that there was no detectable
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decline in the concentration of TNFa over the incubation period studied. Parallel
experiments with cells cultured in the absence of TNFa also showed that this
cytokine was not being produced within the range ofELISA detection (pg/ml) or
therefore at levels from our concentration-response data which would affect the rate
of apoptosis. Likewise there is no evidence to support heterogeneous TNF receptor
expression in neutrophils since in our hands TNFa stimulates uniform CD18-
dependent latex bead binding in nearly 100% of neutrophils (Condliffe et al., 1996)
and flow cytometric analysis of TNFR75 and TNFR55 expression in these cells
demonstrates very homogeneous receptor density between neutrophils. However,
heterogeneous neutrophil responses to other stimuli such as LPS augmentation of
2+
fMLP-induced Ca transients are well documented (Yee and Christou, 1988) and
clearly other factors such as cell maturity may be important in dictating the
susceptibility of individual cells to TNFa-stimulated apoptosis.
An alternative explanation to the finding that only 15-30% of neutrophils undergo
apoptosis in response to TNFa is the ability of TNFa to trigger two opposing
responses in these cells with the 'early' apoptotic response being modulated and
finally overcome by a 'late' and evolving TNFa-induced survival effect; the number
of cells undergoing apoptosis at any one time therefore reflecting the balance
between these two events. This delayed protective effect of TNFa may be direct or
indirect i.e. secondary to TNFa causing the release of a factor or factors that act in an
anti-apoptotic 'autocrine' manner (e.g. via the generation of LTB4; Ishii et al., 1992).
It is also possible that as the neutrophils settle in the plates and a proportion adhere to
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the flexiwell surface that the response to TNFa changes. Certainly this is a well
recognized event with respect to the priming effect of TNFa where adhesion causes
TNFa to act as a full secretagogue (Nathan, 1987, Richter et al., 1989, Nathan et al.,
1989, Dri et al., 1991) i.e. adhesion may switch off or inhibit the capacity of TNFa to
induce apoptosis and/or augment the protective effect and this possibility is explored
further in Chapter 4.
TNFa has also been shown to enhance thrombospondin-mediated phagocytosis of
apoptotic neutrophils by monocyte-derived macrophages (Ren and Savill, 1995).
This suggests a potentially synergistic or dual mechanism whereby TNFa may
enhance the removal of neutrophils from an inflamed site by accelerating apoptosis
and facilitating phagocytic clearance. Of interest, it was also shown in this study that
the neutrophil priming agent GM-CSF, which we have confirmed is a potent
inhibitor of apoptosis in these cells, also upregulates phagocytosis of apoptotic
neutrophils by monocyte-derived macrophages. Since the neutrophil is a short-lived
cell it is interesting to speculate that, depending on the balance of inflammatory
mediators present at an inflamed site, the potential exists for neutrophil function and
longevity to be either up- or down-regulated and also that the subsequent clearance
by macrophage phagocytes may also be under cytokine control.
Under pathophysiological conditions it is clear that the successful resolution of
inflammation requires not only the switch-off or neutralization of the chemoattractant
and secretagogue stimuli but also the prompt and complete clearance of influxed
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granulocytes. Our data establishes the principle that neutrophil apoptosis can indeed
be stimulated by a receptor operated process. This effect of TNFa may explain at
least in part certain in vivo findings, for example how the administration of anti-
TNFa antibodies results in delayed resolution of the neutrophilic alveolitis induced
by Legionella pneumophilia (Skerrett et al., 1994), why pneumococcus (one of the
most potent inducers of alveolar TNFa production; Simpson et al., 1994) causes a
form of pneumonia that usually resolves with minimal residual organ damage
(Robertson et al., 1938).
Several other more recent reports have demonstrated that human peripheral blood
neutrophils can also be triggered to undergo apoptosis in vitro by a variety of other
biological stimuli. A recent study by Liles et al., (1996) proposes an important role
for the Fas/Fas-ligand system in the regulation of neutrophil cell death. Fas is 45 kD
type I protein of the NGF/TNF receptor superfamily and activation by its natural
ligand (FasL), a 37 kD type II protein, is crucial for death signalling in many cell
types the most extensively studied of which is T cells (see Liles et al., 1996). This
study demonstrated that Fas and FasL are constitutively expressed in neutrophils,
unlike in T cells, which have an extremely low rate of constitutive apoptosis, and
require cell activation for the expression of FasL. In the above study stimulation
with anti-Fas agonistic antibodies (CH-11) induced rapid neutrophil death within 3
hr, and antagonistic anti-Fas antibodies reduced spontaneous neutrophil death by
approximately 50% implying that Fas may play a key role in the regulation of
constitutive neutrophil apoptosis. In addition, these studies also showed that
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neutrophils release a soluble factor, of the same molecular weight as FasL, which
could induce apoptosis in Fas-sensitive Jurkat cells suggesting that neutrophils may
represent a biological source of this ligand, perhaps important in the paracrine and
autocrine control of cell death.
Another recent study by Watson et ah, (1996) demonstrated that ingestion of
Escherichia coli by neutrophils in vitro resulted in subsequent cell death by
apoptosis. This phagocytosis-mediated induction of cell death was dependent upon
production of reactive oxygen intermediates, which was not required for the
regulation of spontaneous neutrophil apoptosis, in agreement with previous work
from our own laboratory (Hannah et al., 1995). Further studies by Coxon et al.,
(1996) showed that neutrophil apoptosis can also be induced in vitro following
phagocytosis of complement-opsonized oil red particles. This was again reactive
oxygen intermediate-dependent and was blocked by antagonistic antibodies to
CD1 lb/CD 18 which did not attenuate the constitutive rate of apoptosis of neutrophils
not fed opsonized particles. These data propose a novel role for p2 integrins in the
regulation of phagocytosis-induced neutrophil apoptosis. TNFa remains, however,
the only physiological neutrophil priming and/or activating agent with the ability to
rapidly induce apoptosis in these cells.
In this context in many inflammatory models TNFa is recognized as being the
dominant 'early wave' cytokine present at such sites and hence there may be an early
'window of opportunity' to achieve rapid granulocyte clearance at a stage where the
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build up of alternative cytokines that delay this process has yet to occur. Such in
vivo studies also indicate that the concentration of TNFa present at inflamed sites is
frequently >10 ng/ml and hence confirming the likely physiological relevance of the
in vitro TNFa apoptosis effect (Aggarwal and Puri, 1995). It is also possible that in
patients with severe sepsis associated with systemic TNFa release that TNFa may
induce intravascular apoptosis and contribute towards the accompanying neutropenic
state. In this context recent data demonstrating variations in TNFa gene promoter
region and hence TNFa generation between individuals (McGuire et al., 1994) may
have a bearing on the beneficial as well as the detrimental effects of TNFa.
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Chapter 4: Exogenous regulation of TNFa-induced neutrophil
apoptosis
4.1 Introduction
TNFa is a potent pro-inflammatory cytokine produced mainly by activated
macrophages and monocytes, but also by lymphocytes, fibroblasts, mast cells and
even neutrophils themselves (Dubravek et ah, 1987). TNFa is expressed as a 26 kD
integral transmembrane precursor protein which is proteolytically cleaved to release a
17 kD subunit (Kriegler et ah, 1988). Both the secreted 17 kDa protein and the 26
kDa pre-peptide spontaneously trimerize and form the bioactive ligand (Smith and
Bagiolini, 1987). The membrane-bound form of TNFa is as active as the soluble
form in terms of cytotoxicity and anti-tumour activity (Kriegler et ah, 1988, Perez,
1990) and has recently been demonstrated to have a pro-apoptotic effect on WEHI
164 cells (Monasta et ah, 1996).
TNFa serves to upregulate many aspects of neutrophil function including priming for
enhanced responsiveness to secretagogue agonists (Klebanoff et al., 1986, Shalaby et
al., 1985, Atkinson et ah, 1988), promotion of adherence to endothelial cells and
cells coated with extracellular matrix proteins (Gamble et ah, 1985, Dri et ah, 1991,
Thompson and Matsushima, 1992), stimulation of phagocytosis (Shalaby et ah, 1985,
Klebanoff et ah, 1986) and in adherent cells can trigger degranulation and respiratory
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burst activity directly (Nathan et al., 1987, Richter et ah, 1989, Nathan et ah, 1989,
Dri et ah, 1991).
In the previous chapter an anti-inflammatory role for TNFa was proposed based on
the demonstration of a pro-apoptotic effect of TNFa in human neutrophils. In view
of recent reports demonstrating an inhibition of TNFa-stimulated human neutrophil
apoptosis by LPS in vitro, and insensitivity of rat inflammatory neutrophils (obtained
after intra-peritoneal injection with streptococcus preparation) to the cytotoxic effects
of TNFa (Hachiya et ah, 1995, Tsuchida et ah, 1995) we were particularly keen to
examine whether the pro-apoptotic effect of TNFa is influenced or regulated by other
factors relevant to the inflamed site. Hence this chapter examines the importance of
the functional status of the neutrophil (i.e. quiescent vs. primed), the effects of cell
adherence (which dramatically alters other functional responses of neutrophils to
TNFa; Nathan, 1987, Nathan et al., 1989, Richter et ah, 1989, Dri et ah, 1991), and
the presence of other cytokines on the pro-apoptotic effect of TNFa with a view to
understanding how TNFa may regulate neutrophil apoptosis in vivo. Since the pro-
apoptotic effect of TNFa in other cell types is also highly dependent on culture
conditions (Beyaert and Fiers, 1994), we were keen to explore different strategies to
enhance the efficacy of the pro-apoptotic effect of TNFa and optimize our culture
system for subsequent mechanistic studies.
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4.2 Results
4.2.1 Inter- and intra- donor variability of TNFa-stimulated neutrophil
apoptosis
In view of our observation that only a proportion of the total neutrophil pool undergo
apoptosis when stimulated with TNFa in vitro, and recent data indicating striking
inter-individual variations in TNFa synthesis due to a functional polymorphism at
the promoter region of the TNFa gene, termed the TNF2 allele (McGuire et ah,
1984), the relative pro-apoptotic effect of TNFa on neutrophils from different donors
was compared to establish a range of responsiveness to this cytokine. Neutrophils
prepared from different donors varied with respect to their susceptibility to TNFa-
induced death (figure 4.2.1 A), the 'apoptotic index' (difference at 6 hr between %
apoptosis in TNFa-treated cells % apoptosis in control cells) ranging from 10.4% to
35.8% (median response: control 1.9%, TNFa 20.6%, n=l 1). To determine whether
there was a consistent effect within individual donors for neutrophil responsiveness
to TNFa, cells were prepared from three donors on two occasions (at least twelve
weeks apart) and the rates of TNFa-stimulated apoptosis compared. Figure 4.2. IB
demonstrates that the intra-donor variability for TNFa-induced neutrophil apoptosis
was in fact very small with individuals showing a fairly stereotyped TNFa response
J
across time. This data also implies that minor day-to-day variation in cell
preparation does not dramatically alter the TNFa pro-apoptotic effect.
95
Donor
Figure 4.2.1A Inter-donor variability ofTNFa-stimuIated neutrophil apoptosis
Human neutrophils were purified from eleven donors and incubated (5xl0'7ml) in
serum-supplemented Iscove's MDM in the absence (hatched bars) or presence
(closed bars) of 12.5 ng/ml TNFa. Neutrophils were harvested following 6 hr in
culture and assessed for morphological features of apoptosis. Data represent mean
values of triplicate determinations made in eleven independent experiments. SEM
are not shown for clarity but were consistently <1.6% of the mean values.
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Figure 4.2.IB Intra-donor variability of TNFa-stimulated neutrophil apoptosis
Human neutrophils from three donors (1,2 and 3) were purified on two separate
occasions at least twelve weeks apart and incubated (5xl06/ml) in serum-
supplemented Iscove's MDM in the absence (hatched bars) or presence (closed bars)
of 12.5 ng/ml TNFa. Cells were harvested following 6 hr in culture and assessed for
morphological features of apoptosis. Data represent mean ± SEM from triplicate
determinations made in six independent experiments; where not shown, SEM values
are <2% ofmeans.
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4.2.2 Effect of oral corticosteroid treatment on the pro-apoptotic effect of TNFa
in neutrophils
In an attempt to determine whether neutrophil maturity is an important factor
dictating the susceptibility of individual cells to apoptosis, we compared the pro-
apoptotic effect of TNFa on neutrophils from two volunteer donors both before and
during daily administration of oral glucocorticoid treatment (Prednisolone), which is
known to increase bone marrow release of neutrophils into the peripheral blood (Dale
et al., 1975). A dramatic increase in neutrophil responsiveness to TNFa-mediated
apoptosis was observed on day four of glucocorticoid treatment (Prednisolone, 30 mg
once daily) and this augmented response was sustained throughout the duration of
glucocorticoid administration (figure 4.2.2). Neutrophil counts (xl06/l whole blood)
were monitored in parallel and a steady increase was observed from pretreatment
levels of 3.48 and 3.88 to 9.26 and 7.10 respectively on day seven.
In view of previous reports demonstrating the inhibition of neutrophil apoptosis by
dexamethasone in vitro (Cox, 1995, Meagher et al., 1996), and more recent data
demonstrating partial inhibition of a TNFa-mediated neutrophil apoptosis in vitro by
dexamethasone (Kato et al., 1995), exogenous addition of this synthetic
glucocorticoid was also included in the study. As shown in figure 4.2.2, 1 pM
dexamethasone partially inhibited TNFa-induced neutrophil apoptosis but this
attenuation of the pro-apoptotic effect of TNFa was of similar magnitude both before
and during Prednisolone administration. Hence the enhanced rates of TNFa-induced
apoptosis observed in Prednisolone treated neutrophilic individuals was preserved











Figure 4.2.2 Effect of oral corticosteroid treatment on the pro-apoptotic effect
of TNFa in neutrophils
Human neutrophils were purified from two individual donors on four separate days
(denoted 0, 4, 7 and 9 to indicate days of steroid administration, 30 mg/day single
dose Prednisolone, which commenced post-venipuncture on day 0. Neutrophils
(5xl06/ml) were incubated in serum-supplemented Iscove's MDM (control) or in
identical medium containing: (final concentration) TNFa (12.5 ng/ml),
dexamethasone (Dex, 1 pM), or TNFa (12.5 ng/ml) plus dexamethasone (1 pM).
Neutrophils were harvested following 6 hr in culture and apoptosis assessed
morphologically. Data represent mean ± SEM of 6 determinations from 2
independent experiments performed in triplicate; where not shown, SEM values are
<2% ofmeans.
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4.2.3 Effect of cell concentration on the pro-apoptotic effect of TNFa in
neutrophils
In view of recent data which demonstrated that the anti-apoptotic effect of IL-6 in
human neutrophils was cell concentration dependent (Biffl et al., 1995), the rate of
apoptosis in neutrophils cultured at different densities in the presence, and absence of
TNFa was compared. Figure 4.2.3 demonstrates that the pro-apoptotic effect of
TNFa was most marked at the lowest cell concentration studied (2.5x106
neutrophils/ml) and decreased as the cell concentration was increased up to
10xl06/ml, however no further decline in the extent of TNFa-stimulated neutrophil
apoptosis was observed when the cell concentration was increased from lOxlO6-
15xl06 neutrophils/ml. A cell concentration of 5xl06/ml was selected for use in
subsequent studies as this was the optimal density for preparation and quantification
of cytospins.
4.2.4 Effect of serum concentration on the pro-apoptotic effect of TNFa in
neutrophils
The pro-apoptotic effect of TNFa was not affected by varying the concentration of
autologous serum (up to 10% v/v), serum withdrawal, or substitution with 10% fetal











Figure 4.2.3 Effect of cell concentration on the pro-apoptotic effect ofTNFa in
neutrophils
Human neutrophils were incubated in serum-supplemented Iscove's MDM at
densities of 2.5, 5, 10 or 15xl06/ml in the absence (hatched bars) or presence (closed
bars) of 12.5 ng/ml TNFa. Neutrophils were harvested following 6 hr in culture and
assessed for morphological features of apoptosis. Data represent mean ± SEM of 6
determinations from 2 independent experiments performed in triplicate.
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Figure 4.2.4 Effect of serum concentration on the pro-apoptotic effect of TNFa
in neutrophils
Human neutrophils (5xl06/ml) were cultured in Iscove's MDM alone or in identical
medium containing: (final concentration) fetal calf serum (FCS, 10%), or autologous
serum (0.01-10%) in the absence (hatched bars) or presence (closed bars) of 12.5
ng/ml TNFa. Neutrophils were harvested following 6 hr in culture and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 6
determinations from 2 independent experiments. Where not shown, SEM values are
<2% ofmeans.
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4.2.5 Effect of pre-incubation of cells on the pro-apoptotic effect of TNFa in
neutrophils
In view of our observations that in particular experiments where pre-incubation of
neutrophils was required prior to stimulation with TNFa the pro-apoptotic effect of
TNFa was reduced, the relative rates of TNFa-stimulated apoptosis in cells exposed
to TNFa immediately was compared to that in cells pre-incubated prior to addition of
this cytokine. In these experiments the pro-apoptotic effect of TNFa was shown to
be dramatically abrogated when neutrophils were pre-incubated for 30 min at 37°C in
flexiwell plates (figure 4.2.5), however the cytotoxic effect was partially preserved
when cells were pre-incubated in suspension for the same time period by gentle
agitation in a shaking water bath in polypropylene Eppendorf tubes (figure 4.2.5)
implying that adherence of neutrophils might be one of the factors contributing to
this loss of the pro-apoptotic effect of TNFa.
4.2.6 Effect of delayed addition of TNFa on neutrophil apoptosis
To assess further the effect of delayed addition of TNFa, neutrophils were pre-
incubated in flexiwell plates for 6 hr to allow the cells to adhere fully to the flexiwell
containers prior to addition of TNFa. This pre-incubation completely abrogated the
pro-apoptotic effect ofTNFa (figure 4.2.6). Of note however, despite the complete
loss of the early pro-apoptotic effect of TNFa when addition was delayed by 6 hr, the
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Figure 4.2.5 Effect of pre-incubation of cells on the pro-apoptotic effect of
TNFa in neutrophils
Human neutrophils (5xl06/ml) were cultured in serum-supplemented Iscove's MDM
in the absence (hatched bars) or presence (closed bars) of 12.5 ng/ml TNFa in
flexiwell plates for 6 hr prior to morphological assessment of apoptosis. Left hand
panel: TNFa was added to cells at the beginning of the incubation period performed
in flexiwell plates. Middle panel: neutrophils were pre-incubated in 2 ml
polypropylene Eppendorf tubes in a shaking water-bath at 37°C
for 30 min prior to culture in flexiwell plates in the presence or absence of TNFa.
Right hand panel: neutrophils were pre-incubated in flexiwell plates for 30 min at
37°C prior to addition of TNFa. Data represent mean ± SEM of 3 separate




Figure 4.2.6 Effect of delayed addition ofTNFa on neutrophil apoptosis
Human neutrophils (5xl06/ml) were incubated in the absence (wide hatched bars), or
presence of 12.5 ng/ml TNFa added either at the beginning of the incubation period
(closed hatch bars) or after a delay of 6 hr (filled bars). Neutrophils were harvested
at the time points indicated and assessed for morphological features of apoptosis.
Data represent mean ± SEM of 3 separate experiments, each performed in triplicate.
Where not shown, SEM values are <2% ofmeans.
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4.2.7 Effect of pre-treatment with PAF on basal and TNFa-stimulated apoptosis
in neutrophils
To assess whether the induction of apoptosis by TNFa was influenced by neutrophil
priming, cells were pre-incubated with 1 pM PAF for 5 min prior to the addition of
TNFa. This protocol results in a dramatic upregulation (priming) of fMLP-
stimulated superoxide anion release (Kitchen et al., 1996b). As shown in figure
4.2.7, PAF alone did not influence the rate of apoptosis at 6 hr but completely
abolished the pro-apoptotic effect of TNFa.
4.2.8 Effect of Interleukin-10 on basal and TNFa-stimulated apoptosis in
neutrophils
Incubation of neutrophils with the anti-inflammatory cytokine IL-10 (1-100 ng/ml)
had no influence on either constitutive or TNFa-stimulated neutrophil apoptosis at 6
hr (figure 4.2.9). The biological activity of IL-10 was confirmed in these
experiments by demonstrating its ability to block LPS-stimulated TNFa release from
monocyte-derived peripheral blood macrophages as detected by ELISA (L Bruce,
personal communication; Ward et al., 1997).
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Figure 4.2.7 Effect of pre-treatment with PAF on basal and TNFa-stimulated
apoptosis in neutrophils
Human neutrophils (5xl06/ml) were pre-incubated in serum-supplemented Isco\e"s
MDM in the presence or absence of PAF (1 pM) for 5 min at 37°C prior to culture
for 6 hr in the presence or absence of 12.5 ng/ml TNFa. Neutrophils were harvested
and assessed for morphological features of apoptosis. Data represent mean ± SEM



















Figure 4.2.8 Effect of Interleukin-10 on TNFa-stimuIated neutrophil apoptosis
Human neutrophils (5xl06/ml) were incubated in serum-supplemented Iscove's
MDM alone (control) or in identical medium containing interleukin-10 (IL-1 0r flr.al
concentration 1-100 ng/ml) in the absence (hatched bars) or presence (closed bam of
12.5 ng/ml TNFa. Neutrophils were harvested following 6 hr in culture and assessed
for morphological features of apoptosis. Data represent mean ± SEM of triplicate
determinations in a single representative experiment of 4; where not shown. SEN/
values are <2% ofmeans.
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4.3 Discussion
In the initial studies we established that different donors display a range of
responsiveness of their peripheral blood neutrophils to the pro-apoptotic effect of
TNFa. Moreover, we demonstrated consistency within individual donors with regard
to the pro-apoptotic effect of TNFa on isolated neutrophils. To minimize potential
diurnal variations of cellular responsiveness to TNFa, donor venipuncture,
subsequent neutrophil isolation and experimentation was performed for all
experiments at approximately the same time of day (9 am ± 1 h). This controls for
minor variations in corticosterone levels, which result in an increased release of bone
marrow neutrophils (Dhabhr et al., 1994), that have been shown to inhibit neutrophil
apoptosis in vitro (Cox, 1995, Meagher et al., 1996). It is now well recognized that
inter-individual differences exist in TNFa production by LPS-stimulated human
peripheral blood mononuclear cells (Molvig et al., 1988) and a recent study by
McGuire and colleagues (1994) has demonstrated that a polymorphism in the
promoter region of the TNFa gene (termed the TNF2 allele) is associated with higher
constitutive and inducible levels ofTNFa transcription which alters the clinical
course of cerebral malaria. It may be speculated that inter-individual variations in
constitutive TNFa production may result in differences in the in vitro sensitivity,
coupling or expression of the two TNFR subtypes for this cytokine, i.e. individuals
who are 'high producers' of TNFa may as a consequence display chronic receptor
desensitization. Studies comparing neutrophil responsiveness to the cytocidal effects
of TNFa run in parallel with assays of TNFa production by stimulated peripheral
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blood mononuclear cells from the same donor may help elucidate whether this is in
fact the case. An alternative explanation is that inter-individual variations may exist
in terms of receptor affinity or signal transducing capacity for TNFa and its receptors.
When comparing the responsiveness of neutrophils to the pro-apoptotic effect of
TNFa, it was observed that cells isolated from the blood of donors where
venipuncture was performed >12 weeks after previous donation, the response was
very consistent. However, blood obtained from individuals where donations were
made more frequently (e.g. 40-80 ml venisected weekly) it was observed that the
induction of apoptosis by TNFa was far more variable (data not shown). This led to
speculation that following a single large volume blood donation, there is bone
marrow release ofmore juvenile neutrophils which may be more responsive to the
cytocidal effects of TNFa; caution must be taken however when interpreting such
observations due to the relatively short half-life (about 4 hr) (Price and Dale, 1977)
of neutrophils in the circulation. However, with this in mind and the observation that
even under optimal conditions only a proportion of the total neutrophil pool undergo
apoptosis in response to TNFa led to the design of experiments to address whether
neutrophil maturation had a bearing on cellular responsiveness to TNFa. The much
more modest and variable increase in peripheral neutrophil count following exertion
and the fact that a large proportion of the increase in circulating cells represents
release ofmarginated pulmonary vascular neutrophils rather than marrow release
suggested that a steroid neutrophilia protocol was a more sensible strategy.
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The treatment of 2 individual donors with Prednisolone (30 mg/day) with white
blood cell analysis from whole blood and parallel assessment of TNFa-induced
apoptosis allowed us to analyse the effects of long-term glucocorticoid treatment on
peripheral blood leukocyte levels and the pro-apoptotic effect of TNFa in
neutrophils. In accordance with a previous publication (Schleimer, 1990)
glucocorticoid treatment increased the neutrophil counts in both donors, while
decreasing eosinophil counts, and the neutrophil killing ability ofTNFa was
enhanced dramatically following glucocorticoid treatment. While these data are
preliminary, the results are consistent and striking and a number of speculations can
be made. Contaminating eosinophils, like monocytes, may produce a 'protective
factor' which decreases the responsiveness of the neutrophil to the cytotoxic effects
of TNFa; since there are less surviving eosinophils following glucocorticoid
treatment, the effects of such postulated factors would be diminished. Likewise, the
percentage of younger neutrophils will also be greater in the steroid treated subjects,
and these younger cells may be more sensitive to the pro-apoptotic effects of TNFa.
Recent data reports that rat bone marrow neutrophils are insensitive to TNFa-
mediated apoptosis (Tsuchida et al., 1995), however these cells were harvested from
the bone marrow directly, subjected to a harsh extraction protocol, and the resultant
yield contained only 60% neutrophils. Finally, it is possible that steroids could
increase the ability of TNFa to induce apoptosis in these cells at a
transcription/translation level by increasing receptor affinity and signal transducing
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ability and thereby causing up regulation of the TNFa killing effect or down
regulation of a cell survival effect.
In light of previous demonstrations that the pro-apoptotic effect of TNFa in other cell
systems is dependent on a specific set of culture conditions (Beyaert and Fiers,
1994), a series of experiments were designed to determine whether factors
characteristic of our system influence the responsiveness of the neutrophil to TNFa,
with the particular objective of determining whether the efficacy of the pro-apoptotic
effect of this cytokine could be enhanced. Examination of the influence of cell
concentration on the action of TNFa at 6 hr revealed that the pro-apoptotic effect was
most marked at 2.5-5x106 cells/ml; this may reflect production of a neutrophil (or
even eosinophil/monocytej-derived protective factor(s) which at higher cell densities
is produced in saturating concentrations, or reflect the loss of any potential surface
effects as the cells no longer settle in a monolayer on the flexiwell surface.
In view of the fact that TNFR55 and TNFR75 can be proteolytically cleaved from the
cell surface and thus form soluble TNFa binding proteins (TNFR55-BP and
TNFR75-BP; Olsson et ah, 1989, Seckinger et ah, 1989, Engelmann et ah, 1989) that
have been detected in human serum (Petree et ah, 1988), the effect of serum
withdrawal on the pro-apoptotic effect of TNFa was assessed. In our experiments
however, neither serum withdrawal or substitution with 10% fetal calf serum had any
influence on the pro-apoptotic effect of TNFa, implying that neither the intra-donor
variation in the pro-apoptotic neutrophil responsiveness to TNFa, or the observation
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that only a proportion of cells undergo apoptosis in response to this cytokine, can be
attributed to inhibition of TNFa action by TNF-BPs in the serum. Moreover, these
data eliminate the possibility that other serum factors, such as the proteinase 0.2-
macroglobulin, which has been shown to bind a number of cytokines (LaMarre et al.,
1991), are binding to or having a major neutralizing effect on the activity of
exogenously added TNFa. This would be more appropriately studied however using
an EC50 concentration of TNFa which would provide a far more sensitive index of
the capacity of serum factors to influence TNFa-stimulated apoptosis.
The loss of the pro-apoptotic effect of TNFa when cells were cultured for 6 hr prior
to cytokine addition was considered to be most likely attributable to cell adhesion
since in shorter (30 min) pre-incubation experiments the cytotoxic effect ofTNFa
was partially preserved, especially when the cells were pre-incubated in suspension
by gentle agitation in polypropylene tubes; the influence of cell adhesion could be
examined in more detail by assessing the ability of TNFa to induce apoptosis in pre-
incubated non-adherent cells e.g. in the presence of CD 18 F(ab')2 monoclonal
antibodies. The loss of the pro-apoptotic effect of TNFa under adherent conditions
may well reflect the major decline in TNFR55 and TNFR75 expression observed
over this period as demonstrated in Chapter 5 (5.2.3B). This hypothesis is supported
by data from Tsuchida and colleagues (1995) who showed a correlation between
TNF affinity (although not number) and TNFa-induced apoptosis in rat neutrophils
harvested from bone marrow, peripheral blood and the inflamed peritoneum. This
hypothesis does not however account for the enhanced inhibitory effect of TNFa
113
observed at 20 hr under these conditions. In view of data from a number of groups,
including our own, demonstrating that adhesion primes the neutrophil for enhanced
respiratory burst activity and converts TNFa into a full secretagogue for superoxide
anion generation (Nathan, 1987, Richter et ah, 1989, Nathan et ah, 1989, Dri et ah,
1991, Nathan and Sanchez, 1990; ER Chilvers and AM Condliffe, personal
communication), it is reasonable to speculate that the enhanced late apoptotic
inhibitory effect of TNFa may reflect direct triggering of the release of an anti-
apoptotic factor(s) e.g. LTB4 (Ishii et al., 1992).
Of relevance to the inflamed site, the ability of TNFa to accelerate apoptosis was
completely lost if neutrophils were primed with PAF (1 pM, 10 min) prior to
cytokine addition. Moreover, as demonstrated in Chapter 5 (5.2.3B) this effect was
not secondary to decreased TNFR55 or TNFR75 expression. Although a previous
study has reported that PAF induces a 50% decline in total TNFR expression using
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I-TNFa binding, this effect was obtained only following a 2 hr rather than 5 min
incubation period and employed PAF at a supra-pharmacological concentration of
100 pM (Schleiffenbaum and Fehr, 1990). It is possible however that PAF
influences receptor coupling rather than expression and/or that TNFa is sensitive to
PAF-induced protease release. Studies employing the long-acting PAF receptor
antagonist UK-74,505 (Alabaster et ah, 1991), or other rapidly-acting priming agents
such as IL-8 (10 min; Daniels et ah, 1992) may help elucidate whether this PAF-
mediated attenuation is a general consequence of the activation status of the
neutrophil (i.e. priming) or a specific receptor-mediated event.
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A further study (Hachiya et al., 1995) has demonstrated a dose-dependent albeit
partial inhibition of TNFa-stimulated apoptosis in human neutrophils by LPS. These
experiments employed very high concentrations of LPS (1-100 pg/ml) used over a
short pre-incubation time (30 min; maximal priming with LPS requires 120 min;
Guthrie et al., 1984) and hence it is most likely that the attenuated pro-apoptotic
effect of TNFa observed with LPS was secondary to a modest reduction in
expression of both receptor subtypes as previously reported (Porteu and Nathan,
1990).
Of interest, a recent study by Tsuchida et al., (1995) compared the sensitivity of rat
neutrophils, obtained from various tissues and sites, to the pro-apoptotic effect of
TNFa in vitro. The study showed that while peripheral blood neutrophils were
responsive to the pro-apoptotic effect of TNFa, peritoneally exudated neutrophils
(PEN) and inflammatory peripheral blood neutrophils, both obtained after an intra¬
peritoneal (i.p.) injection of proteose peptone (a neutrophil chemoattractant) were
resistant to the cytotoxic effect of this cytokine. Although these differences could not
be ascribed to variations in TNFa receptor number, the neutrophils from these
different sources did show differences in the affinity of TNFa binding with a higher
Kd observed in the non-responsive cells. Kinetic analysis of the inflammatory
peripheral blood neutrophils revealed that the sensitivity to TNFa started to decrease
;
at 3 hr after i.p. injection, was lowest at 12 hr and was almost fully restored after 52
hr. Of note, an inverse correlation was observed between cell number and cell
sensitivity to TNFa. One other fascinating finding of this study was that peritoneal
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neutrophils elicited by i.p. injection of physiological saline retained their sensitivity
to TNFa.
In another recent study it was demonstrated that exudated human salivary neutrophils
were unresponsive to TNFa (and G-CSF), as assessed by priming for fMLP-
stimulated superoxide anion generation, as compared to peripheral blood neutrophils
examined in parallel. This effect was again associated with a decrease in TNF
receptor affinity but not in receptor density (Niwa et al., 1996). These studies and
other reports, demonstrating that treatment of neutrophils with priming and/or
activating agents such as fMLP or C5a decrease TNFR density and affinity
(Solomskin et al., 1994), highlight the complex and delicate interplay that must occur
between cytokines in controlling neutrophil behaviour within an inflammatory focus
in vivo.
Finally, to explore whether the efficacy of the pro-apoptotic effect of TNFa in vitro
could be enhanced by anti-inflammatory cytokines, we examined the effect of IL-10
on TNFa-stimulated neutrophil apoptosis. IL-10 exerts potent anti-inflammatory
effects in vivo, which have been attributed to inhibition of cytokine production by
monocytes/macrophages (De Waal Malefyt et al., 1991, Gerard et al., 1993, Howard
et al., 1993); in this context, TNFa-dependent mechanisms are diminished (Lo et al.,
1992). In addition, neutrophil production of regulatory mediators such as cytokines
(e.g. TNFa and GM-CSF), and the IL-1 receptor antagonist, are also subject to
regulation by IL-10 (Cassatella et al., 1993).
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In our studies IL-10 had no influence on the rate of constitutive or TNFa-stimulated
neutrophil apoptosis. Of interest, in a recent in vivo study in rats by Cox (1996), it
was demonstrated that while intra-tracheal administration of IL-10 did not modulate
the onset or peak of neutrophil accumulation in response to intra-tracheal LPS
challenge, this cytokine did promote the clearance of recruited neutrophils. During
ex-vivo culture of cells obtained by bronchoalveolar lavage (BAL), neutrophil
apoptosis and subsequent macrophage ingestion was accelerated in the BAL of IL-
10-treated rats. Exogenously added IL-10, however, did not influence the rate of
apoptosis of neutrophils prepared from rat peripheral blood neutrophils but did
inhibit LPS-mediated inhibition of cell death in a concentration-dependent manner.
These data indicate the potential for IL-10 to act in concert with other inflammatory
cytokines in vivo to up-regulate the rate of neutrophil apoptosis. The inability of IL-
10 to influence TNFa-mediated apoptosis however suggests that the activity of this
cytokine is not directly pro-apoptotic, but rather functions to down-regulate the
inhibition of apoptosis by other inflammatory cytokines, either by inhibiting their
production, or by modulating their ability to enhance survival.
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Chapter 5: Role of the TNFR55 and TNFR75 subtypes in the
regulation of neutrophil apoptosis by TNFa
5.1 Introduction
Two distinct receptor subtypes for TNFa with molecular masses of 55 kD (TNFR55)
and 75 kD (TNFR75) have now been identified (Flohmann et al., 1990, Brockhaus et
ah, 1990), and human and mouse cDNAs corresponding to both receptor types have
been isolated and characterized (Loetscher et ah, 1990, Schall et ah, 1990, Smith et
ah, 1990, Lewis et ah, 1991, Goodwin et ah, 1991). These receptors are members of
a superfamily of receptors referred to as the NGF/TNF receptor family which are
characterized by functional trimerization and the presence of one to six cysteine-rich
repeats of approximately 40 amino acids in the extracellular domain that provide the
motif for binding to shared structures in the ligand (section 1.3.7). TNFR55 is found
on almost all cell types whereas TNFR75 has a far more restricted distribution with
expression on cells of haematopoietic lineage and endothelium (Flohmann et ah,
1989, Brockhaus et ah, 1990, Shalaby et ah, 1990, Porteau et ah, 1991, Mackay et ah,
1993).
The extracellular domains of the two human TNFRs are 28% identical and have no
more homology to each other than to other members of the NGF/TNF receptor
superfamily. Likewise, there is no significant homology between the intracellular
domains of the two TNFRs, indicating that these receptors almost certainly employ
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different signalling mechanisms (Lewis et al., 1991). TNFR55 contains a classical
death-domain sequence (Tartaglia et al., 1993a) and has been reported to be the sole
mediator of the TNFa-mediated death signal in most non-haematopoietic cell types.
Despite this, the TNFR75, which lacks such a death domain sequence, has been
proposed to play a key role in mediating TNFa-induced cytotoxicity in murine CD8+
peripheral T-cells (Zheng et al., 1995). Hence the aim of the work presented in this




5.2.1 Effect of TNFR55 agonist polyclonal antibodies on early neutrophil
apoptosis
The potential role of TNFR55 in mediating the early pro-apoptotic effect ofTNFa in
neutrophils was initially investigated using a total goat IgG anti-human soluble
TNFR55 activating polyclonal antibody. This antibody has been reported to interact
with cell surface TNFR55 and, in the presence of actinomycin D, induce cytotoxicity
in human A549 cells (EC50 5-10 pg/ml) and murine L929 cells (EC50 10-15 pg/ml; R
& D systems catalogue, 1996). Figure 5.2.1 however demonstrates the inability of
this antibody to mimic the pro-apoptotic effect of 12.5 ng/ml TNFa following a 6 hr
incubation. The functional activity of this antibody was confirmed in experiments
demonstrating its ability (at a concentration of 1 pg/ml) to mimic TNFa-induced
priming of fMLP (100 nM)-stimulated superoxide anion generation in suspension
neutrophils (E Kitchen, Ph D Thesis, 1997). These data imply that activation of the
TNFR55 subtype alone may be insufficient for transmission of a TNFa-mediated
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Figure 5.2.1 Effect of TNFR55 agonist polyclonal antibodies on the pro-
apoptotic effect of TNFa in neutrophils
Human neutrophils (5xl06/ml) were cultured in serum-supplemented Iscove's MDM
alone (control) or in identical medium containing: (final concentration) TNFa (12.5
ng/ml) or total goat IgG anti-human TNFR55 polyclonal antibody (pAb, 0.1-100
p.g/ml). Neutrophils were harvested following 6 hr in culture and apoptosis assessed
morphologically. Data represent mean ± SEM of triplicate determinations in a single
representative experiment of 3.
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5.2.2 Effect of TNFR55 blocking monoclonal antibodies on the pro-apoptotic
effect of TNFa in neutrophils
Further investigation into the involvement of TNFR55 in the pro-apoptotic effect of
TNFa in neutrophils was performed using a mouse anti-human IgG, TNFR55
blocking monoclonal antibody. Pre-incubation of human neutrophils for 30 min with
this antibody completely abrogated the pro-apoptotic effect of TNFa at 6 hr without
affecting the basal rate of apoptosis (figure 5.2.2), indicating a requirement for
TNFR55 activity in TNFa-signalling for neutrophil death. The relatively small pro-
apoptotic effect of TNFa observed in these experiments (approximately 15% at 6 hr)
compared to data presented in Chapter 3 (e.g. figure 3.2.2) reflects the need to pre-
incubate cells for 30 min prior to exposure to TNFa (see Chapter 4). The specificity
of the antibody for the TNFR55 was confirmed in additional experiments where
TNFa-induced priming of fMLP (100 nM)-stimulated superoxide generation was
completely blocked (E Kitchen, Ph D Thesis, 1997).
5.2.3A Flow cytometric analysis of TNFR55 and TNFR75 on human
neutrophils
Flow cytometric analysis of TNFR55 and TNFR75 in freshly isolated human
neutrophils demonstrated a single population of TNFR55 and TNFR75 positive cells
(figure 5.2.3A) with mean fluorescence values of 4.06 ± 0.26 and 5.40 ± 0.53,
respectively (CD2 control values 1.50 ±0.10, n=9). Moreover, TNFR55 and
TNFR75 were expressed in approximately equal densities (figure 5.3.3B).
122
Figure 5.2.2 Effect of TNFR55 blocking monoclonal antibodies on the pro-
apoptotic effect of TNFa in neutrophils
Human neutrophils (5xl06/ml) were pre-incubated with 28 pg/ml mouse IgG, anti-
human TNFR55 monoclonal antibody (mAb) in serum-supplemented Iscove's MDM
for 30 min at 37°C prior to culture the presence or absence of 12.5 ng/ml TNFa.
Neutrophils were harvested following 6 hr in culture and apoptosis assessed
morphologically. Data in mean ± SEM of 6 determinations from 2 independent
experiments of 4; where not shown, SEM values are <2% ofmeans.
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Figure 5.2.3A Flow cytometric analysis of TNFR55 and TNFR75 in human
neutrophils
Freshly purified human neutrophils were incubated at 4°C for 30 min with a
saturating concentration ofmouse anti-human TNFR55, TNFR75, or CD2 (negative
control) mAbs and subsequently with FITC-conjugated goat anti-mouse
immunoglobulin (30 min). Histograms represent profiles of cell count against log
fluorescence and are representative examples from 9 separate experiments
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5.2.3B Time course for TNFR55 and TNFR75 expression in human neutrophils
in the presence and absence of PAF
Flow cytometric analysis of TNFR55 and TNFR75 expression in neutrophils
incubated for 0,1,2,3 or 6 hr demonstrated a time-dependent decrease in both
TNFR55 and TNFR75 expression (figure 5.2.3B); however, pre-incubation of cells
with PAF (1 pM) for 5 min, which completely abolished the ability of TNFa to
induce apoptosis at 6 hr (section 4.2.7), had no effect on either TNFR55 or TNFR75
expression (figure 5.2.3B).
5.2.4 Effect of TNFR75 blocking monoclonal antibodies on the pro-apoptotic
effect of TNFa on neutrophils
In view of the fact that neutrophils cells express TNFR55 and TNFR75 in
approximately equal numbers, and that agonistic TNFR55 antibodies failed to induce
apoptosis in these cells, the potential role of the TNFR75 in mediating the pro-
apoptotic effect of TNFa in neutrophils was investigated using a rat IgG2b anti-human
TNFR75 monoclonal antibody. As shown in figure 4.2.6, pre-incubation of
neutrophils for 30 min with this antibody also caused a near complete (81.2 ± 7.0%)
abrogation of the pro-apoptotic effect of TNFa in neutrophils without affecting the
basal rate of apoptosis. Failure of an isotype matched rat anti-human IL-2 receptor
antibody to affect this response (figure 4.2.6) confirmed that the inhibition observed
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5.2.3B Time course for TNFR55 and TNFR75 expression in human neutrophils
in the presence and absence of PAF
Human neutrophils (5xl06/ml) were pre-incubated in serum-supplemented Iscove's
MDM in the presence or absence ofPAF (1 pM) for 5 min at prior to incubation for
0, 1, 2, 3 or 6 hr in flexiwell plates at 37°C. At these time points TNFR55 (figure
5.2.3B(i) and TNFR75 (figure 5.2.3B (ii) expression was quantified by flow
cytometry as detailed in Materials and Methods (2.2.6). Data represent % of specific
receptor expression values obtained in freshly isolated cells with each point being the
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Figure 5.2.4 Effect of TNFR75 blocking monoclonal antibodies on the pro-
apoptotic effect of TNFa in neutrophils
Human neutrophils (5xl06/ml) were pre-incubated in serum-supplemented Iscove's
MDM with 28 pg/ml rat IgG2b anti-human TNFR75 monoclonal antibody (mAb) or
isotype matched rat anti-human IL-2 receptor antibody (IL-2R mAb, negative
control) for 30 min at 37°C prior to culture in the presence or absence of 12.5 ng/ml
TNFa as indicated. Neutrophils were harvested following 6 hr in culture and
apoptosis assessed morphologically. Data represent mean ± SEM of 4 experiments,
each performed in triplicate.
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experiments demonstrated that the ariti-TNFR75 antibody had no effect on TNFa-
mediated priming of fMLP (100 nM)-stimulated superoxide generation in neutrophils
(E Kitchen, Ph D Thesis, 1997). These data imply that co-activation of TNFR75 is
required for TNFa-signalling for apoptosis in neutrophils.
5.2.5 Effect of TNFR55-selective mutants on early neutrophil apoptosis
In the absence of available TNFR75 agonistic antibodies, complementary
experiments were performed in collaboration with Dr. Jeffrey A. J. Barbara (Renal
Unit, Flinders Medical Centre, Bedford Park, South Australia 5042) to assess the
effects of the TNFR55-selective TNFa agonistic mutants E146K and R32W-86T and
the TNFR75-selective mutant D143F (Barbara et al., 1994) on neutrophil apoptosis.
The former TNFR55-selective peptides have a 3300- and 5000-fold lower affinity for
the TNFR75 receptor with only marginal (2- and 2.2-fold) reduction in TNFR55
affinity whereas the TNFR75 ligand D143F displays a 30-fold reduced affinity for
TNFR75 and no binding to TNFR55 (Van Ostade et al., 1994, Loetscher et al., 1993).
Figure 4.2.5 demonstrates the ability of both TNFR55 mutants to induce apoptosis
(as assessed by morphological criteria), albeit with a lower potency than recombinant
TNFa (ECS0 values, ng/ml: wild type TNFa, 5.0; E146K, 82.7; R32W-S86T, 69.5;
both p <0.01 compared to TNFa). The TNFR75 selective agonist (D143F) did not
induce apoptosis even at a concentration of 100 ng/ml. These data imply that one
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Figure 5.2.5 Effect of TNFa receptor selective muteins on human neutrophil
apoptosis
Human neutrophils were incubated in RPMI-1640 medium supplemented with 0.1%
bovine serum albumin (BSA) with 0.01-100 ng/ml of wild-type TNFa (wtTNFa,
squares), the TNFR55-selective muteins R32W-S86T (circles) or E146K (diamonds),
and the TNFR75-selective mutein D143F (triangles). Apoptosis was assessed
morphologically after 3 hr. Data represent mean ± SEM of three experiments, each
performed in triplicate (experimental data provided by Dr. Jeffrey Barbara).
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role of the TNFR75 is to facilitate the ability of TNFR55 to induce apoptosis in
human neutrophils.
5.2.6 Effect of TNFR75 blocking antibody on TNFa-mediated inhibition of
apoptosis at 20 hr
The involvement of TNFR75 in mediating the later, inhibitory effect of TNFa in
neutrophils was also evaluated using the rat anti-human IgG2b monoclonal antibody
which blocked the pro-apoptotic effect of TNFa as described in 4.2.4. Figure 4.2.6
demonstrates that pre-incubation of neutrophils for 30 min with this antibody, or the
isotype matched IL-2R control antibody, had no influence on the late inhibitory
effect of TNFa on apoptosis observed at 20 hr. This lack of effect of the TNFR75
blocking antibody on the late inhibition of neutrophil apoptosis by TNFa was not a
result of loss of functional activity since flow cytometric analysis of antibody binding
was identical for fresh antibody and for antibody incubated for 20 hr in serum-
supplemented medium (data not shown). These data indicate that, in contrast to its
essential role in mediating the early pro-apoptotic effect of TNFa, TNFR75 does not
appear to be involved in signaling the later anti-apoptotic effect of TNFa. In
equivalent experiments designed to assess the role of TNFR55 in this system the
TNFR55 blocking antibody itself appeared to inhibit slightly the basal rate of
apoptosis at 20 hr excluding further analysis (data not shown).
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5.2.6 Effect of TNFR75 blocking monoclonal antibody on TNFa-mediated
inhibition of neutrophil apoptosis
Human neutrophils (5xl06/ml) were pre-incubated with 28 pg/ml rat IgG2b anti-
human TNFR75 monoclonal Ab (mAb) or isotype matched rat anti-human IL-2
receptor mAb (IL-2R mAb, negative control) in serum-supplemented Iscove's MDM
for 30 min at 37°C prior to culture in the presence or absence of 12.5 ng/ml TNFa as
indicated. Neutrophils were harvested following 20 hr in culture and apoptosis
assessed morphologically. Data represent mean ± SEM of triplicate determinations
in a single representative experiment of 2.
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5.3 Discussion
The absolute number of TNFRs on the cell surface of human neutrophils is rather low,
falling within the range of 500-6000 (Shalaby et ah, 1987, Larrick et ah, 1987,
Schleiffenbaum and Fehr, 1990, Porteu and Nathan, 1990). In the work presented in
this chapter we have demonstrated that TNFR55 and TNFR75 are expressed in
approximately equal densities on freshly isolated human peripheral blood neutrophils.
Unlike this finding in agreement with the previous report of Barbara and co-workers
(1994), a study by Abe et ah, (1995) using in-house agonistic rabbit anti-human
TNFR polyclonal antibodies suggested that the TNFR75 was the predominant
receptor expressed on these cells. An earlier study by Lantz et ah, (1994)
demonstrated shedding of TNFRs in human neutrophils following adherence or
activation by both PMA and fMLP, which was more pronounced for TNFR55. The
neutrophil isolation technique used in our studies results in minimal priming which
can occur as a consequence of other cell preparation methods (e.g. Ficoll gradient
separation or red cell lysis, Haslett et ah, 1985). Since shape-change and aggregation
accompany neutrophil priming, one might speculate that disparities in the literature
with regard to the relative expression of the two TNFRs may be a consequence of
selective receptor shedding occurring during different cell preparation methods. The
time-dependent decrease in TNFR55 and TNFR75 during neutrophil culture is
consistent with the demonstration of adherence-induced TNFR shedding by Lantz et
ah, (1994), and is discussed in detail in Chapter 4.
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TNFa activates TNFR55 and TNFR75 by oligomerization through the trimeric
ligand. The ability of TNFR-specific agonistic antibodies to mimic TNFa activities
is evidence that the sole function of TNFa is clustering of its receptors and that no
additional activities of this cytokine are required after internalization of the ligand-
receptor complex (Espevik et al., 1990). The kd values of TNFR55 and TNFR75 for
TNFa are approximately 0.5 nM and 0.1 nM respectively (Loetscher et al., 1990,
Schall et al., 1990, Smith et al., 1990).
A number of studies have attempted to examine the function of TNFR55 and
TNFR75 in neutrophils. These studies have employed a variety of selective mono-
and polyclonal blocking and agonist antibodies together more recently with specific
agonist mutant proteins. Very few of these studies however have used more than one
type of reagent and there have been no comparative studies examining the effects of
these agents. Flence, although most authors have demonstrated a major role for
TNFR55 in priming of respiratory burst activity and degranulation, considerable
debate remains about the functional role of TNFR75. Hence Abe and colleagues
(1995) using in-house polyclonal antibodies claimed that TNFR55 is the only
receptor subtype involved in TNFa-induced priming of elastase, lactoferrin and
superoxide release. In contrast, Barbara et al., (1994) using selective mutein
agonists, concluded that TNFR75 activation facilitates TNFR55 function. Similarly,
in adherent neutrophils, where TNFa functions as a full secretagogue (Nathan et al.,
1987, Richter et al., 1989, Nathan et al., 1989, Dri et al., 1991), Meganazzi and co¬
workers (1994) describe TNFR55 as being fully competent to induce superoxide
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generation whereas Richter et al., (1995) report an absolute requirement for TNFR75
activation for this response. Preliminary data from our group employing selective
TNFR55 and TNFR75 blocking monoclonal antibodies indicate that, at least in
suspension cells, TNFR75 is not involved in TNFa-induced neutrophil priming (E
Kitchen, Ph D Thesis, 1996).
In these studies we have demonstrated using receptor blocking antibodies that dual
activation of TNFR55 and TNFR75 is required for TNFa-mediated apoptosis in
human neutrophils. Moreover, the effectiveness of the TNFR55-selective mutants
E146K and R32W-S86T to induce apoptosis in these cells implies that TNFR75 most
likely functions to facilitate a death signal primarily initiated via TNFR55. These
data regarding the pro-apoptotic effects of TNFa are similar to results obtained in
studies using the TNFR-specific muteins to investigate the relative receptor-
dependency of the pro-inflammatory activities of TNFa (Barbara et al., 1994). In
this report the author suggested that the inability of the TNFR75 receptor mutein
D143F on its own to stimulate neutrophil functions may be due to its 30-fold
reduction in affinity for TNFR75 compared to wild-type TNFa which may result in
suboptimal receptor clustering (a pre-requisite for TNFa-signalling) especially at low
receptor numbers. In support of this, D143F induced GM-CSF production in PC60-
hTNFR75+ cells which have a higher expression of this receptor.
Involvement of TNFR75 in TNFa-mediated death appears to be restricted to
haematopoietic cells and was initially thought to reflect the ability of the higher
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affinity TNFR75 to present TNFa to the lower affinity TNFR55 via a 'ligand
passing' effect (Tartaglia et al., 1993b). However, our results demonstrating (i) the
inability of TNFR55 agonistic antibodies to induce neutrophil apoptosis while
maintaining full agonist activity in priming of fMLP-stimulated superoxide
generation, and (ii) data presented in Chapter 6 (section 6.2.1), excluding
involvement of the sphingomyelinase-ceramide pathway in the induction of
neutrophil cell death, a principal signalling route associated with TNFR55, suggests
that, at least in the neutrophil, this is not the case. Moreover, data in PC60 T-cell
hybridomas, where co-expression of high levels of TNFR75 in addition to low levels
TNFR55 is likewise required to observe TNFa-stimulated apoptosis, have excluded
such a mechanism (Vandenabeele et al., 1995).
The involvement of TNFR75-derived intracellular signals in the death effect of
TNFa is supported by the recent demonstration that TNFa can induce T-cell
receptor-induced apoptosis in p55'A mice indicating that under certain circumstances
TNFR75 can function alone to induce apoptotic cell death (Zheng et al., 1995) and
similar conclusions have been reached in HeLa cells using TNFR75-selective
antibodies (Bigda et al., 1994). The precise mechanism whereby TNFR75 initiates
apoptosis or permits TNFR55-induced death remains uncertain however, not least
because this receptor has a relatively short cytoplasmic domain with no intrinsic
kinase activity or death domain sequence (as found in TNFR55 and Fas (Tartaglia et
al., 1993a). However, the recent discovery of a TNFR75-associated kinase which
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phosphorylates both TNFRs provides a potential mechanism whereby TNFR75 could
facilitate TNFR55 intracellularly (Dornay et ah, 1994).
Weiss and co-workers (1997) have recently indicated a role for the TNF receptor-
associated factor-2 (TRAF2) in the cross-talk between TNFR55 and TNFR75 that
underlies TNFa-mediated cytotoxicity in HeLa transfectants expressing wild-type
TNFR75. In these studies, selective stimulation of TNFR75 with agonist mAbs was
insufficient to induce apoptosis, however TNFR55-mediated cytotoxicity was
enhanced 1000-fold by co-stimulation of TNFR75. Moreover, the use of selective
agonistic Abs to induce dual receptor stimulation ruled out that the enhancement
observed was a result of ligand passing. A role for TRAF2 in this receptor synergy
model was suggested by the inability ofHeLa TNFR75 deletion mutants, which
lacked the TRAF2 binding, to potentiate TNFR55-mediated cytotoxicity in these
cells. Although TRAF2 appears to mediate both TNFR55 and TNFR75-induced
activation ofNFkB, as well as that related to CD40 receptor stimulation (Rothe et ah,
1995b, Hsu et ah, 1996a), several lines of evidence suggest that the TNFR75-
mediated potentiation of TNFR55-stimulated cytotoxicity observed was independent
of activation of this transcription factor; (i) while co-stimulation of both receptors
resulted in a 1000-fold increase in cytotoxicity over that observed with TNFR55
stimulation alone, the induction ofNFxB-dependent responses (IL-6 and manganese
superoxide dismutase generation) was additive, (ii) the TNFR75-mediated co-
operativity was only effective in the presence of protein synthesis inhibitors, making
association with NFKB-dependent gene expression unlikely and (iii), there are now
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several reports in the literature to support a protective role for NFkB in TNFa-
mediated apoptosis (Beg and Baltimore, 1996, Wang et al., 1996, Van Antwerp et al.,
1996, Liu et al., 1996).
An independent pro-apoptotic role for TRAF2 is supported by studies demonstrating
that CD30 and CD40, which can induce cytotoxicity under certain conditions, can
also bind TRAF2 (Mosialos et al., 1995, Cheng et al., 1995, Lee et al., 1996). In the
case of CD30-mediated TCR-dependent cell death of T cell hybridomas, the receptor
binding site of TRAF2 is also necessary for the induction of cytotoxicity (Lee et al.,
1996). Moreover, synergistic actions of TNFR55 and CD40 have been demonstrated
in FleLa cells (Hess and Engelmann, 1996).
As the direct functional role for TRAF2 in TNFR75-mediated potentiation of
TNFR55-dependent cytotoxic signalling has yet to be defined, it cannot be
overlooked that TRAF2 may not be involved in this process and that the TRAF2
binding site for TNFR75 may bind or co-operate in the binding of as yet another
unidentified factor(s) responsible for apoptotic signalling. Finally, of interest, the
TNFR55-associated protein TRADD, which is necessary for TNFR55-mediated
apoptosis (Hsu et al., 1995, 1996b), interacts directly with TRAF2 in intact cells and
therefore affords a further direct link between TNFR55 and TNFR75 signalling (Hsu
et al., 1996a).
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Chapter 6: Signalling pathways in TNFa-stimulated apoptosis in
human neutrophils
6.1 Introduction
In the previous chapters we have established and characterized the ability of TNFa to
induce apoptosis in human neutrophils at early time points. Moreover, we have
demonstrated that this pro-apoptotic effect of TNFa is mediated via an
unconventional route whereby the TNFR75 facilitates and permits cell death
mediated by TNFR55, which contains the classical death-domain sequence (Tartaglia
et al., 1993a). There are now a number of reports in the literature which describe
studies designed to investigate the role of signalling pathways in TNFa-mediated
cytotoxicity in various cell types, and these are summarized in table 6.1.1.
While it is currently difficult to provide a unifying hypothesis from such data, the
general theme emerges that inhibition of protein kinase (PK) activity, be it PKC,
protein tyrosine (PTyr)K or cyclic nucleotide-dependent kinases (PKA, PKG), and/or
concurrent activation of ceramide generation, may underlie TNFa-stimulated
apoptosis. In the neutrophil such a hypothesis would be supported by data indicating
the majority of agents that activate cells and switch on one or more of these kinase
pathways appear to delay apoptosis and also existing results demonstrating that
pharmacological activation of the PKC, PKA and PKG pathways also enhance
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CELL TYPE PROPOSED SIGNALLING ROUTE FOR TNFa-INDUCED
CYTOTOXICITY
U937 TNFa-induced apoptosis was mimicked by C2-ceramide and
the pro-apoptotic effects of both agents were prevented by the
pharmacological PKC activator, PMA (Obeid et ah, 1993).
U937 Calyculin A and okadaic acid, protein phosphatase inhibitors,
augmented TNFa-induced apoptosis in U937 cells and




TNFa-induced apoptosis was mimicked by C8-ceramide and
neutral sphingomyelinase (Jarvis et ah, 1994).
Human neutrophils TNFa-induced apoptosis in vitro was mimicked by




TNFa-induced cytotoxicity in the presence of cycloheximide
was inhibited (by approximately 50%) by the protein tyrosine
kinase inhibitor AG1288 (Novogrodsky et ah, 1994).
Mouse hepatocytes TNFa-induced apoptotic and secondary necrotic liver injury in
GalN-sensitized mice in vivo was completely prevented by
pharmacological doses ofNO donor sodium nitroprusside
(Bohlinger et ah, 1995).
Rat hepatocytes TNFa-induced apoptosis in the presence of actinomycin-D in
vitro was inhibited by NO donor SNAP (Kim et ah, 1997).
Table 6.1.1 Proposed signalling routes for TNFa-stimulated apoptosis in
various cell models
(PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; GalN, D-
galactosamine; NO, nitric oxide; SNAP, S-nitroso-N-acetylpenicillamine).
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neutrophil survival (MKB Whyte, Ph D Thesis, 1993, Rossi et al., 1995, Cousin et
ah, 1997; TW Wong, AG Rossi and ER Chilvers, personal communication).
To begin to examine the potential signalling pathway(s) involved in mediating the
TNFa death signal in neutrophils, selective pathway inhibitors or cell-permeable
mimetics that block TNFa-mediated cytotoxicity in other cell models were exploited.
In view of previous reports demonstrating that in certain cell lines, in particular the
murine fibrosarcoma L929 cell line, the cytotoxic effects of TNFa could be
abrogated by culturing cells either under anoxic conditions (Matthews et al., 1987) or
by co-incubating with anti-oxidants or mitochondrial inhibitors (Yamauchi et al.,
1989, Matsuda et al., 1991, Chang et al., 1992, Schulze-Osthoff et al., 1993,
O'Donnell et al., 1995, Talley et al., 1995, Goossens et al., 1995), additional
experiments were designed to assess the ability of TNFa to induce apoptosis in cells
cultured under anoxic conditions. Such an approach allows us to determine whether
the pro-apoptotic effect of this cytokine in neutrophils is mediated by (or dependent
upon) the generation of reactive oxygen species or a capacity for aerobic respiration.
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6.2 Results
6.2.1 Effect of C6-ceramide and neutral sphingomyelinase on neutrophil
apoptosis
In view of recent reports implicating TNFa-stimulated sphingomyelin hydrolysis and
ceramide generation in mediating the pro-apoptotic activities of TNFa in leukaemic
cell lines (Obeid et ah, 1993, Jarvis et ah, 1994), the effects of exogenous ceramide
and sphingomyelinase on neutrophil apoptosis were examined. Incubation of
neutrophils with a synthetic, cell-permeable C6-ceramide analogue (10 pM) or a
bacterial preparation of neutral sphingomyelinase (200 mU/ml), at concentrations
known to induce apoptosis in other myeloid models (Obeid et ah, 1993, Jarvis et ah,
1994), did not induce apoptosis in these cells (figure 6.2.1). Identical data were
obtained using 10 pM of the shorter chained synthetic C2-ceramide (data not shown).
In a separate series of experiments C2- and C6-ceramides were shown to mimic the
effects of TNFa in inducing apoptosis in HL-60 cells as assessed by DNA
fragmentation (MF Lawson, personal communication), confirming both the activity
of the sphingolipids used in these studies and previously published data in this cell
type (Jarvis et ah, 1994). Hence, the capacity of exogenously applied ceramide to




Figure 6.2.1 Effect of C6-ceramide and neutral sphingomyelinase on neutrophil
apoptosis
Human neutrophils (5xl06/ml) were cultured for 6 hr either in serum-supplemented
Iscove's MDM alone (control) or in identical medium containing : (final
concentration) TNFa (12.5 ng/ml), C6-ceramide (C6-cer, 10pM), ethanol (0.1%,
ceramide vehicle control), neutral sphingomyelinase (S'Mase, 200 mU/ml), or
glycerol (0.27%, sphingomyelinase vehicle control). Neutrophils were harvested and
assessed for morphological features of apoptosis. Data represent mean ± SEM of 3
separate experiments, each performed in triplicate. Where not shown, SEM values
are <2%.
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6.2.2 Effect of C6-ceramide and neutral sphingomyelinase on fMLP-stimulated
superoxide anion generation in neutrophils
Addition of the cell-permeable ceramide analogue C6-ceramide (30 pM, 30 min,
37°C) produced no discernible direct or fMLP-priming effect on superoxide anion
release; neutrophils from the same donor incubated in parallel with TNFa as a
positive control exhibited classical augmentation of the superoxide anion response to
fMLP (figure 6.2.2). The slight apparent effect of sphingomyelinase on superoxide
generation observed was attributable to its vehicle (50% glycerol/PBS, 50 mM Tris-
HC1, pH 7.5). It was concluded therefore that ceramide does not appear in isolation
to mediate the priming effects of TNFa in human neutrophils, which agrees with data
obtained by Yanaga and Watson (1995).
6.2.3 Effect of sphingosine on basal and TNFa-stimulated neutrophil apoptosis
In view of a previous report demonstrating that the pro-apoptotic effect of TNFa in
human neutrophils could be mimicked by sphingosine (15 pM; Ohta et al., 1994), the
effects of this sphingolipid on the rates of constitutive and TNFa-stimulated
apoptosis was examined in these cells. In agreement with the previous study, the rate
of apoptosis in neutrophils incubated for a 6 hr period in the presence of sphingosine
(15 pM) was almost identical to that recorded for TNFa-stimulated cells (figure
6.2.3); the cells stimulated with sphingosine displayed classical morphological
features of apoptosis. However the pro-apoptotic effect of sphingosine was entirely
additive to that of TNFa, (figure 6.2.3), implying that these agents may utilize
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Figure 6.2.2 Effect ofC6-ceramide and neutral sphingomyelinase on fMLP-
stimulated superoxide anion generation in neutrophils
Human neutrophils (106 in 90 pi PBS with CaCl2 and MgCl2) were incubated at 37°C
with C6-ceramide (C6-cer, 30 pM), neutral sphingomyelinase (S'Mase, 200 mU/ml),
TNFa (200 U/ml) or the appropriate vehicle for 30 min prior to the addition of pre-
warmed cytochrome C (final concentration 1.2 mg/ml), and fMLP (final
concentration 100 nM, filled bars) or buffer (hatched bars) to a final volume of 1 ml.
SOD 375 U was incubated in one of each set of quadruplicate incubations. After 15
min the cells were pelleted at 4°C and the optical density of the supernatants
determined by scanning spectrophotometry (550 nm); superoxide anion generation
was calculated as described in the Materials and Methods section (2.5). Data
represent mean ± SEM of 3 separate experiments, each performed in triplicate.
(Experimental data provided by Dr AM Condliffe).
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Figure 6.2.3 Effect of sphingosine on basal and TNFa-stimulated neutrophil
apoptosis
Human neutrophils (5xl06/ml) were incubated in serum-supplemented MDM alone
(control) or in identical medium containing: (final concentration) TNFa (12.5 ng/ml),
sphingosine (SP'sine, 15 pM) or TNFa (12.5 ng/ml) plus sphingosine (15 pM).
Neutrophils were harvested following 6 hr in culture and apoptosis assessed
morphologically. Data represent mean ± SEM of triplicate determinations in a single
representative experiment of 3.
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distinct rather than identical routes to signal cell death in human neutrophils. The
pattern of effect of sphingosine was also very similar to that subsequently obtained
using the PKC inhibitor Ro31-8220 (table 6.2.7) which may well explain the
mechanistic basis of the sphingosine effect which would appear to work in parallel
with the pro-apoptotic effects of TNFa.
6.2.4 The involvement of phosphoinositide 3-kinase in TNFa-stimulated
neutrophil apoptosis
A number of very recent reports have proposed that agonist-stimulated activation of
the phosphoinositide 3-kinase (PI3K) resulting in a phosphatidylinositol 3,4,5-
trisphosphate (Ptd Ins (3,4,5) P3)-dependent stimulation of PKB (Akt-1) is a
powerful anti-apoptotic signal in certain cells (Hemmings, 1997, Toker and Cantley,
1997). To investigate the involvement ofPI3K activity in mediating the pro-
apoptotic effect of TNFa in neutrophils we examined the effect of the fungal
metabolite wortmannin, which at the concentrations used in this study is a highly
selective PI3K inhibitor (100 nM; Arcaro and Wyman, 1993), on basal and TNFa-
stimulated neutrophil apoptosis. This agent, although highly unstable in an aqueous
environment, causes rapid and irreversible inhibition ofPI3K activity which is
mediated via its interaction with the ATP binding site of the pi 10 subunits of both
the PI3K isoforms found in neutrophils (Yano et al., 1993). This agent is non-toxic
to neutrophils over 20 hr (trypan blue exclusion) and in parallel studies has been








Figure 6.2.4 The involvement ofPI3K in TNFa-stimulated neutrophil apoptosis
Human neutrophils (10xl06/mi) were incubated for 6 hr in serum-supplemented
Iscove's MDM in a final volume of 2 ml in bags prepared from heat-sealed Teflon
film (Chemical Fabrics Corporation, New Hampshire, U.K.). Neutrophils were
incubated for 6 hr either in Iscove's MDM alone (control) or in identical medium
containing: (final concentration) TNFa (12.5 ng/ml), wortmannin (WM, 100 nM),
TNFcc (12.5 ng/ml) plus WM (100 nM), or DMSO vehicle (0.1%). WM was
replenished hourly (10 pi, final concentration 50 nM) due to its instability in aqueous
solution; controls and treatments were topped up simultaneously with medium or
vehicle to control for the potential effects of cell resuspension, volume increase or
cumulative DMSO effects. Neutrophils were harvested and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 3 separate
experiments, each performed in triplicate.
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does not affect PMA-induced NADPH activation (Laudanna et al., 1993; Dr ER
Chilvers, personal communication).
Incubation of neutrophils with wortmannin (100 nM) alone had no effect on the basal
rate of apoptosis at 6 hr but greatly augmented the ability ofTNFa to induce
apoptosis (figure 6.2.4). Augmentation ofTNFa-stimulated apoptosis however was
only observed when the concentration of wortmannin (100 nM) was replenished
hourly (data not shown). Even using such a replenishment regime, wortmannin
either on its own, or in the presence of TNFa, had no effect on cell viability or
recovery. The relatively small pro-apoptotic effect of TNFa recorded in these
experiments compared to data presented in chapter 3 reflects the combined effects of
the higher cell concentrations used, and the requirement for a 30 min inhibitor pre¬
incubation period prior to TNFa addition (as discussed in Chapter 4).
6.2.5 The role of p38 MAP kinase in TNFa-mediated stimulation and LPS-
mediated inhibition of apoptosis in neutrophils
The potential role of the p38 MAP kinase cascade in mediating the pro- and anti-
apoptotic effects ofTNFa and LPS respectively on neutrophils was examined by pre¬
incubation of cells with SB 203580 (20 pM, 30 min) an inhibitor of p38
Kinase (Lee et al., 1994). SB 203580 was originally discovered as an inhibitor of
LPS-induced cytokine (IL-1 and TNFa) synthesis in THP-1 monocytes (IC50 1 pM)
(Lee et al., 1994) and subsequently to inhibit LPS-induced activation ofMAPKAP
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kinase-2, a physiological substrate for p38 kinase.(IC50 0.6 pM). SB 203580 has also
been shown to prevent the phosphorylation of heat shock protein (hsp) 27 in response
to IL-1, cellular stress and LPS in KB and PC 12 cells (Cuenda et al., 1995) and block
TNFa-induced transcription of the IL-6 gene in fibroblasts (Bayaert et al., 1996).
Preliminary data obtained in collaboration with Drs R Plevin and A Paul (University
of Strathclyde) and Professor P Cohen (University of Dundee) have demonstrated the
capacity of SB 203580 to inhibit LPS and TNFa stimulated p38 activation and block
LPS-induced DNA synthesis in RAW 264.7 macrophages (Paul et al., manuscript
submitted).
Pre-incubation of neutrophils with SB 203580 (20 pM, 30 min) prior to stimulation
with TNFa or LPS despite having no effect on basal apoptosis at these time points
clearly potentiated TNFa-induced apoptosis (6 hr) (figure 6.2.5A) and suppressed
LPS-mediated inhibition of apoptosis (20 hr) (figure 6.2.5B). These data implicate
p38 MAP kinase activation in protection of neutrophils against apoptotic stimuli.
6.2.6 The role of the p42/44 MAP/ERK cascade in TNFa-mediated stimulation
and LPS-mediated inhibition of apoptosis in neutrophils
The role of the "classical" p42/44 MAP/ERK cascade in mediating the pro- and anti-
apoptotic effects of TNFa and LPS in neutrophils was examined by pre-incubation of
cells with PD 098059 (50 pM, 30 min), a specific inhibitor ofMEK-1 (Dudley et al.,
1995), which lies immediately upstream of the p42/44 isoforms ofMAPK. PD 098059
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Figure 6.2.5 The role of p38 MAP kinase in TNFa-mediated stimulation and
LPS-mediated inhibition of apoptosis in neutrophils
Human neutrophils (5xl06/ml) were pre-incubated (37°C, 30 min) with 20 pM p38
MAP kinase inhibitor (SB 203580), or diluent control, in serum-supplemented
Iscove's MDM for 30 min at 37°C prior to culture in the presence or absence of: 12.5
ng/ml TNFa for 6 hr (left hand panel), or 1 pg/ml LPS for 20 hr (right hand panel).
Data represent mean ± SEM of 6 determinations from 2 independent experiments.
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Figure 6.2.6 The role of the p42/44 MAP/ERK kinase cascade in TNFa-
mediated stimulation and LPS-mediated inhibition of apoptosis in neutrophils
Human neutrophils (5xl06/ml) were pre-incubated (37°C, 30 min) with 50 pM of the
MEK-1 inhibitor (PD 098059), or diluent control, in serum-supplemented Iscove's
MDM for 30 min at 37°C prior to culture in the presence or absence of: 12.5 ng/ml
TNFa for 6 hr (left hand panel), or 1 pg/ml LPS for 20 hr (right hand panel). Data
represent mean ± SEM of 6 determinations from 2 independent experiments.
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has been demonstrated to prevent the activation ofMEK-1 by Raf or MEKK in vitro
(IC50 2-7 pM; Alessi et ah, 1995) but does not appear to compete at the ATP binding
or MAPK binding site but inhibits in an unconventional manner through an allosteric
mechanism which accounts for its high degree of selectivity for MEK-1 inhibition
(Dudley et ah, 1995). Furthermore, PD 098059 does not inhibit the biological
function ofMEK-1 once phosphorylated but instead prevents the activation and
phosphorylation ofMEK-1 (Dudley et ah, 1995).
Pre-incubation of neutrophils with PD 098059 prior to stimulation with TNFa or LPS
again potentiated the early TNFa-induced pro-apoptotic signal (6 hr) (figure 6.2.6A)
but also completely attenuated the LPS-mediated inhibition of apoptosis (20 hr)
(figure 6.2.6B) implying that stimulation of the p42/44 MAP/ERK cascade is a major
pathway for LPS 'anti-apoptotic' signalling in neutrophils. These data are in
agreement with a previous study performed in rat PC-12 cells where apoptosis was
suppressed by NGF (which activates the p42/44 MAP/ERKs) and subsequent
withdrawal ofNGF from the culture medium led to p42/44 ERK inhibition which
was accompanied by a stimulation of apoptosis (Xia et ah, 1995).
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6.2.7 The role of protein kinases in constitutive and TNFa-stimulated
neutrophil apoptosis
In view of previous reports suggesting a role for protein tyrosine phosphorylation in
the regulation of apoptosis in myeloid cells (Bergamaschi et ah, 1993, Yousefi et al.,
1994, Novogrodsky et al., 1994), we exploited known inhibitors of protein tyrosine
kinases to assess the potential role of these enzymes in TNFa-induced neutrophil
apoptosis. Neither genestein (50 pM), which has been reported to block GM-CSF-
mediated inhibition of neutrophil apoptosis (Yousefi et al., 1994), or tyrphostin AG
1288 (10 pM), which has been shown to inhibit TNFa-induced cytotoxity in murine
A9 fibroblasts (Novogrodsky et al., 1994), had any influence on TNFa-stimulated
neutrophil apoptosis (table 6.2.7) indicating that an overall increase in protein
tyrosine phosphorylation is not essential for TNFa-mediated cytotoxicity in these
cells.
H-89, a specific inhibitor PKA (Combest et al., 1988, Chijiwa et al., 1990), has been
used extensively in the neutrophil to examine the role of cAMP/PKA-mediated
signalling events and has been recently demonstrated by our group to completely
antagonise the survival effect in neutrophils of a range of prostanoid analogues and
cAMP mimetics (Rossi et al., 1995). Likewise, it has been reported that TNFa
inhibits cAMP accumulation in adherent neutrophils (Nathan and Sanchez, 1990)
thereby suggesting the potential for TNFa to induce neutrophil apoptosis by reducing
the concentration of this anti-apoptotic signalling molecule.
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H-89 (100 pM), which should therefore enhance constitutive and/or TNFa-
stimulated apoptosis, had no effect on either the basal rate of apoptosis at 6 hr or the
early pro-apoptotic effect of TNFa (table 6.2.7). The conclusion that inhibiting
cAMP is unlikely to explain the pro-apoptotic effect of TNFa is further supported by
data presented in section 6.2.8 where pre-elevation of cAMP (using dibutyryl-cAMP)
does not block TNFa cytotoxicity.
% Apoptosis Control Genistein Tyr AG H-89 Ro31-8220
Control 4.3 ± 1.2 2.1 ±0.7 4.1 ± 1.2 6.1 ± 1.9 21.415.6
TNFa 10.5 + 1.2 8.2 + 2.2 10.9 + 2.1 10.9 + 2.0 25.1 +4.5
Table 6.2.7 The role of protein kinases in constitutive and TNFa-stimulated
neutrophil apoptosis
Human neutrophils (5xl06/ml) were pre-incubated (37°C, 30 min) in serum-
supplemented Iscove's MDM alone (control) or in identical medium containing:
(final concentration) genistein (50 pM), tyrphostin AG 1288 (tyr AG, 10 pM), H-89,
dihydrochloride (100 pM) or Ro31-8220 (1 pM) in the presence (closed bars) or
absence (hatched bars) of 12.5 ng/ml TNFa. Neutrophils were harvested and
assessed for morphological features of apoptosis. Data represent mean ± SEM of 5
separate experiments, each performed in triplicate.
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In view of studies in U937 cells demonstrating an inhibition of TNFa-mediated
apoptosis by the protein kinase C (PKC) activator PMA (Obeid et al., 1993), the role
ofPKC in TNFa-mediated neutrophil apoptosis was also assessed using Ro31-8220
(1 (J.M), a selective inhibitor of this enzyme. In agreement with a previous report
(MKB Whyte, Ph D Thesis, 1993, Cousin et al., 1997), this inhibitor caused a
marked increase in the rate of constitutive and TNFa-stimulated apoptosis (table
6.2.7) however, as with the previously detailed sphingosine data, it is difficult to
draw mechanistic conclusions since these results most likely demonstrate activation
of a parallel and complementary apoptotic pathway. The data however clearly do not
support a role for TNFa-stimulated PKC in driving apoptosis and are very different
to the results obtained by Obeid et al., (1993) in U937 cells.
It is important to re-emphasize that the relatively low pro-apoptotic effect of TNFa
observed reflects the need in some of these experiments to pre-incubate neutrophils
prior to exposure to TNFa which, as discussed in Chapter 4, severely abrogates the
apoptotic efficacy of TNFa.
6.2.8 Involvement of cyclic nucleotides, nitric oxide and calcium-dependent
signalling in TNFa-stimulated neutrophil apoptosis
Having failed to identify an obvious target kinase for TNFa-mediated apoptosis, a
second panel of inhibitors were assayed to (i) provide additional data to support the
premise that TNFa-mediated inhibition of cAMP accumulation was not critical to
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this response, (ii) exclude a role for inducible nitric oxide synthase (iNOS) and Ca2+
in regulating TNFa-induced apoptosis (Bohlinger et al., 1995, Kim et al., 1997) and
(iii) to explore in neutrophils, the report in U937 cells that protein phosphatase (PP)
inhibitors augment TNFa-induced apoptosis (Wright et al., 1993).
Co-incubation with Ro-20-1724 (100 pM), a potent and selective inhibitor of cAMP-
specific phosphodiesterase (PDE 4), which has previously been demonstrated to
inhibit fMLP-stimulated superoxide anion generation in human neutrophils (Lad et
al., 1985), caused a small and reproducible attenuation of TNFa-induced apoptosis
(figure 6.2.8), however with n=4 experiments this failed to reach statistical
significance. A similar but less pronounced trend was also observed with the stable
and membrane permeable analogue of cAMP, dibutyryl cAMP (0.2 mM) (figure
6.2.8).
L-NIO HC1, a potent NO synthase inhibitor (Rees et al., 1990), and the Ca2+
ionophore A23187, that causes a profound suppression of neutrophil apoptosis at 20
hr (Whyte et al., 1993b), had no effect on basal or TNFa-stimulated apoptosis at 6 hr
(figure 6.2.8). Finally, the role of protein phosphorylation in TNFa-mediated
neutrophil apoptosis was investigated using calyculin A (20 nM), a cell-permeable
serine-threonine phosphatase inhibitor, which potently inhibits both PP1 and PP2A at
sub-nanomolar concentrations (Ishihara et al., 1989) and has been demonstrated to
enhance fMLP-induced superoxide anion generation in human neutrophils
(Djerdjouri et al., 1995). This also failed to influence TNFa-mediated neutrophil
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Figure 6.2.8 Involvement of specific signalling pathway in TNFa-stimulated
neutrophil apoptosis
Human neutrophils (5xl06/ml) were incubated for 6 hr in serum-supplemented
Iscove's MDM alone (control) or in identical medium containing : final
concentration) Ro-20-1724 (100 |JM), dibutyryl-cAMP (db-cAMP, 0.2 mM), L-NIO.
HC1 (100 (iM), A23187 calcium ionophore (0.1 pM) or calyculin A (20 nM) in the
presence (closed bars) or absence (hatched bars) of TNFa (12.5 ng/ml). Neutrophils
were harvested following 6 hr in culture and assessed for morphological features of
apoptosis. Data represent mean ± SEM of 4 separate experiments, each performed in
triplicate.
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apoptosis (figure 6.2.8). These data suggest that, at least in the neutrophil, an overall
increase in the level of serine-threonine protein phosphorylation is not an essential
2+
step in TNFa-mediated cytotoxicity and that early elevation of cAMP and Ca fail to
suppress the TNFa effect.
6.2.9 Effect of hypoxia on the pro-apoptotic effect of TNFa in neutrophils
To address whether the pro-apoptotic effect of TNFa in neutrophils involves or
requires oxidative metabolism or reactive oxygen intermediates, the effect of extreme
hypoxia on this response was examined. Neutrophils were cultured in the presence
or absence of TNFa under normoxic (21% 02) or 'anoxic' conditions using medium
which had been fully deoxygenated before addition of TNFa. The pro-apoptotic
effect of TNFa was greatly reduced under anoxic conditions (figure 6.2.9)
implicating an essential role for molecular oxygen in the cytocidal effect of TNFa.
In an initial set of experiments (data not shown) neutrophils were cultured under
anoxic conditions but using medium which had not been deoxygenated prior to
TNFa stimulation where full anoxia is not fully established until 30-60 min into the
incubation period (KI Mecklenburgh, personal communication). Under these
conditions TNFa induced neutrophil apoptosis at a rate not significantly different
from its effect under normoxic conditions, indicating that the commitment of cells to
undergo apoptosis in response to TNFa is likely to be extremely rapid, occurring
within 30 min of exposure to this cytokine.
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6.2.9 Effect of hypoxia on the pro-apoptotic effect of TNFa in neutrophils
Human neutrophils (5xl06/ml) were cultured in serum-supplemented Iscove's MDM
in the presence or absence of 12.5 ng/ml TNFa under conditions of normoxia (21%
02) or anoxia (medium was fully deoxygenated prior to TNFa addition). Neutrophils
were harvested following 6 hr in culture and apoptosis assessed morphologically.
Data represent mean ± SEM of 3 separate experiments, each performed in triplicate;




In these studies we have sought to identify the intracellular mechanism(s) underlying
the induction of neutrophil apoptosis by TNFa. In view of recent reports implicating
TNFa-stimulated sphingomyelin hydrolysis and ceramide generation in mediating
the pro-apoptotic effects of TNFa in leukaemic cell lines (Obeid et ah, 1993, Jarvis et
ah, 1994) we wanted initially to explore the involvement of the
ceramide/sphingomyelinase pathway in TNFa-induced apoptosis in neutrophils.
Addition of a cell-permeable synthetic C6-ceramide or a bacterial preparation of
neutral sphingomyelinase, at concentrations that have been shown to induce rapid
and highly efficient apoptosis in a number of other cell types (Obeid et ah, 1993,
Jarvis et ah, 1994), was unable to induce apoptosis in neutrophils, or mimic TNFa-
induced priming of fMLP-stimulated superoxide generation. In this context, it is
interesting to note that bacterial endotoxin (LPS), which has a strong structural and
functional resemblance to ceramide (Wright and Kolesnick, 1995), likewise inhibits
rather than promotes neutrophil apoptosis even at early times (Lee et al., 1993).
These data suggest that the sphingomyelin/ceramide pathway may not be the
principal signalling route employed by TNFa in human neutrophils.
Despite such data, a number of other factors need to be considered prior to
dismissing completely a role for TNFa-induced ceramide generation in the pro-
apoptotic response in the neutrophil. Hence, in a collaborative study with Drs ML
Barnard and JD Bell (Hammersmith Hospital, London) we have obtained evidence
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on NMR spectroscopy for a relatively selective accumulation of phosphocholine (a
by-product of ceramide generation from sphingomyelin) in TNFa-stimulated
neutrophils (Nunn et ah, 1996). Secondly, in agreement with a previous report of
Ohta et ah, (1994), our results indicate that sphingosine, an immediate downstream
product of ceramide metabolism can both mimic and augment TNFa-induced
apoptosis in neutrophils. Furthermore, in the study of Ohta and co-workers (1994), it
is clear that TNFa can indeed stimulate both ceramide (68% increase, 5 min) and
sphingosine (95% increase, 60 min) accumulation in neutrophils and from the
kinetics of these two responses the authors propose that the increase in sphingosine
observed following TNFa stimulation may have resulted from degradation of the
newly-formed ceramide, moreover, the very high concentration of ceramide present
in unstimulated cells again suggests that sphingosine rather than ceramide itself
might function as an endogenous mediator of TNFa-induced apoptosis.
Hence, the role and function of the ceramide/sphingosine pathway in neutrophil
apoptosis remains somewhat uncertain. If sphingosine is a genuine intermediate in
this pathway, the lack of a similar response to sphingosine-1-phosphate (Ohta et ah,
1994), the initial product of sphingosine catabolism, makes a direct effect of
sphingosine-most likely the inhibition ofPKC (Hannun et ah, 1986)-the most
probable mechanism of action.
Finally, a recent report by Higuchi and co-workers (1996) which demonstrated that
addition of cell permeable ceramides was ineffective in inducing apoptosis, in the
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myeloid cell line ML-la (which is extremely sensitive to TNFa and cycloheximide-
induced cell death), also showed that the calcium channel blocker SR33557 which
inhibits the acidic (lysosomal) but not neutral sphingomyelinase (Jaffrezou et ah,
1991, 1992) caused an approximately 50% inhibition of the pro-apoptotic effect of
TNFa. Of note, this inhibition was partially reversed (by approximately 50%)
following the addition of ceramides. From this study the authors concluded that
ceramide generated by an acidic sphingomyelinase may be required but is insufficient
alone for a TNFa-mediated death signal in these cells.
To explore the potential involvement of the PI3K pathway in TNFa-induced
neutrophil apoptosis, we examined the effect of the fungal metabolite wortmannin, a
highly specific PI3K inhibitor which abolishes agonist-stimulated superoxide anion
generation in human neutrophils (Laudanna et al., 1993). In our experiments,
wortmannin had no influence on the basal rate of apoptosis at 6 hr but augmented the
cytocidal effect of TNFa. The suggestion that co-activation ofPI3K may inhibit or
retard the primary TNFa-stimulated apoptotic signalling pathway is supported by
data showing that this enzyme plays a crucial role in NGF and PDGF-mediated
survival in PC-12 cells (Yao and Cooper, 1995, 1996 Minshall et al., 1996) and
several very recent reports proposing that agonist-stimulated activation ofPI3K
resulting in a Ptd Ins (3,4,5)P3-dependent stimulation ofPKB (Akt-1) is a powerful
anti-apoptotic signal in certain cells (Toker and Cantley, 1997, Hemmings, 1997).
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The inability ofwortmannin to influence the basal rate of apoptosis in neutrophils
suggests either a lack of involvement of this enzyme in regulating the rate of early
constitutive apoptosis in these cells or inefficient enzyme inhibition perhaps due to
involvement of the plOl/pl 10 PI3K also found in neutrophils that is relatively
insensitive to wortmannin. One particularly interesting aspect of the wortmannin-
mediated augmentation of TNFa-induced apoptosis is that these data would support
our earlier hypothesis that TNFa initiates dual survival and death signals reflected by
the early induction and later inhibition of apoptosis by this cytokine. It is possible
therefore that the late TNFR55-triggered survival signal is PI3K-mediated and that a
much higher TNFa apoptotic response can be achieved if this synchronously
triggered survival signal is abolished.
There has been a recent flurry of interest in mitogen-activated protein kinase
(MAPK)-mediated signal transduction cascades which are conserved eukaryotic
signalling pathways that convert receptor derived signals into a variety of cellular
functions (for reviews see Davis , 1993, Marshall, 1995, Hunter, 1995). MAPKs are
a family of dual-specificity protein kinases activated through threonine/tyrosine
phosphorylation by MAPK kinases (MEKs), which are themselves activated by a
series ofMAPK kinase kinases (MEKKs; Blenis, 1993). Currently three distinct
mammalian MAPKs, each with apparently unique signalling functions, have been
identified. The ERK (extracellular signal-regulated kinase) group ofMAPKs are
activated by growth factors via /As-dependent kinases (Raf and MEKK) that
phosphorylate and activate the MAP/ERK kinases (MEK-1 and MEK-2) which in
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turn activate the ERK-1 and ERK-2 MAPKs (p42 and p44 MAPKs; Derijard et al.,
1995).
The JNK group ofMAP kinases (also known as stress-activated protein kinases,
SAPKs) activate the transcription factor c-Jun in response pro-inflammatory
cytokines and cell exposure to several forms of environmental stress (Sanchez et al.,
1994). JNK is activated by JNK kinase (Minden et al., 1994, Sanchez et al., 1994,
Lin et al., 1995, Derijard et al., 1995,) which is itself regulated by phosphorylation by
an upstream MEK kinase (MEKK; Lange-Carter et al., 1993); the MEKK-regulated
JNK cascade is parallel to the Raf/ERK pathway.
The third group ofMAPKs are mammalian homologues of HOG 1 found in yeast and
have been designated p38 MAP kinases on account of their molecular weight in
murine cells (Han et al., 1994). In response to environmental stresses, mitogens, and
pro-inflammatory cytokines, p38 MAPK is activated, and in turn stimulates MAPK-
activated protein (MAPKAP) kinase-2 (Rouse et al., 1994, Freshney et al., 1994)
which has been shown to be activated in human neutrophils upon stimulation by
PMA or fMLP (Zu et al., 1996). The in vivo substrates ofMAPKAP kinase-2
include heat shock protein (hsp) 27 and the transcription factors CREB and AFT1
(Cuenda et al., 1995, Tan et al., 1996). The phosphorylation of hsp27 is thought to
stimulate the phosphorylation of actin, and thus help repair the actin microfilament
network that becomes disrupted during cellular stress, thereby aiding cell survival
(Lavioe et al., 1995).
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A recent detailed study performed in rat PC-12 pheochromocytoma cells implicated
the 'classical' Ras-dependent MAP kinase pathway (p42/44) and the cytokine-
activated p38 MAP kinase pathway in the prevention and induction of apoptosis
respectively (Xia et ah, 1995). Moreover, it has also been demonstrated in myeloid
cells that TNFa and LPS stimulate both the p42/p44 MAP/ERK and p38 kinase
cascades (Yuo et ah, 1993, Rafiee et ah, 1995, Nick et ah, 1996, Nahas et ah, 1996).
We were therefore keen to explore using selective pathway inhibitors the relative
contribution of these MAPK cascades in TNFa-mediated induction and LPS-
mediated inhibition of neutrophil apoptosis.
Both SB 203580, a specific inhibitor of p38 kinase (Cuenda et ah, 1995, Lee et ah,
1994), and PD 098059, an inhibitor ofMEK-1 activation of p42/p44 MAPK (Alessi
et ah, 1995, Dudley et ah, 1995), potentiated TNFa-mediated induction of apoptosis
at 6 hr. Furthermore, PD 098059 completely reversed, and SB 203580 partially
reversed, LPS-mediated inhibition of apoptosis at 20 hr. Taken together, these data
implicate MAP/ERKs (p42/44) MAP kinases and to a lesser extent, p38 MAP kinase,
in the protection of neutrophils against apoptotic stimuli.
The importance of the p42/p44 MAP/ERK kinases in cellular protection against
apoptosis is consistent with the study performed in rat PC-12 cells, where apoptosis
was suppressed by NGF which activates the p42/44 MAP kinases (Xia et ah, 1995).
The potential anti-apoptotic role of p38 MAP kinase was not identified in the studies
however since withdrawal ofNGF from the culture medium led to a sustained
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activation of transfected p38 MAP kinase and JNK, and inhibition of p42/44 ERKs,
which was accompanied by a stimulation of apoptosis. These data were interpreted
as showing that apoptosis in NGF-differentiated PC-12 cells is regulated by the
opposing actions ofERK and JNK-p38 MAP kinase pathways, however it is possible
that activation of JNK was the dominant death trigger and that a true protective
influence of p38 was missed. Although this issue remains to be resolved, it is clear
that the dynamic balance that exists between the ERK and stress-activated JNK-p3 8
pathways may be crucial in determining whether a cell survives or undergoes
apoptosis. Likewise, the capacity ofPD098059 to protect neutrophils from the
(adverse) effects of LPS on neutrophil survival, without affecting LPS priming (Drs
M-H Sparagno and AG Rossi, personal communication), represents an important
advance since it offers a potential route to enhance neutrophil clearance by inducing
selective blockage of survival factor-induced cell longevity.
In view of previous studies implicating protein tyrosine phosphorylation in the
regulation of apoptosis in myeloid cells (Bergamschi et ah, 1993, Yousefi et ah,
Novogrodsky et ah, 1994) we also sought to define the potential role of protein
tyrosine kinases in TNFa-mediated neutrophil apoptosis again by exploiting well-
established inhibitors of these enzymes. Neither genestein, which has been shown to
inhibit both GM-CSF-mediated inhibition of neutrophil apoptosis (Yousefi et ah,
1994) and TNFa-stimulated neutrophil adhesion to endothelial cell monolayers in
vitro (McGregor et ah, 1994), or tyrphostin AG 1288 which has been demonstrated
to inhibit TNFa-induced cytotoxicity in murine A9 fibroblasts (Novogrodsky et ah,
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1994), had any influence on TNFa-stimulated neutrophil apoptosis, implying that an
overall increase in protein tyrosine phosphorylation is not an essential step in TNFa-
mediated cytotoxicity in these cells.
In view of previous studies demonstrating inhibition of TNFa and C2-ceramide-
induced apoptosis in U937 cells by the PKC activator PMA and a similar inhibition
of constitutive apoptosis in human neutrophils (Obeid et ah, 1993, MKB Whyte, Ph
D thesis, Cousin et ah, 1997) the potential role ofPKC activation in TNFa-induced
neutrophil apoptosis was investigated. In agreement with the study by Cousin and
colleagues (1997), the PKC inhibitor Ro-318220 induced a marked increase in the
rate of neutrophil apoptosis. However, although the extent of TNFa-induced
apoptosis was greater in the presence ofRo-318220, the ability of this agent to
stimulate apoptosis per se makes it very difficult to assess the 'serial' role of PKC
inhibition in TNFa-mediated neutrophil apoptosis. Indeed, the near-additivity of the
TNFa and Ro-318220 pro-apoptotic effects makes it likely that PKC regulation of
neutrophil apoptosis is independent of the TNFa-mediated death signal.
To explore the TNFa-mediated death signal in neutrophils in more detail, inhibitors
of specific pathways implicated in TNFa-mediated cytotoxicity in other cell models
were exploited. It is well documented that agonist-induced activation of human
neutrophils is inhibited by cAMP-elevating agents such as the adenylyl cyclase
activator forskolin, phosphodiesterase inhibitors, and receptor-directed
prostaglandins (Darius et ah, 1994, Pons et ah, 1994, Armstrong et ah, 1994).
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Despite numerous reports demonstrating that elevation of cAMP promotes apoptosis
in myeloid cells (e.g. McConkey et al., 1990, Lomo et al., 1995), a recent report from
our laboratory demonstrated a paradoxical and profound inhibition of human
neutrophil apoptosis by cAMP analogues and cAMP elevating agents which was
completely reversed with H-89, a selective inhibitor of PKA (Rossi et al., 1995). In
view of these data, and a previous report demonstrating that TNFa and CD11/CD18
((32) integrins act synergistically to inhibit cAMP accumulation in human neutrophils
(Nathan and Sanchez, 1990), our first strategy was to assess the potential for TNFa to
induce apoptosis by inhibiting cAMP levels. Flowever, elevation of intracellular
cAMP with the cell-permeable mimetic, dibutyryl cAMP, or by inhibition of
phosphodiesterase activity failed to ameliorate the pro-apoptotic effect of TNFa and
likewise the PKA inhibitor H-89 did not enhance either basal or TNFa driven
apoptosis.
Nitric oxide (NO) is a short-lived biological mediator which may be either pro¬
inflammatory or anti-inflammatory depending on its effective concentration at sites
of inflammation (Barnes and Belvisi, 1993, Albina and Reichner, 1995, Brady and
Poole-Wilson, 1995, Kubes, 1995, Loscalzo and Welsh, 1995, Moilanen and
Vapaatalo, 1995, Barnes, 1996). A previous in vivo study has demonstrated that
pharmacological doses of the NO donor sodium nitroprusside conferred complete
protection against TNFa-induced hepatocyte apoptosis and secondary necrosis in D-
galactosamine-sensitized mice (Bohlinger et al., 1995). In addition, a more recent
study has demonstrated that the NO donor S-nitroso-N-acetylpenicillamine (SNAP)
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protects rat hepatocytes from TNFa-stimulated apoptosis in vitro by inducing heat
shock protein 70 expression (Kim et al., 1997). In view of these findings, the role of
NO in TNFa-mediated neutrophil cytotoxicity was examined. While we have not
performed a detailed biochemical analysis of the effects of iNOS expression or NO
generation, incubation of neutrophils with an NO synthase inhibitor had no influence
on basal or TNFa-mediated neutrophil apoptosis implying that NO generation does
not function as a principal apoptotic signalling intermediate, or a protective factor.
2+
The potential role of intracellular calcium ([Ca ]i) in TNFa-mediated neutrophil
apoptosis was investigated using A23187, a calcium ionophore which has been
previously reported to inhibit the constitutive rate of neutrophil apoptosis in vitro via
2+
transient elevations of [Ca ]i (Whyte et al., 1993b). It was predicted therefore that if
2+
the apoptogenic effect of TNFa was mediated via inhibition of basal [Ca ]i levels
that A23187 would block its effect; however, A23187 had no influence on the pro-
apoptotic effect of TNFa indicating that this cytokine signals neutrophil death via a
calcium-independent route. This data is supported by a previous study from our
laboratory which demonstrated that TNFa does not influence basal or agonist-
2+
induced Ins(l,4,5)P3 or [Ca ]i levels in neutrophils (Drs AM Condliffe and ER
Chilvers, personal communication).
A previous study has demonstrated that okadaic acid and calyculin A, inhibitors of
protein phosphatases, PP1 and PP2A, were synergistic with TNFa in the induction of
apoptosis in wild type U937 cells and completely reversed the resistance of a TNFa-
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resistant variant (U9-TR; Wright et al., 1993), indicating that protein phosphorylation
may function as a critical factor determining sensitivity or resistance to TNFa-
induced cytotoxicity in these cells. With this data in mind, we sought to explore the
potential role of protein phosphorylation in TNFa-mediated neutrophil apoptosis.
The cell-permeable serine-threonine inhibitor calyculin A had no influence on TNFa-
mediated neutrophil apoptosis implying that, at least in the neutrophil, an overall
increase in the levels of protein phosphorylation is certainly not an essential step in
TNFa-mediated cytotoxicity
In certain cell lines, in particular the murine fibrosarcoma cell line L929, the
cytotoxic effect of TNFa has been abrogated by culturing cells either under anoxic
conditions (Matthews et al., 1987), or by co-incubating with anti-oxidants or
mitochondrial inhibitors (Yamauchi et al., 1989, Matsuda et al., 1991, Chang et al.,
1992, O'Donnell et al., 1995, Talley et al., 1995, Goossens et al., 1995). Moreover,
cellular sensitivity or resistance to TNFa has been correlated with decreased or
increased levels of superoxide dismutase respectively (Hirose et al., 1993). In
addition, in L929 cells TNFa stimulation has been shown to result in a rapid and
receptor-mediated rise in the intracellular levels of reactive oxygen species
(Matthews et al., 1987, Larrick and Wright, 1992, Goossens et al., 1995), and
ultrastructural changes in mitochondrial morphology that occur without any
pronounced damage to other cellular organelles (Matthews et al., 1987, Schulze-
Osthoff et al., 1992). These data lead to the proposal that TNFa induces cell death
by causing mitochondrial dysfunction and upregulation of the production of
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intracellular reactive oxygen intermediates. A recent publication from our laboratory
reported that the constitutive rate of neutrophil apoptosis is inhibited when cells are
cultured under hypoxic conditions (Hannah et ah, 1995) and subsequently, the pro-
apoptotic effects of E.Coli ingestion and phagocytosis of serum-opsonized Oil-red-O
particles have been attributed to an oxidant-induced killing mechanism (Watson et
ah, 1996, Coxon et ah, 1996).
To determine whether the pro-apoptotic effect of TNFa in neutrophils is mediated via
generation of reactive oxygen species, the ability of this cytokine to mediate a death
signal in cells cultured under anoxic conditions was investigated. In agreement with
other studies implicating oxidative stress in TNFa-mediated cytotoxicity, cell culture
under near anoxic conditions was the one intervention that resulted in a dramatic
abrogation of the pro-apoptotic effect of TNFa. Of relevance, a recent detailed report
presented data demonstrating that physical hypoxia (substitution of 02 by nitrogen)
and chemical hypoxia (induction by sodium cyanide) did not alter expression of the
neutrophil TNFR55 (Scannel et ah, 1995). This result eliminates the possibility that
the inhibition of the pro-apoptotic effect observed in our studies was secondary to
shedding or down-regulation of the TNFR55 receptor subtype. It is interesting to
note however that a large number of agents that induce a dramatic respiratory burst
response in the neutrophil and hence lead to the accumulation and release of
substantial quantities of reactive oxygen intermediates do not trigger apoptosis, and
wortmannin which blocks all activation of the NADPH oxidase as just shown does
not in any way abrogate the TNFa killing effect. Hence further studies are needed to
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determine whether TNFa-stimulated apoptosis in neutrophils can also be abrogated
by other anti-oxidant strategies including mitochondrial inhibitors and uncouplers,
and iron chelators in order to define the precise mechanism underlying the inhibition
by hypoxia of the apoptotic effect of TNFa in these cells.
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Chapter 7: Summary
Granulocyte apoptosis has been proposed as an important mechanism underlying the
removal of redundant neutrophils from an inflammatory focus. The ability ofmany
pro-inflammatory agents to impede this event in vitro suggests that such agents act
not only in a priming and/or secretagogue capacity but also increase neutrophil
longevity by delaying apoptosis. This thesis has examined whether this hypothesis
holds true for all priming agents, in particular TNFa, which has been variably
reported to either induce, delay, or have no effect on neutrophil apoptosis.
Incubation of neutrophils with various priming and activating agents for 20 hr either
inhibited (LPS, LTB4, GM-CSF, IP6) or had no effect on (fMLP, PAF) the extent of
neutrophil apoptosis. TNFa however, although causing a significant inhibition of
neutrophil apoptosis at 20 hr, was pro-apoptotic at earlier times (8 hr) when the
constitutive rate of apoptosis is still low; this effect was not observed with any of the
other priming or activating agents examined at this time. Thus TNFa appears to act
in a unique, bimodal manner to enhance the rate of constitutive neutrophil apoptosis
at early times (6 hr) while inhibiting apoptosis at more delayed times (>12 hr).
The early pro-apoptotic effect of TNFa was confirmed by DNA fragmentation and
propidium iodide binding and shown to be concentration-dependent with a near-
identical EC50 value (2.8 ng/ml) to that observed for TNFa-induced priming of
fMLP-stimulated superoxide anion generation. Moreover, the early cytocidal effect
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of this cytokine was detectable within 2 hr, abolished by TNFa neutralizing antibody,
and not associated with any change in cell viability or recovery.
While neutrophils prepared from different donors varied with respect to their
susceptibility to TNFa-induced apoptosis, the intra-donor variation was very small
with individuals showing a fairly stereotyped TNFa response across time. While the
responsiveness of cells to the pro-apoptotic effect of TNFa was dramatically up-
regulated following an oral glucocorticosteroid neutrophilia-induction protocol,
short-term addition of the synthetic glucocorticoid, dexamethasone, partially
inhibited TNFa-mediated cytotoxicity.
In optimizing our culture conditions, we observed that the pro-apoptotic effect of
TNFa was greatest at lower cell densities, attenuated by even a short pre-incubation
period prior to cytokine addition, and was independent of serum concentration.
Of relevance to the inflamed site, the ability of TNFa to accelerate apoptosis was
completely lost if neutrophils were pre-treated with the priming agent PAF (1 pM, 5
min) or aged for 6 hr prior to TNFa addition. While the latter condition enhanced
TNFa-mediated inhibition of apoptosis observed at 20 hr, the efficacy of the pro-
apoptotic effect was not enhanced by co-culture with the anti-inflammatory cytokine
IL-10.
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TNFa-stimulated apoptosis was abolished by pre-incubation of neutrophils with
selective blocking antibodies to both the TNFR55 (which contains the classical
death-domain sequence and is entirely responsible for the TNFa priming effect in
suspension neutrophils) and TNFR75 receptor subtypes. Moreover, TNFR55-
selective agonist mutant proteins (E146K, R32W-S86T) induced neutrophil
apoptosis but with a potency 14-fold lower than wild type TNFa, while a TNFR75-
selective mutant (D143F) did not induce apoptosis. These data indicate that TNFa
has the ability, apparently unique to this priming agent, to induce apoptosis in human
neutrophils at early time points via a mechanism whereby the TNFR75 acts to
facilitate and permit TNFR55-mediated induction of cell death.
The pro-apoptotic effect of TNFa was not mimicked by exogenous addition of cell-
permeable synthetic ceramides or neutral sphingomyelinase, suggesting that a
sphingomyelin/ceramide triggered death pathway as observed in certain leukaemic
cell lines may not be the principal signalling route employed by TNFa in human
neutrophils. Inhibition of p38 MAP kinase and MAPKK-1 potentiated the pro-
apoptotic effect of TNFa, while suppressing the protective effect of LPS at a later (20
hr) time, implicating the p38 and p42/44 MAP kinases in the protection of
neutrophils against apoptotic stimuli. Additional pharmacological inhibitor-based
studies excluded a major role for cAMP-PKA, PKC, PTK and NO/cGMP/PKG
pathways in mediating the cytotoxic effect of TNFa.
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Finally, although human neutrophils appear quite resistant to oxidant-induced killing
(e.g. by H202, hyperoxia or NADPH oxidase activation), and wortmannin which
ablates superoxide anion generation in these cells actually augments TNFa-induced
killing, culture of neutrophils under hypoxic conditions was the one intervention that
resulted in a dramatic abrogation of the pro-apoptotic effect of TNFa. This latter
finding implicates either an oxygen-dependent step in TNFa-mediated neutrophil
apoptosis or the capacity for the survival response triggered by anoxia to override the
TNFa killing effect.
The recognition that neutrophil apoptosis can be stimulated by TNFa and that the
priming and apoptotic effects of this cytokine can be dissociated may help in the
design ofmore rational and selective anti-inflammatory therapies and underlines
further the potential benefits of local TNFa generation at an inflamed site.
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Regulation of Neutrophil Apoptosis by Tumor Necrosis Factor-a:
Requirement for TNFR55 and TNFR75 for Induction of Apoptosis In Vitro
By Joanna Murray, Jeffrey A.J. Barbara, Sarah A. Dunkley, Angel F. Lopez, Xaveer Van Ostade, Alison M. Condliffe,
Ian Dransfield, Christopher Haslett, and Edwin R. Chilvers
Granulocyte apoptosis is an important mechanism underly¬
ing the removal of redundant neutrophils from an inflam¬
matory focus. The ability of many proinflammatory agents
to impede this event suggests that such agents act not only
in a priming or secretagogue capacity but also increase neu¬
trophil longevity by delaying apoptosis. We have examined
whether this hypothesis holds true for all neutrophil priming
agents, in particular tumor necrosis factor-a (TNF-a), which
has been variably reported to either induce, delay, or have
no effect on neutrophil apoptosis. After 20 hours coincuba-
tion TNF-a inhibited neutrophil apoptosis; however, more
detailed analysis demonstrated its ability to promote
apoptosis in a subpopulation of cells at earlier (2 to 8 hours)
times. Formyl-Met-Leu-Phe, platelet-activating factor, inosi¬
tol hexakisphosphate, lipopolysaccharide, leukotriene B4,
and granulocyte-macrophage colony-stimulating factor all
inhibited apoptosis at 6 and 20 hours. The early proapoptotic
NEUTROPHIL APOPTOSIS, which results in the recog¬nition and uptake of these cells by macrophages, has
been proposed as an important mechanism for the removal
of neutrophils from sites of inflammation.1"6 Experimental
data obtained using human peripheral blood neutrophils
show that these cells undergo constitutive apoptosis when
aged in vitro and that this process is associated with mainte¬
nance ofmembrane integrity, hyporesponsiveness to external
secretagogue signals, and the capacity to be phagocytosed
intact by macrophages and certain other cells with phago¬
cytic potential.1*5,7 The speed and capacity of the macrophage
phagocytic response toward apoptotic neutrophils, together
with the observation that engulfment does not excite a proin¬
flammatory macrophage response,8 predicts that this process
plays an important role in the safe disposal of intact but
effete neutrophils from an inflamed focus. This view is sup¬
ported by the recent demonstration of this process occurring
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effect of TNF-a was concentration-dependent (EC50 2.8 ng/
mL), abolished by TNF-a neutralizing antibody, and was not
associated with any change in cell viability or recovery. Of
relevance to the inflamed site, the ability of TNF-a to acceler¬
ate apoptosis was lost if neutrophils were primed with 1
/umol/L PAF or aged for 6 hours before TNF-a addition. The
TI\IFR55-selective TNF-a mutants (E146K, R32W-S86T) in¬
duced neutrophil apoptosis but with a potency 14-fold lower
than wild-type TNF-a. Although the TNFR75-selective mu¬
tant (D143F) did not induce apoptosis, blocking antibodies
to both receptor subtypes abolished TNF-a-stimulated
apoptosis. Hence, TNF-a has the unique ability to induce
apoptosis in human neutrophils via a mechanism where
TNFR75 facilitates the dominant TNFR55 death effect. This
may be an important mechanism controlling neutrophil lon¬
gevity and clearance in vivo.
© 1997 by The American Society of Hematology.
in vivo; for example, in endotoxin-induced experimental
lung injury,9 the neonatal respiratory distress syndrome,10
and experimental glomerulonephritis."
Although the mechanisms involved in regulating neutro¬
phil survival and death are poorly understood, there is now
considerable evidence to suggest that this process is not
immutable because the rate at which these cells undergo
apoptosis, at least in vitro, can be altered. For example, the
colony-stimulating factors granulocyte colony-stimulating
factor (G-CSF) and granulocyte-macrophage-CSF (GM-
CSF), lipopolysaccharide (LPS), and hypoxia all increase
the survival of these cells by delaying apoptosis12*17 implying
that certain agents may upregulate neutrophil function both
by priming for enhanced functional responsiveness to secre¬
tagogue agonists and by delaying apoptosis which prolongs
their functional life span.16
One cytokine of particular interest in this paradigm is
tumour necrosis factor-a (TNF-a). This agent is a powerful
priming agonist in neutrophils yet has the capacity along
with other low-affinity nerve growth factor (NGF) receptor
ligands to induce apoptosis in a variety of cells, including
T lymphocytes18 and HL-60 cells.19 In contrast, a number of
reports have indicated that TNF-a has the opposite effect,
ie, delays apoptosis, in human monocytes, neutrophils, and
B104 lymphoma cells.20"22 Interest in this area has been
heightened by the recent finding of Zheng et al,18 who
showed that the induction of apoptosis in CD8+ T cells by
TNF-a is mediated via the TNFR75 rather than the classical
death domain-containing TNFR55.23
The aim of this study was to undertake a detailed charac¬
terization of the effects of TNF-a on neutrophil apoptosis
in vitro. We show that while prolonged incubation (>12
hours) of human neutrophils with TNF-a indeed causes a
decrease in the extent of apoptosis, TNF-a can induce
apoptosis in a proportion of cells at earlier times (<8 hours).
The early proapoptotic effect of TNF-a (1) appears to be
unique to this cytokine because it is not observed with other
priming or secretagogue agonists, (2) is abolished by initial
priming of the cells with platelet-activating factor (PAF), an
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effect that is not secondary to a change in TNFR55 or
TNFR75 expression, and (3) appears critically dependent
on TNF-a interaction with both TNF receptor subtypes as
determined by blocking TNF-a receptor antibodies and
TNF-a mutants which display selective binding to the two
TNF-a receptors.24"26
MATERIALS AND METHODS
Neutrophil preparation and culture. Human neutrophils were
purified from the peripheral blood of healthy human volunteers ex¬
actly as detailed previously.27 Cell purity was assessed using cyto-
centrifuge preparations fixed in methanol and stained with May/
Griinwald/Giemsa (Merck Ltd, Lutterworth, Leicestershire, UK) and
was routinely greater than 95% neutrophils with less than 0.1%
mononuclear cell contamination. Viability was assessed by the abil¬
ity of the cells to exclude trypan blue and was consistently greater
than 99% under all experimental conditions reported. Freshly har¬
vested neutrophils were routinely suspended at a density of 5 X 106/
mL in Iscove's modified Dulbecco's medium (MDM) supplemented
with 10% autologous serum and 50 U/mL penicillin and streptomy¬
cin and cultured at 6.75 X 105 cells/150 pL in flat-bottomed 96-
well Falcon flexiwell plates (Becton Dickinson, Oxford, UK) in a
humidified 5% C02 atmosphere at 37°C.
To examine the effects of neutrophil priming agents, freshly iso¬
lated cells were cultured in the presence or absence of (final concen¬
trations) formyl-Met-Leu-Phe (fMLP) (1 nmol/L), PAF (1 pmol/L),
inositol hexakisphosphate (InsP,,; 100 pmol/L), LPS (100 ng/mL),
leukotriene B4 (LTB4: 100 nmol/L). GM-CSF (50 U/mL), or TNF-
a (0.005 to 100 ng/mL). After incubation for the time periods indi¬
cated (1 to 20 hours), apoptosis was quantified as detailed below.
Morphological assessment of PMN apoptosis. After gentle re-
suspension, neutrophils were harvested, cytocentrifuged, and the re¬
sulting slide preparations fixed and stained as described above with
cell viability (trypan blue exclusion) and recovery assessed in paral¬
lel. Cell morphology was examined under oil immersion light mi¬
croscopy, and apoptotic neutrophils defined as cells containing
darkly stained pyknotic nuclei.' For each condition examined, slides
were prepared from triplicate incubations and a total of at least 500
neutrophils covering five high-power fields counted with the ob¬
server blinded to the assay conditions.
Chromatin fragmentation assay and propidium iodide staining.
For preparation of genomic DNA, neutrophils were incubated in the
presence or absence of 1 to 100 ng/mL TNF-a or 10 and 100 ng/
mL E146K and D143F for 3 hours, pelleted, and resuspended in 2
mL 150 mmol/L sodium acetate, 5 mmol/L EDTA (pH 7). After
addition of a further 2 mL of sodium acetate/EDTA containing 0.2
mg/mL proteinase K and 1% sodium dodecyl sulphate (SDS) the
Fig 1. Time course for the effect of TNF-a on apoptosis in human
neutrophils. Human neutrophils (5 x 106/mL) were incubated in MDM
containing 10% autologous serum alone (S3), or in the presence of
25 ng/mL TNF-a (■) or 50 U/mL GM-CSF (□) at 37°C. At the time
periods indicated, the cells were resuspended and cytocentrifuge
preparations made. These were fixed, stained, and percent apoptosis
assessed morphologically. (A) Represents the effects of TNF-a after
3, 6, 12, and 20 hours of incubation with the results from a separate
series of experiments over a 1- to 8-hour time course shown in (B).
The comparative effects of GM-CSF on neutrophil apoptosis at 6 and
20 hours are shown in (C). All values represent mean ± SEM of n
= 3 separate experiments, each performed in triplicate t*P < .05
compared with time-matched controls). Where not shown, SEM val¬
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Fig 2. Effect of TNF-a on neutrophil morphology and propidium iodide (PI) staining. Human neutrophils were incubated in the presence (A
and B, righthand panels) or absence (A and B, lefthand panels) of 12.5 ng/mL TNF-a as detailed in the legend to Fig 1. (A) Cytocentrifuge
preparations were prepared after 6 hours and cells fixed, stained, and examined under 100x objective oil immersion light microscopy. Cells
with classical apoptotic morphology are arrowed. (B) After 6 or 20 hours in culture cells were resuspended in ice-cold 70% ethanol, washed
in PBS, and incubated with PI in the presence of RNAase before analysis using an EPICS Profile II. Mean fluorescence values are shown for a
minimum of 5,000 cells for each condition and are representative of six to nine determinations in three separate experiments.
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Fig 3. Effect of neutrophil cell concentration on the early proapo-
ptotic effect of TNF-a. Human neutrophils were incubated at a cell
concentration of 2.5 to 15 x 106/mL in the presence !■) or absence
(E3) of TNF-a (12.5 ng/mL) for 6 hours at 37°C. Cytocentrifuge slides
were then prepared for morphological assessment of apoptosis. Data
represent the mean ± SEM of six observations in two separate exper¬
iments.
samples were incubated overnight at 55°C. Fresh proteinase K (0.1
mg/mL) was added and samples were incubated for a further 1 hour
at 55°C before cooling to room temperature. Thereafter, 4 mL of
phenol was added, samples mixed for 30 minutes, centrifuged
(5,000g, 10 minutes), and the DNA phase extracted in an equal
volume of phenol/chloroform. After centrifugation the upper phase
was removed and extracted in an equal volume of chloroform and
the DNA precipitated with 2 vol of absolute ethanol. The precipitate
was washed in 75% ethanol followed by absolute ethanol. After
evaporation of the ethanol at room temperature the pellet was dis¬
solved in 250 mL TE buffer (10 mmol/L Tris/HCl, I mmol/L EDTA,
pH 8) and quantified by reading the absorbance at 260 nm (DU-50
Beckman spectrophotometer, High Wycombe, UK). Loading buffer
(0.25% bromophenol blue, 0.25% xylene cyanol FF. 30% glycerol
in water) containing RNAase A (1:100 dilution of 10 mg/mL) was
added and 3 to 10 pg DNA electrophoresed in a 1.2% agarose gel
at 40 V in 40 mmol/L Tris-acetate, 1 mmol/L EDTA.
Propidium iodide (PI) staining was assessed according to Nicoletti
et al,28 with the following modifications: 0.4 X 106 cells were sus¬
pended in 100 pL ice-cold 70% ethanol for 10 minutes, washed
(X3) in phosphate-buffered saline (PBS) (4°C), and resuspended in
30 pL PBS and 30 pL RNAase (100 /rg/mL). After gentle mixing
60 pL of propidium iodide (100 pg/mL in PBS) was added; the
cells were incubated in the dark at room temperature for 15 minutes
and after washing in PBS stored at 4°C before analysis using an
EPICS Profile II (Coulter Electronics, Luton, UK). Mean fluores¬
cence values were determined from a minimum of 5,000 cells within
an analysis region corresponding to nonfragmented neutrophils.
Measurement of superoxide anion generation. The release of
superoxide anions was determined by means of the superoxide dis-
mutase-inhibitable reduction of cytochrome C. Neutrophils (106 in
90 pL PBS containing CaCL and MgCl2) were placed in 2-mL
polypropylene tubes containing 10 pL TNF-a to give a final concen¬
tration of 0.05 to 50 ng/mL, or PBS (control). Each reaction was
performed in quadruplicate. Samples were incubated in the presence
or absence of TNF-a for 30 minutes at 37°C in a shaking water bath
before the addition of 750 ph cytochrome C (final concentration 1.2
mg/mL) to all samples and 50 pL of superoxide dismutase (20 pgl
mL in PBS) to one sample in each quadruplicate. After a final 10-
minute incubation with PBS or fMLP (100 nmol/L), samples were
placed on ice and the optical density of the supernatants determined
using a scanning spectrophotometer (Pye-Unicam 8700; Unicam Ltd,
Cambridge, UK) measuring peak height at 550 nm with the paired
dismutase-containing supernatants as reference. Superoxide release
(nmoles/106 cells) was calculated using the extinction coefficient 21
X 103 (mol/L)_1 -crrr1.
Effects of TNF-a neutralizing antibodies, TNFR55 and TNFR75
blocking antibodies, and TNF-a receptor-selective mutants on basal
and TNF-a-stimulated neutrophil apoptosis. Freshly isolated neu¬
trophils were cultured as detailed above in either MDM plus 10%
autologous serum alone (control), TNF-a (12.5 ng/mL), mouse IgG,
antihuman TNF-a neutralizing monoclonal antibody (MoAb) (1 pgl
mL), or an identical concentration of TNF-a preincubated for 90
minutes at 37°C with the neutralizing antibody. At 6 hours cells
were harvested and apoptosis assessed as indicated above. To assess
the effect of TNFR55 and TNFR75 blocking antibodies on the ability
of TNF-a to modulate the rate of neutrophil apoptosis, cells (5 X
106/mL) were preincubated for 30 minutes at 37°C in MDM con¬
taining 10% autologous serum in the presence or absence of 28 pgl
mL of mouse IgG, antihuman TNFR55, rat IgG21, antihuman
TNFR75, or isotype-matched IL-2a (p55) receptor MoAb before a
6- or 20- hour incubation with TNF-a (12.5 ng/mL) or buffer and
morphological assessment of apoptosis. The saturating concentration
of TNFR75 MoAb used was predetermined using a flow cytometry
antibody titration assay2' and TNFR55 MoAb used at an identical
concentration. In experiments using the TNFR55-selective mutants
E146K and R32W-S86T or TNFR75-selective mutant D143F,
freshly isolated neutrophils were incubated for 3 or 6 hours in the
presence or absence of 0.01 to 100 ng/mL mutein or rhTNF-a as
previously detailed30 before morphological quantification of
apoptosis or examination of DNA fragmentation.
Flow cytometric analysis of TNFR55 and TNFR75 expression.
Neutrophils were prepared, preincubated for 5 minutes with I
p,mol/L PAF or buffer, and then incubated (6.75 X 105 cells/150 ph
MDM containing 10% autologous serum) in flexiwell plates at 37°C
for 0 to 6 hours as detailed above. At the appropriate time points
the cells were transferred to prechilled U-bottomed flexiwell plates,
Table 1. Effect of Incubation Time and Neutrophil Presence on the
Concentration of TNF-a in Supernatants
Time Medium + TNF-a Neutrophils + TNF-ar Neutrophils - TNF-a
(h) (ng/mL) (ng/mL) (ng/mL)
0 8.87 ± 0.59 10.29 ± 1.10 0*
3 8.33 ± 0.54 7.84 ± 0.62 0
6 9.18 ± 0.90 8.67 ± 0.97 0
12 8.96 ± 1.08 8.29 ± 0.68 0
20 8.69 ± 0.63 7.97 ± 0.67 0
Human neutrophils (5 X 106/mL) or medium alone (MDM containing
10% autologous serum) were incubated in the presence (+TNF-a)
or absence (■ TNF-a) of 12.5 ng/mL TNF-a in flexiwell plates in an
humidified 5% C02 incubator at 37°C for 0 to 20 hours. The superna¬
tants were harvested, frozen, and immunoreactive human TNF-a
quantified by ELISA as detailed in the Materials and Methods section.
Data represent mean ± SEM of six measurements performed in two
separate experiments.
* Assay sensitivity 15.6 pg/mL.
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washed with ice-cold PBS containing 0.2% bovine serum albumin
(BSA) and 0.1% sodium azide, and resuspended in 40 /zL of a
saturating concentration of mouse-antihuman TNFR55, TNFR75, or
CD2 MoAb as a negative control (UCHT-1 clone, IgG,; SAPU,
Carluke, UK). After a 30-minute period on ice the cells were washed
twice and incubated with 40 /zL fluorescein isothiocyanate (FITC)-
conjugated goat-antimouse Ig (Dako, Buckinghamshire, UK; diluted
1 in 40 with PBS/BSA/azide buffer). After washing, samples were
analyzed using an EPICS Profile II (Coulter Electronics) and mean
fluorescence values from a minimum of 3,000 cells determined.
Enzyme-linked immunosorbent assay (ELISA) for TNF-a. Extra¬
cellular immunoreactive human TNF-a was quantified using a modi¬
fication of the double-ligand method as previously described.31 In
brief, flat-bottomed 96-well microtiter plates (Immulon I; Dynatech,
Billinghurst, UK) were coated with 100 /zL/well mouse-antihuman
TNF-a MoAb (2.5 /zg/mL in coating buffer; Dynatech) for 3 hours
at 37°C and then washed with PBS (pH 7.5), 0.05% Tween-20 (PBS-
Tween-20). Microtiter plate nonspecific binding sites were blocked
with Dynatech blocking buffer (30 minutes, 37°C). The plates were
washed four times (PBS-Tween-20) and cell-free supernatants or
TNF-a standards (half-log dilutions of recombinant human [rh]TNF-
a, from 7.8 to 500 pg/mL) added in 100-/zL aliquots in duplicate
and incubated for 16 hours at 4°C. Plates were washed four times
(PBS-Tween-20), followed by the addition of 100 /zL/well rabbit
polyclonal antihuman TNF-a antibody (1 /zg/mL in assay diluent;
Dynatech) and the plates were incubated for 3 hours at room temper¬
ature. The plates were again washed, alkaline phosphatase-conju-
gated donkey-antirabbit IgG added, and following a further incuba¬
tion of 3 hours at room temperature, p-nitrophenyl phosphate
substrate added in 10% diethylamine (DEA) buffer. Plates were read
at 410 nm in an ELISA reader.
Statistics. All values are presented as the mean ± SEM of (n)
number of independent experiments. The data were evaluated statis¬
tically using the paired or unpaired Students ?-test: P values <.05
were considered to be statistically significant.
Materials. Recombinant human TNF-a (10 ^zg/mL in PBS) and
GM-CSF (1 /zg/mL in PBS) were purchased from Genzyme (Cam¬
bridge, MA) and stored at —70°C before use. Rat-antihuman
TNFR75 MoAb and interleukin-2 (IL-2) receptor MoAb were also
purchased from Genzyme (Cambridge, MA) and stored at 0.4 to 1
mg/mL in PBS (4°C). The mouse IgG, antihuman TNF-a neutraliz¬
ing MoAb and mouse-antihuman TNFR55 and TNFR75 MoAbs
were purchased from R&D Systems Europe (Abingdon, Oxon,
UK). LTB4, LPS (Escherichia coli 0111:B4, 7-irradiated), InsP6 (di-
potassium salt), fMLP, superoxide dismutase, cytochrome C, Dul-
becco's PBS (with or without CaCl2 and MgCl2), p-nitrophenyl
phosphate, proteinase K, trypan blue, and dextran-500 were all pur¬
chased from Sigma Chemical Co (Poole, Dorset, UK). fMLP was
dissolved in sterile dimethyl sulfoxide (DMSO) at a stock concentra¬
tion of 1 mmol/L and stored at —20°C. LTB4 was stored in ethanol
at 100 ^zg/mL at -20°C. CI8 PAF was obtained from Calbiochem-
Novabiochem UK Ltd (Nottingham, UK) and dissolved in ethanol
Fig 4. Concentration-response relationships for TNF-a-induced
apoptosis, priming, and direct superoxide anion generation. Human
neutrophils were prepared and incubated at 5 x 106/mL with 0 to
100 ng/mL TNF-a for 6 hours for assessment of apoptosis (A) or at
107/mL with 0 to 100 ng/mL TNF-a for 30 minutes before assessment
of fMLP-stimulated (100 nmol/L, 10 minutes) (B) or direct superoxide
anion generation (10 minutes) (C) using a cytochrome C reduction
assay (see Materials and Methods). Values represent mean ± SEM
of n = 3 separate experiments, each performed in triplicate. Where
not shown, SEM values are less than 2% and fall within the symbols.
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at a stock concentration of 10 mmol/L. Percoll was obtained from
Pharmacia Biotech (St Albans, Hertfordshire, UK). MDM was ob¬
tained from Life Technologies (Paisley, Scotland, UK). Alkaline
phosphatase-conjugated donkey-antirabbit IgG was purchased from
Stratech Scientific Ltd (Luton, Bedfordshire, UK). All other reagents
were obtained from Sigma Chemical Co or Merck Ltd and were of
the highest purity available.
RESULTS
Effect of TNF-a on the rate of neutrophil apoptosis in
vitro. In agreement with previous studies,21 coincubation
of human neutrophils with 25 ng/mL TNF-a for 20 hours
caused a small but significant inhibition of neutrophil
apoptosis (Fig 1A and C). This effect concurs with our previ¬
ous observations that many other agents that prime or acti¬
vate human neutrophils either delay (GM-CSF, Fig 1C, C5a,
LPS,16 InsP6,32 and LTB4, results not shown), or have no
effect on (fMLP and PAF, results not shown), the rate of
constitutive apoptosis when assessed at this time point. How¬
ever, when cytospins were prepared at earlier times (3 to 6
hours) when the basal rate of apoptosis was still low, TNF-
a caused a significant increase in the number of apoptotic
cells present (Fig 1 A). This early proapoptotic effect of TNF-
a was rapid (observed in all experiments by 2 hours, Fig
IB), maximal in terms of the ratio of apoptotic to nonapo-
ptotic cells by 6 hours (Fig IB), and was not observed with
any of the other priming/activating agents tested at 6 hours
(50 U/mL GM-CSF [Fig 1C], 1 and 100 nmol/L fMLP, 1
/tmol/L PAF, 100 /rmol/L InsP6, or 100 /rmol/L LTB4, data
not shown). Accurate quantification of the effects of such
agents (including TNF-a) beyond 24 hours was not possible
because of the development of secondary necrosis at these
times.
The induction of apoptosis by TNF-a at early time points
was confirmed by DNA electrophoresis, which showed a
typical ladder pattern in TNF-a-treated neutrophils indica¬
tive of endonuclease-dependent internucleosomal cleavage
(see Fig 8), and by PI staining, which revealed an increase
in the percentage of cells with hypodiploid DNA content in
TNF-a-treated cells (Fig 2B) (control 6 hours, 4.4% ±
0.3%; 12.5 ng/mL TNF-a 6 hours, 18.2% ± 0.1%; P <
.05, n = 3). These latter values exactly match the extent of
apoptosis assessed by morphological criteria (Fig 2A) (con¬
trol 6 hours, 4.6% ± 0.2%; 12.5 ng/mL TNF-a 6 hours,
17.2% ± 1.4%; P < .05, n = 3). The late inhibitory effect
of TNF-a on neutrophil apoptosis (20 hours) was also con¬
firmed using this technique (Fig 2B) (percent low PI stained
cells: control 20 hours, 55.9% ± 0.3%; 12.5 ng/mL TNF-a
20 hours, 46.9% ± 1.5%; P < .05, n = 3).
The specificity of action of TNF-a was shown in experi¬
ments where the proapoptotic effect of TNF-a was com¬
pletely abolished by preincubation with mouse-antihuman
TNF-a neutralizing antibody (percent apoptosis at 6 hours:
control, 6.7% ± 0.6%; 25 ng/mL TNF-a, 17.3% ± 1.4%;
TNF-a antibody, 6.2% ± 0.8%; TNF-a + TNF-a antibody,
6.0 ± 0.7%; n = 3). In addition, TNF-a did not affect neutro¬
phil viability (trypan blue exclusion) or recovery rates (data
not shown), excluding the possibility that the increased rates







Fig 5. Loss of the early proapoptotic effect of TNF-a in human
neutrophils after delayed addition of TNF-a or pretreatment with
PAF. (A) To assess the effect of delayed addition of TNF-a, human
neutrophils were incubated at 5 x 106/mL in the absence (0) or
presence of 12.5 ng/mL TNF-a added either at the beginning of the
incubation period (SS) or after a delay of 6 hours (■). The extent
of apoptosis was then assessed morphologically at the time points
indicated. All data values represent the mean ±SEIVlofn = 3 separate
experiments, each performed in triplicate {*P < .05 compared with
time-matched controls). Where not shown, SEIVI values are less than
2% of means. (B) Human neutrophils (5 x 106/mL) were incubated in
MDM containing 10% autologous serum in the presence or absence
of PAF (1 /umol/L) for 5 minutes before being placed in 96-well flexi-
well plates for a 6-hour incubation with 12.5 ng/mL TNF-a or buffer.
Apoptosis was then determined on cytocentrifuge preparations us¬
ing standard morphological criteria. Values represent mean ± SEWI
of three separate experiments, each performed in triplicate (*P< .05
compared with controls).
adhesion of nonapoptotic cells33 or a TNF-a-induced switch
between necrosis and apoptosis as seen in human leukemic
cells treated with high concentrations of alkylating agents.34
Examination of the influence of neutrophil cell concentration
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Fig 6. Time-course for TNFR55 and TNFR75 expression in the presence and absence of PAF. (A) Flow cytometric analysis of CD2 (negative
control), TNFR55, and TNFR75 receptor expression in freshly isolated neutrophils. Flistograms represent profiles of cell count against log
fluorescence and are representative examples from nine separate experiments. (B and C) Human neutrophils (5 x 106/mL) were incubated in
MDM containing 10% autologous serum in the presence or absence of PAF (1 /itmol/L) for 5 minutes before incubation for 1 to 6 hours in
flexiwell plates at 37°C. At these time points TNFR55 (B) and TNFR75 (C) expression was quantified by flow cytometry as detailed in Materials
and Methods. Data represent percent of specific receptor expression values obtained in freshly isolated cells with each point being the mean
± SEM of three separate experiments, each performed in triplicate.
on the action of TNF-a at 6 hours showed that the proapo-
ptotic effect was most marked at 2.5 to 5 X 106 cells/mL
(Fig 3). A cell concentration of 5 X 10'VmL was selected
for use in subsequent studies as this was the optimal cell
density for preparation and quantification of cytospins.
Assay of the TNF-cr concentration present in cell superna-
tants at 0, 6, and 20 hours showed no evidence of spontane¬
ous TNF-a production35 or decline in the level of exoge-
nously added TNF-a (Table 1).
Relationship between TNF-a-induced apoptosis and
priming. The potential physiological relevance of the pro-
apoptotic effect of TNF-a was assessed initially by compar-
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ing the concentration-dependency of this response with the
ability of TNF-a to directly stimulate superoxide anion gen¬
eration in neutrophils and to prime fMLP (100 nmol/L)-
stimulated respiratory burst activity. Figure 4 shows the very
similar concentration-response relationships for all three ef¬
fects with an EC50 for TNF-a-induced apoptosis of 2.8 ng/
mL.
To assess whether the induction of apoptosis by TNF-a
was itself influenced by neutrophil priming, cells were either
preincubated in flexiwell plates for 6 hours or pretreated
with 1 /rmol/L PAF for 5 minutes before the addition of
TNF-a. Priming with PAF resulted in a dramatic upregula-
tion of fMLP-stimulated superoxide anion release (superox¬
ide anion release, nmol/106 cells/10 min, control 0.9 ±0.1,
100 nmol/L fMLP 3.4 ± 0.4, 1 /rmol/L PAF 0.8 ± 0.1, I
/rmol/L PAF + 100 nmol/L fMLP 33.1 ± 2.0, n = 3) with
the adhesion-based model also converting TNF-a into a full
secretagogue agonist33,36 (and data not shown). As shown in
Fig 5, both strategies abolished the proapoptotic effect of
TNF-a, although by contrast, the late inhibitory effect of
TNF-a on apoptosis at 20 hours appeared to be enhanced
when TNF-a addition was delayed (Fig 5A). Flow cytomet¬
ric analysis of TNFR55 and TNFR75 expression in freshly
isolated neutrophils demonstrated a single population of
TNFR55 and TNFR75 positive cells (Fig 6A) with mean
fluorescence values of 4.06 ± 0.26 and 5.40 ± 0.53, respec¬
tively (CD2 control values 1.50 ± 0.10. n = 9). Incubation of
neutrophils in flexiwell plates under the identical conditions
described above resulted in a time-dependent decrease in
both TNFR55 and TNFR75 expression (Fig 6B and C); how¬
ever, preincubation of neutrophils with 1 /rmol/L PAF for 5
minutes, which completely abolished the ability of TNF-a
to induce apoptosis, had no effect on either TNFR55 or
TNFR75 expression (Fig 6B and C).
TNFR55 and TNFR75 dependency of TNF-a-stimulated
neutrophil apoptosis. The involvement of TNFR55 and
TNFR75 in mediating the early proapoptotic effect of TNF-
a was examined using TNF-a receptor subtype selective
blocking MoAbs and agonistic mutants. In preliminary ex¬
periments the dominant role of TNFR55 in mediating TNF-
a-induced priming of superoxide anion generation in neu¬
trophils in suspension was confirmed37,38 in that the TNFR55
MoAb completely blocked TNF-a-induced priming of
fMLP-stimulated superoxide anion generation whereas the
TNFR75 MoAb had no effect on this response (data not
shown). In contrast, however, an identical 30-minute prein¬
cubation of neutrophils with either TNFR55 or TNFR75
MoAb completely abrogated the proapoptotic effect of TNF-
a (Fig 7). Neither the antibodies themselves (Fig 7) nor
isotype-matched control MoAbs (data not shown) affected
basal or, in the latter case, TNF-a-stimulated apoptosis.
Of interest, the TNFR75 MoAb did not influence the late
inhibitory effect of TNF-a on apoptosis observed at 20 hours
(percent apoptosis at 20 hours: control, 58.7% ± 1.2%; TNF-
a, 38.7% ± 3.4%; TNFR75 MoAb, 51.4% ± 1.6%; TNF-a
+ TNFR75 MoAb, 32.4% ± 1.0%). These data indicate that
the TNF-a-induced priming and late inhibitory effect on
apoptosis are mediated via TNFR55, but the early proapo¬
ptotic effect is dependent on both TNFR55 and TNFR75
activation.
H H
Fig 7. Effect of TNFR55 and TNFR75 blocking antibodies on TNF-
a-induced apoptosis in human neutrophils. Human neutrophils (5 x
106/mL) were preincubated with antihuman TNFR55 or TNFR75
MoAbs for 30 minutes at 37°C before a 6-hour incubation in the pres¬
ence or absence of 12.5 ng/mL TNF-a. The extent of apoptosis was
then assessed by morphological examination of cytocentrifuge prep¬
arations. Data represent mean ± SEM of three separate experiments
each performed in triplicate. Where not shown, SEIVI values are less
than 5% of means.
Complementary experiments were performed using the
TNFR55-selective TNF-a agonistic mutants E146K and
R32W-S86T and the TNFR75-selective mutant D143F. The
former peptides have a 3,300- and 5,000-fold lower affinity
for the TNFR75 receptor with only marginal (2- and 2.2-
fold) reduction in TNFR55 affinity whereas the TNFR75
ligand D143F displays a 30-fold reduced affinity to TNFR75
and no binding to TNFR55.25,26 Figure 8 shows the ability
of both TNFR55 mutants to induce morphological and DNA
ladder evidence of neutrophil apoptosis, albeit with a lower
potency than recombinant human TNF-a (EC50 values, ng/
mL: wild-type TNF-a, 5.0; E146K, 82.7; R32W-S86T, 69.5;
both P < .01 compared with TNF-a). The induction of
apoptosis by E146K and R32W-S86T was also inhibited
completely by preincubation with TNFR55 MoAb (Fig 9).
The TNFR75 selective agonist D143F, which causes a
prompt induction of GM-CSF production in TNFR75 trans-
fected PC 12 cells that lack TNFR55 expression,30 did not
induce apoptosis even at a concentration of 100 ng/mL (Fig
8). These data imply that TNFR75 facilitates the ability of
TNFR55 to induce apoptosis in human neutrophils.
DISCUSSION
We have shown that TNF-a has a unique and bimodal
effect on the rate of apoptosis in human neutrophils and have
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Fig 8. Effect of TNF-a recep¬
tor selective mutants on human
neutrophil apoptosis. (A) Human
neutrophils were incubated with
0.01 to 100 ng/mL of wild-
type TNF-a (wtTNF-a, ■), the
TNFR55-selective mutants R32W-
S86T {•) or E146K (♦), and the
TNFR75 selective mutant D143F
(A). Apoptosis was assessed
morphologically after 3 hours.
Data represent mean ± SEM of
three experiments each per¬
formed in triplicate. (B) Neutro¬
phils were incubated under iden¬
tical conditions with 0 to 100 ng/
mL wild-type TNF-a, 10 to 100
ng/mL E146K, or 10 to 100 ng/
mL D143F. Thereafter the ceils
were pelletted and incubated
overnight in sodium acetate/
EDTA/proteinase K/1% SDS be¬
fore phenol/chloroform DNA ex¬
traction as detailed in Materials
and Methods. After precipitation
with ethanol, 10 pg of DNA was
loaded per lane and separated
on a 1.2% agarose gel.
provided an explanation for the previous divergent reports
that TNF-a either inhibits,2' has no effect on,39 or induces
apoptosis in neutrophils.40'41 Our data also reveal that the
early proapoptotic effect of TNF-a:, in contrast to its priming
effect observed in neutrophils in suspension, or indeed the
apoptotic effect of TNF-a observed in nonhematopoietic
cells, is critically dependent on engagement of both TNFR55
and TNFR75 receptors.
Neutrophils undergo constitutive apoptosis when aged in
vitro,1 ' yet appear highly resistant to any attempt to acceler¬
ate this process using physiological agonists. Indeed, we
have shown that even stimuli that are potent inducers of
apoptosis in other cell types (eg, corticosteroids, elevation
of intracellular Ca2+ and hypoxia) all inhibit rather than aug¬
ment the rate of apoptosis in these cells.17,42'43 The only other
physiological agonist reported to induce neutrophil apoptosis
is IL-644; however, this effect was small, has not been con¬
firmed by at least two other groups,40'45 and the extent of
apoptosis recorded (10% compared to 15% in the presence
of IL-6 at 24 hours) is very different than that reported in
all other comparable studies. Hence, TNF-a appears to have
the unique ability not shared by other neutrophil priming
and activating agents to induce neutrophil apoptosis.
The effectiveness of the TNFR55-selective mutants
E146K and R32W-S86T to induce apoptosis in human neu¬
trophils implies that TNFR75 functions to facilitate a death
signal primarily initiated via TNFR55. This conclusion is
supported by experiments using rat neutrophils where indue-








Fig 9. Effect of TNFR55 blocking antibodies on TNFR55-selective
mutant-induced neutrophil apoptosis. Human neutrophils (5 x 106/
mL) were preincubated in the presence (0) or absence {■} of antihu-
man TNFR55 MoAbs before stimulation with medium alone (control),
12.5 ng/mL TNF-a, or 100 ng/mL of the TNFR55 selective mutant
proteins E146K or RWS86T for 6 hours. The extent of apoptosis was
assessed morphologically. Data represent mean ± SEM of three sepa¬
rate experiments, each performed in triplicate.
tion of apoptosis occurs with human TNF-a that does not
interact with the mouse TNFR75 receptor.41 Involvement of
TNFR75 in TNF-a-induced death appears to be restricted
to hematopoietic cells and was initially thought to reflect the
ability of TNFR75 to present TNF-a to TNFR55 via a "li-
gand passing" effect.46 However data in PC60 T-cell hybrid-
oma cells, where coexpression of high levels of TNFR75 in
addition to low levels of TNFR55 is likewise required to
observe TNF-a-stimulated apoptosis, have excluded such a
mechanism 47 The involvement of TNFR75-derived intracel¬
lular signals in mediating the death effect of TNF-a is sup¬
ported by the recent demonstration that TNF-a can induce
T-cell receptor-induced apoptosis in p55~'~ mice, indicating
that under certain circumstances TNFR75 can function alone
to induce apoptotic cell death,18 and similar conclusions have
been reached in HeLa cells using TNFR75 selective antibod¬
ies.48 The precise mechanism whereby TNFR75 initiates
apoptosis or permits TNFR55-induced death remains uncer¬
tain, not least because this receptor subtype has a relatively
short cytoplasmic domain with no intrinsic kinase activity
or death domain sequence (as found in TNFR55 and Fas).23
However, the discovery of a TNFR75-associated kinase that
phosphorylates both TNF-a receptors provides a potential
mechanism whereby TNFR75 could facilitate TNFR55 intra-
cellularly.49
The observation that only a proportion of neutrophils un¬
dergo apoptosis in response to TNF-a is of particular inter¬
est, not least because there was no detectable decline in
TNF-a levels over the 20-hour incubation period studied.
There is no evidence to support heterogeneous TNF-a recep¬
tor expression in neutrophils because TNF-a stimulates uni¬
form CD18-dependent latex bead binding in nearly 100% of
neutrophils50 and flow cytometric analysis demonstrates a
single population of TNFR55 and TNFR75 positive cells
(Fig 6A). However, heterogeneous neutrophil responses to
other stimuli such as LPS augmentation of fMLP-induced
Ca2+ transients are well documented51 and other factors such
as cell maturity may be important in dictating the susceptibil¬
ity of individual cells to apoptosis. Our data have also shown
a discrete TNFR55-mediated survival effect of TNF-a which
is evident at later incubation times and is particularly obvious
when the early proapoptotic effect is abolished (Fig 5A);
this effect is likely to limit the extent of apoptosis occurring
at earlier times. Furthermore, TNF-a induces substantial
TNFR55 and TNFR75 loss under our assay conditions
(S.A.D., J.M., and I.D., unpublished observations), which
again may further curtail the proapoptotic effect of TNF-a.52
Such a proposal would agree with the findings of Tsuchida et
al,41 who have shown a correlation in rat neutrophils between
TNF-a receptor numbers and TNF-a-induced apoptosis.
The loss of the proapoptotic effect of TNF-a when cells
were cultured for 6 hours before cytokine addition may well
reflect the major decrease in TNFR55 and TNFR75 expres¬
sion that occurs over this period (Fig 6B and C), but this
mechanism does not appear to account for the similar effect
observed with PAF where no change in TNFR55 or TNFR75
expression was observed. Although a previous study has
reported that PAF induces a 50% decline in total TNFR
expression using l25I-TNF-a binding, this effect was ob¬
tained after a 2-hour rather than a 5-nrinute incubation period
and used PAF at a concentration of 100 pmol/L.31 However,
it is possible that PAF influences receptor coupling rather
than expression and/or that TNF-a is sensitive to PAF-in-
duced protease release. TNF-a has also been shown to en¬
hance thrombospondin-mediated phagocytosis of apoptotic
neutrophils by monocyte-derived macrophages,53 suggesting
a potentially synergistic or dual mechanism whereby TNF-
a may enhance the removal of neutrophils from an inflamed
site by accelerating apoptosis and facilitating clearance.
These data indicate that in addition to its ability to upregu-
late many aspects of neutrophil function,54'55 TNF-a also has
the capacity, unique among other priming/activating agents,
to promote neutrophil apoptosis. Although the neutrophil is
a short-lived cell, it is interesting to speculate that depending
on the balance of inflammatory mediators present at an in¬
flamed site, there is clearly the potential for neutrophil func¬
tion and longevity to be either upregulated or downregulated.
This effect of TNF-a may explain at least in part certain in
vivo findings; for example, how the administration of anti-
TNF-a antibodies results in delayed resolution of the neutro¬
philic alveolitis induced by Legionella pneumophila,5'' and
why pneumococcus (one of the most potent inducers of alve¬
olar macrophage TNF-a production57) causes a form of
pneumonia that usually resolves with minimal residual organ
damage.58 In view of recent observations that genetic varia¬
tions in the TNF-a gene promotor region are associated with
differences in constitutive and inducible concentrations of
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TNF-a and that this alters the clinical course of malaria and
tuberculosis infection,59 it is also tempting to speculate that
similar influences may also have a bearing on neutrophil
influx and clearance at sites of inflammation. The recognition
that neutrophil apoptosis can be stimulated by TNF-a and
that the priming and apoptotic effects of this cytokine can
be dissociated may help in the design of more rational and/
or selective anti-inflammatory therapy.
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